臨床検査医学分野

1,200  件  
※ 登録方法の違いにより重複して表示されている場合があります。

  1. Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T: Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast cancer (Tokyo, Japan). 2026.07; 33 (4): 839-840. ( PubMed , DOI )

  2. Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast cancer (Tokyo, Japan). 2026.07; 33 (4): 829-838. ( PubMed , DOI )

  3. Tachibana H, Matsuura K, Onimaru R, Yoshida D, Kobayashi T, Ueda T, Nakahira M, Ohkoshi A, Omura G, Mukaigawa T, Katagiri K, Asakage T, Shinomiya H, Ito F, Asada Y, Beppu T, Fujii T, Hirayama Y, Tsukahara K, Saito Y, Ichikawa K, Uemura H, Tahara M, Hanai N, Kiyota N, Iwamoto S, Sasaki K, Mizusawa J, Fukuda H, Homma A, JCOG Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG): Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212. ESMO open. 2026.07; 11 (8): 108336. ( PubMed , DOI )

  4. Jorge E Cortes, Delphine Rea, Michael J Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael Deininger, Yeow-Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gómez García de Soria, Philipp le Coutre, Francois-Xavier Mahon, Daniel J DeAngelo, Andrea Damon, Shruti Kapoor, Gessami Sanchez-Olle, Matthias Hoch, Nithya Agrawal, Sara Quenet, Timothy P Hughes: Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results. Leukemia. 2026.07; ( PubMed , DOI )

  5. Oriol Calvete, Julia Mestre, Lorea Chaparro-González, Lucía Ruiz Pérez-Hita, Alba Mesa Tudel, Blanca Xicoy, Lurdes Zamora, Isabel Granada, Mar Mallo, Emili Cid, Estefania Mancici, Claudia Lozano, Laura Palomo, Pamela Acha, Maria Julia Montoro, Koji Sasaki, Courtney D DiNardo, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Neus Torres Hernandez, Marta Santiago Balsera, José Cervera, Gonzalo Maortua, Raquel de Paz, Martí Mascaró, Alfonso Garcia Da Vila, Sara Garcia-Avila, Juan Jose Rodríguez-Sevilla, Leonor Arenillas, Beatriz Bellosillo, Rashmi Kanagal-Shamanna, Francesc Sole: Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms. Blood Adv. 2026.07; ( PubMed , DOI )

  6. Hyper‐CVAD Versus Hyper‐CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis 2026.07; 101 (7): 1729-1736. ( PubMed , DOI )

  7. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. 2026.07; 101 (7): 1737-1747. ( PubMed , DOI )

  8. Saki Kanehira, Yusuke Ota, Kazunari Sonobe, Naoya Ichimura, Koh Okamoto, Yoshiaki Gu, Koji Sasaki, Ryoichi Saito: Draft genome sequence of a multidrug-resistant Streptococcus agalactiae sequence type 1665 strain isolated from ascitic fluid. Microbiol Resour Announc. 2026.06; e0041226. ( PubMed , DOI )

  9. Nguyen D, Kantarjian HM, Bidikian A, Manuel CM, Qiao W, Ning J, DiNardo CD, Kadia TM, Daver N, Borthakur G, Jabbour E, Yilmaz M, Maiti A, Sasaki K, Montalban-Bravo G, Chien K, Hammond D, Pierce S, Andreeff M, Ravandi F, Short NJ, Garcia-Manero G, Issa GC: Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026.06; ( PubMed , DOI )

  10. Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation. 2026.05; ( PubMed , DOI )

  11. Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment. 2026.05; ( PubMed , DOI )

  12. Sasaki K, Ishiba T, Nishibuchi I, Hara F, Sekino Y, Machida R, Shibata T, Kawahara D, Sagara Y, Naito Y, Terata K, Ozaki Y, Shimomura A, Sakai T, Shigematsu H, Sudo K, Nozawa K, Yoshimura M, Shikama N, Mizowaki T, Shien T: A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). Japanese journal of clinical oncology. 2026.05; 56 (5): 659-665. ( PubMed , DOI )

  13. Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL. 2026.05; ( PubMed , DOI )

  14. Ryohei Takada, Hiroshi Fujita, Kan Sasaki, Toshiki Iwase, Tatsuro Sakurai, Hisanori Oura, Takkan Morishima, Fumiaki Nishisaka, Nao Shibanuma, Masaru Kadowaki, Naoyuki Katayama, Hiromi Otsuka: Incidence of periprosthetic femoral fracture after total hip arthroplasty using the exeter stem: A retrospective multicenter cohort study in Japan. J Orthop Sci. 2026.05; ( PubMed , DOI )

  15. Ishitobi M, Tanaka K, Shimomura A, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T: Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized clinical trial. The British journal of surgery. 2026.05; 113 (5): ( PubMed , DOI )

  16. Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial 2026.04; ( PubMed , DOI )

  17. Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms. 2026.04; 40 (4): 841-844. ( PubMed , DOI )

  18. Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. 2026.04; 40 (4): 856. ( PubMed , DOI )

  19. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. 2026.04; 101 (7): 1717-1722. ( PubMed , DOI )

  20. Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. 2026.03; 26 (5): e678-e682.e1. ( PubMed , DOI )

  21. A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. 2026.03; 1-8. ( PubMed , DOI )

  22. Shigematsu H, Fujisawa T, Hara F, Iwata H, Ishiba T, Ozaki Y, Sakai T, Sagara Y, Shimomura A, Sudo K, Terata K, Naito Y, Nozawa K, Sasaki K, Mitome N, Sadachi R, Shibata T, Shien T: Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial. International journal of clinical oncology. 2026.03; 31 (3): 528-536. ( PubMed , DOI )

  23. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes 2026.03; 16 (1): ( PubMed , DOI )

  24. Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor. 2026.02; 147 (23): 2809-2820. ( PubMed , DOI )

  25. Ryo Iwase, Nobuo Sanjo, Tadashi Kanouchi, Yurie Nose, Miho Akaza, Motonori Hashimoto, Satoru Egawa, Toshitaka Yoshii, Takanori Yokota: Quantitative evaluation of iron chelator effects on central motor and sensory tracts in superficial siderosis. Front Neurol. 2026.02; 17 1734951. ( PubMed , DOI )

  26. Corrigendum to "Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group" [Modern Pathology. 2024;37(2):100406]. 2026.02; 39 (2): 100952. ( PubMed , DOI )

  27. BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. 2026.02; 40 (2): 304-313. ( PubMed , DOI )

  28. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia 2026.01; 147 (5): 547-556. ( PubMed , DOI )

  29. Thida Aung, Hiroshi Churei, Kairi Hayashi, Kazuyoshi Tsuchiya, Kazuma Sasaki, Gen Tanabe, Toshiaki Ueno, Kenji Fueki: Development of a device for continuous salivary pH measurement at two locations in the oral cavity. J Prosthodont Res. 2026.01; ( PubMed , DOI )

  30. Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. 2026.01; 40 (1): 262. ( PubMed , DOI )

  31. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. 2026.01; 10 (1): e70289. ( PubMed , DOI )

  32. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia 2026.01; 67 (1): 220-224. ( PubMed , DOI )

  1. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. 2025.12; 9 e2500494. ( PubMed , DOI )

  2. Araki J, Mori K, Yasunaga Y, Nakagawa M, Onitsuka T, Yurikusa T, Kimata Y, Sakuraba M, Higashino T, Hyodo I, Ishida K, Miyamoto S, Takanari K, Sasaki K, Arikawa M, Umezawa H, Kadota H, Matsumoto H, Tanaka K, Fujii M, Hamahata A, Kubo T, Yanagisawa D, Kurosawa K, Umekawa K, Iida T, Sarukawa S, Migita H: Functional Outcomes after Subtotal/Total Glossectomy with Microsurgical Reconstruction: A Multicenter Prospective Observational Study in Japan. Annals of surgical oncology. 2025.11; 32 (12): 9198-9213. ( PubMed , DOI )

  3. Otani, T; Akaza, M; Kawabata, S; Natsui, H; Watanabe, T; Miyano, Y; Hanazawa, R; Adachi, Y; Sekihara, K; Kanouchi, T; Yokota, T: Magnetomyographic evaluation of motor unit size that is robust to changes in distance to sensor BRAIN COMMUNICATIONS. 2025.08; 7 (4): fcaf294. ( PubMed , DOI )

  4. Miura Motoki, Shintaku Hiroshi, Numasawa Yoshiyuki, Ozaki Kokoro, Kanouchi Tadashi, Ishikawa Kinya, Yokota Takanori: 球脊髄性筋萎縮症と多系統萎縮症を合併した1剖検例(An autopsy case of coexisting spinal and bulbar muscular atrophy and multiple system atrophy) NEUROPATHOLOGY. 2025.08; 45 (4): neup.13031. ( 医中誌 )

  5. Ken Sasaki, Toru Sasaki, Akiko Yamamoto, Teruhiko Sekiguchi, Yoshiaki Wakabayashi: Functional Recovery of Posterior Interosseous Nerve Injury Treated With a Nerve Conduit: A Case Report. Cureus. 2025.05; 17 (5): e83303. ( PubMed , DOI )

  6. Hiroaki Nozawa, Sono Ito, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Shinichi Yamauchi, Yusuke Kinugasa, Yoichi Ajioka, Soichiro Ishihara: Role of Adjuvant Chemotherapy After Surgical Resection of Paraaortic Lymph Node Metastasis from Colorectal Cancer-A Multicenter Retrospective Study Annals of surgical oncology. 2025.04; 32 (4): 2282-2291. ( DOI )

  7. Hirotaka Shinomiya, Kazuto Matsuura, Rikiya Onimaru, Akira Ohkoshi, Yuki Saito, Hiroyuki Tachibana, Kiyoto Shiga, Tsutomu Ueda, Yukinori Asada, Hirokazu Uemura, Takeshi Beppu, Akira Seto, Ryuji Yasumatsu, Mitsuhiko Nakahira, Go Omura, Takahiro Asakage, Shujiro Minami, Takashi Fujii, Yuji Hirayama, Daisuke Yoshida, Kenichi Nakamura, Keita Sasaki, Junki Mizusawa, Haruhiko Fukuda, Akihiro Homma, : Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis. Int J Clin Oncol. 2025.03; 30 (3): 489-496. ( PubMed , DOI )

  1. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. 2024.11; 147 107612. ( PubMed , DOI )

  2. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. 2024.10; 20 (38): 1-11. ( PubMed , DOI )

  3. Nogami, A; Amemiya, HJ; Fujiwara, H; Umezawa, Y; Tohda, S; Nagao, T: Targeting USP14/UCHL5: A Breakthrough Approach to Overcoming Treatment-Resistant FLT3-ITD-Positive AML INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024.10; 25 (19): ( PubMed , DOI )

  4. Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K: Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology. 2024.08; 120 (2): 203-211. ( PubMed , DOI )

  5. Kenji Fueki, Yuta Manabe, Keiichi Sasaki, Katsuhiko Kimoto, Mamoru Hashimoto, Takayuki Ueda, Kumiko Utsumi, Tomohisa Ishikawa, Kazuyoshi Baba, Manabu Ikeda, Takuo Kuboki: Medical-dental collaboration on an exploratory research project on the correlation between cognitive and oral function: The ECCO project. J Prosthodont Res. 2024.07; ( PubMed , DOI )

  6. Umezawa Y, Yoshifuji K, Tanaka K, Nogami A, Nagano K, Tsuji A, Nagao T, Yamamoto M, Kajiwara M, Tohda S, Mori T: Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation. Annals of hematology. 2024.05; 103 (5): 1737-1744. ( PubMed , DOI )

  7. Mai Itoh, Shun Sasaki, Shuji Tohda: Renin-Angiotensin System Inhibitors Suppress the Growth of Leukemia Cells. Anticancer Res. 2024.03; 44 (3): 1183-1192. ( PubMed , DOI )

  8. Kumada H, Itoh M, Tohda S: Effect of Ferroptosis Inducers and Inhibitors on Cell Proliferation in Acute Leukemia. Anticancer research. 2024.03; 44 (3): 1003-1010. ( PubMed , DOI )

  9. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients 2024.02; 65 (3): 378-382. ( PubMed , DOI )

  10. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax 2024.02; 30 (7): 1319-1326. ( PubMed , DOI )

  11. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial 2024.02; 99 (5): 836-843. ( PubMed , DOI )

  12. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. 2024.02; 11 (3): e186-e195. ( PubMed , DOI )

  13. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups 2024.02; 99 (4): 792-796. ( PubMed , DOI )

  14. Goto Y, Nagamine Y, Hanafusa M, Kawahara T, Nawa N, Tateishi U, Ueki Y, Miyamae S, Wakabayashi K, Nosaka N, Miyazaki Y, Tohda S, Fujiwara T: Association of excess visceral fat and severe illness in hospitalized COVID-19 patients in Japan: a retrospective cohort study. International journal of obesity (2005). 2024.01; 48 (5): 674-682. ( PubMed , DOI )

  15. Outcomes of Patients with IDH1-Mutated Myeloid Neoplasms Treated with Olutasidenib 2024; 26 (2): e223-e228.e3. ( PubMed , DOI )

  16. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission 2024; 143 (5): 417-421. ( PubMed , DOI )

  1. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. 2023.12; 79 (2): 297-306. ( PubMed , DOI )

  2. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: a Report From the BCR::ABL1 Pathology Group. 2023.12; 37 (2): 100406. ( PubMed , DOI )

  3. Azusa Yamazaki, Yoko Nukui, Takahiro Kameda, Ryoichi Saito, Yuki Koda, Naoya Ichimura, Shuji Tohda, Ryunosuke Ohkawa: Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality. Sci Rep. 2023.12; 13 (1): 21493. ( PubMed , DOI )

  4. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression 2023.12; 38 (3): 545-556. ( PubMed , DOI )

  5. Early mortality after chemotherapy as a quality indicator—the leukemia perspective 2023.12; 13 (1): 176. ( PubMed , DOI )

  6. Motomura, Y; Yoshifuji, K; Tachibana, T; Takase, H; Arai, A; Tanaka, K; Okada, K; Nogami, A; Umezawa, Y; Sakashita, C; Yamamoto, M; Mori, T; Nagao, T: Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma BRITISH JOURNAL OF HAEMATOLOGY. 2023.12; ( PubMed , DOI )

  7. Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes. 2023.11; 10 (11): e872. ( PubMed , DOI )

  8. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure 2023.10; 98 (10): E281-E284-E284. ( PubMed , DOI )

  9. Tomoko Mizuno, Tadashi Kanouchi, Yumie Tamura, Ko Hirata, Runa Emoto, Tomonori Suzuki, Kenichi Kashimada, Tomohiro Morio: Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports. BMC Neurol. 2023.10; 23 (1): 392. ( PubMed , DOI )

  10. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era 2023.10; 98 (10): 1619-1626. ( PubMed , DOI )

  11. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. 2023.09; 129 (23): 3805-3814. ( PubMed , DOI )

  12. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants 2023.09; 98 (11): 1780-1790. ( PubMed , DOI )

  13. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation 2023.09; 98 (9): 1383-1393. ( PubMed , DOI )

  14. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. 2023.09; 13 (1): 148. ( PubMed , DOI )

  15. The role of therapy in the outcome of patients with myelofibrosis 2023.09; 129 (18): 2828-2835. ( PubMed , DOI )

  16. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. 2023.08; 29 (21): 4352-4360. ( PubMed , DOI )

  17. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. 2023.08; 109 (1): 293-297. ( PubMed , DOI )

  18. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia 2023.08; 203 (4): 581-592. ( PubMed , DOI )

  19. Iida S, Kanouchi T, Hattori T, Kanai K, Nakazato T, Hattori N, Yokota T: Verification of propagation hypothesis in patients with sporadic hand onset amyotrophic lateral sclerosis. Acta neurologica Belgica. 2023.08; 123 (4): 1511-1517. ( PubMed , DOI )

  20. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia 2023.08; 23 (12): 905-910. ( PubMed , DOI )

  21. FIGURE 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma 2023.08; 3 (8): 1435-1446. ( PubMed , DOI )

  22. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results 2023.08; 23 (11): e369-e378-e378. ( PubMed , DOI )

  23. Noguchi K, Itoh M, Ito C, Tohda S: Effects of MYC Inhibitors on the Growth of Acute Leukaemia Cells. Anticancer research. 2023.07; 43 (7): 3023-3028. ( PubMed , DOI )

  24. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. 2023.07; 142 (19): 1647-1657. ( PubMed , DOI )

  25. ROS1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients. 2023.07; 36 (11): 100294. ( PubMed , DOI )

  26. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. 2023.06; 7 (11): 2378-2387. ( PubMed , DOI )

  27. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results 2023.05; 23 (10): 742-748. ( PubMed , DOI )

  28. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. 2023.05; 10 (6): e433-e444-e444. ( PubMed , DOI )

  29. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results 2023.05; 37 (5): 1048-1059. ( PubMed , DOI )

  30. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. 2023.05; 7 e2200707. ( PubMed , DOI )

  31. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution 2023.05; 99 (2): 329-330. ( PubMed , DOI )

  32. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. 2023.05; 16 (1): 44. ( PubMed , DOI )

  33. Management of chronic myeloid leukemia in 2023 – common ground and common sense 2023.04; 13 (1): 58. ( PubMed , DOI )

  34. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia 2023.04; 127 107044. ( PubMed , DOI )

  35. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. 2023.04; 98 (4): E91-E94-E94. ( PubMed , DOI )

  36. Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities 2023.04; 15 (8): ( PubMed , DOI )

  37. Association between bariatric surgery and outcomes in chronic myeloid leukemia. 2023.03; 129 (12): 1866-1872. ( PubMed , DOI )

  38. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. 2023.03; 37 (3): 617-626. ( PubMed , DOI )

  39. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. 2023.03; 7 (13): 3284-3296. ( PubMed , DOI )

  40. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). 2023.03; 108 (9): 2331-2342. ( PubMed , DOI )

  41. Early Caffeine Therapy on the Prevention of Severe Hyperkalemia in Preterm Infants. 2023.03; 65 (1): e15526. ( PubMed , DOI )

  42. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. 2023.03; 129 (12): 1856-1865. ( PubMed , DOI )

  43. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. 2023.03; 98 (3): 493-501. ( PubMed , DOI )

  44. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. 2023.03; 7 (6): 933-942. ( PubMed , DOI )

  45. Takatsuki Y., Takahashi Y., Nakajima J., Iwasaki Y., Nagano K., Tani-Sassa C., Yuasa S., Kanehira S., Sonobe K., Nukui Y., Takeuchi H., Tanimoto K., Tanaka Y., Kimura A., Ichimura N., and Tohda S.: Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite higher infectivity of BA.5. Immunity, Inflammation and Disease. 2023.02; 11 (2): e783. ( PubMed , DOI )

  46. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. 2023.02; 129 (4): 560-568. ( PubMed , DOI )

  47. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring 2023.02; 64 (3): 746-749. ( PubMed , DOI )

  48. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. 2023.01; 29 (1): 115-126. ( PubMed , DOI )

  49. Current Understanding of DDX41 Mutations in Myeloid Neoplasms. 2023.01; 15 (2): ( PubMed , DOI )

  50. Yoshihiro Umezawa, Koji Sasaki: Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol. 2023.01; 117 (1): 24-29. ( PubMed , DOI )

  51. Hanafusa M, Nawa N, Goto Y, Kawahara T, Miyamae S, Ueki Y, Nosaka N, Wakabayashi K, Tohda S, Tateishi U, Fujiwara T*: Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: a hospital-based observational study. J Med Virol. 2023.01; 95 (1): e28168. ( PubMed , DOI )

  52. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1 2023; 37 (6): 1336-1348. ( PubMed , DOI )

  53. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia 2023; 129 (7): 1017-1029. ( PubMed , DOI )

  54. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations 2023; 37 (6): 1397-1400. ( PubMed , DOI )

  55. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib 2023; 26 (1): 915-923. ( PubMed , DOI )

  56. Oba S, Hosoya T, Kaneshige R, Kawata D, Yamaguchi T, Mitsumura T, Shimada S, Shibata S, Tateishi T, Koike R, Tohda S, Hirakawa A, Yoko N, Otomo Y, Nojima J, Miyazaki Y, Yasuda S: Thrombosis and antiphospholipid antibodies in Japanese COVID-19: based on propensity score matching. Frontiers in immunology. 2023; 14 1227547. ( PubMed , DOI )

  57. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor 2023; 98 (4): 639-644. ( PubMed , DOI )

  58. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors 2023; 98 (4): 658-665. ( PubMed , DOI )

  1. Nagao T, Yoshifuji K, Sadato D, Motomura Y, Saito M, Yamamoto K, Yamamoto K, Nogami A: Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. Experimental hematology. 2022.12; 116 37-49. ( PubMed , DOI )

  2. Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS) 2022.11; 140 6952-6954. ( DOI )

  3. Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy 2022.11; 140 9626-9628. ( DOI )

  4. Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab 2022.11; 140 11663-11665. ( DOI )

  5. Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy 2022.11; 140 8652-8654. ( DOI )

  6. Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study 2022.11; 140 11698-11701. ( DOI )

  7. Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia 2022.11; 140 3895-3896. ( DOI )

  8. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia 2022.11; 140 1493-1494. ( DOI )

  9. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML 2022.11; 140 ( DOI )

  10. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies 2022.11; 140 11830-11832. ( DOI )

  11. More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia 2022.11; 140 3897-3899. ( DOI )

  12. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure 2022.11; 140 6206-6208. ( DOI )

  13. A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow- 2022.11; 140 9005-9007. ( DOI )

  14. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph plus ) Acute Myeloid Leukemia (AML) 2022.11; 140 3880-3882. ( DOI )

  15. Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome 2022.11; 140 9793-9795. ( DOI )

  16. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia 2022.11; 140 3253-3255. ( DOI )

  17. A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA 2022.11; 140 6739-6741. ( DOI )

  18. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. 2022.11; 36 (11): 2729-2733. ( PubMed , DOI )

  19. ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI) 2022.11; 140 6784-6786. ( DOI )

  20. Aplastic anemia following the severe acute respiratory syndrome coronavirus-2 vaccine. 2022.11; 4 (1): 288-90. ( PubMed , DOI )

  21. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data 2022.11; 140 ( DOI )

  22. Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype 2022.11; 140 7844-7845. ( DOI )

  23. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. 2022.11; 97 (11): 1443-1452. ( PubMed , DOI )

  24. Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients 2022.11; 140 4042-4044. ( DOI )

  25. Ohara M, Sanjo N, Kanouchi T, Yokota T: Entrapment partly participates in the longitudinal progression of neuropathy with anti-MAG antibodies. Revue neurologique. 2022.11; 179 (1-2): 118-122. ( PubMed , DOI )

  26. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis 2022.11; 140 ( DOI )

  27. Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression 2022.11; 140 ( DOI )

  28. Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia 2022.11; 140 2007-2009. ( DOI )

  29. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia 2022.11; 140 ( DOI )

  30. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2022.11; 140 9050-9053. ( DOI )

  31. Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study 2022.11; 140 9041-9043. ( DOI )

  32. Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1 2022.11; 140 5860-5861. ( DOI )

  33. Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53 2022.11; 140 8807-8808. ( DOI )

  34. Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results 2022.11; 140 3250-3252. ( DOI )

  35. Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype 2022.11; 140 1353-1354. ( DOI )

  36. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia 2022.11; 140 1427-1429. ( DOI )

  37. Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies 2022.11; 140 6328-6330. ( DOI )

  38. The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study 2022.11; 140 8966-8968. ( DOI )

  39. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. 2022.11; 115 44-53. ( PubMed , DOI )

  40. A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia 2022.10; 22 S239-S240. ( DOI )

  41. Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients 2022.10; 22 S201-S202. ( DOI )

  42. Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial 2022.10; 22 S300. ( DOI )

  43. Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration 2022.10; 22 S233-S234. ( PubMed , DOI )

  44. Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome 2022.10; 22 S310. ( DOI )

  45. Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia 2022.10; 22 S291. ( DOI )

  46. Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2022.10; 22 S204. ( DOI )

  47. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. 2022.10; 12 (10): 144. ( PubMed , DOI )

  48. Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update 2022.10; 22 S295-S296. ( DOI )

  49. Yoshifuji Kota, Sasaki Koji: Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia FRONTIERS IN ONCOLOGY. 2022.10; 12 1021662. ( PubMed , DOI )

  50. The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34) 2022.10; 22 S258. ( DOI )

  51. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS 2022.09; 1 (10): ( DOI )

  52. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. 2022.09; 63 (9): 2161-2170. ( PubMed , DOI )

  53. Takahiro Mitsumura, Tsukasa Okamoto, Mizuho Tosaka, Takashi Yamana, Sho Shimada, Yuki Iijima, Rie Sakakibara, Sho Shibata, Takayuki Honda, Tsuyoshi Shirai, Masahiro Ishizuka, Junichi Aiboshi, Haruhiko Furusawa, Tomoya Tateishi, Meiyo Tamaoka, Hidenobu Shigemitsu, Hirokuni Arai, Yasuhiro Otomo, Shuji Tohda, Tatsuhiko Anzai, Kunihiko Takahashi, Shinsuke Yasuda, Yasunari Miyazaki: Association of SARS-CoV-2 RNA Copy Number with the COVID-19 Mortality Rate and Its Effect on the Predictive Performance of Mortality in Severe Cases. Jpn J Infect Dis. 2022.09; 75 (5): 504-510. ( PubMed , DOI )

  54. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. 2022.09; 35 (9): 1212-1219. ( PubMed , DOI )

  55. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance 2022.09; 36 (9): 2306-2316. ( PubMed , DOI )

  56. Nogami A., Sasaki K.: Therapeutic Advances in Immunotherapies for Hematological Malignancies Therapeutic Advances in Immunotherapies for Hematological Malignancies. International Journal of Molecular Sciences . 2022.09; 23 11526.

  57. Mitsumura Takahiro, Okamoto Tsukasa, Tosaka Mizuho, Yamana Takashi, Shimada Sho, Iijima Yuki, Sakakibara Rie, Shibata Sho, Honda Takayuki, Shirai Tsuyoshi, Ishizuka Masahiro, Aiboshi Junichi, Furusawa Haruhiko, Tateishi Tomoya, Tamaoka Meiyo, Shigemitsu Hidenobu, Arai Hirokuni, Otomo Yasuhiro, Tohda Shuji, Anzai Tatsuhiko, Takahashi Kunihiko, Yasuda Shinsuke, Miyazaki Yasunari: Association of SARS-CoV-2 RNA Copy Number with the COVID-19 Mortality Rate and Its Effect on the Predictive Performance of Mortality in Severe Cases(タイトル和訳中) Japanese Journal of Infectious Diseases. 2022.09; 75 (5): 504-510. ( 医中誌 )

  58. Real‐life incidence of thrombotic events in leukemia patients treated with ponatinib 2022.09; 97 (9): E350-E352-E352. ( PubMed , DOI )

  59. Transcatheter arterial embolization for hemothorax caused by spinal fracture without arterial injury: a case report and review of the literature. 2022.09; 16 (1): 332. ( PubMed , DOI )

  60. Therapeutic Advances in Immunotherapies for Hematological Malignancies. 2022.09; 23 (19): ( PubMed , DOI )

  61. Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis 2022.08; 97 (11): 1413-1418. ( PubMed , DOI )

  62. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. 2022.08; 97 (8): 1035-1043. ( PubMed , DOI )

  63. Yusuke Ota, Chihiro Tani Sassa, Masayo Kashiwagi, Chikako Okawara, Shuji Tohda, Ryoichi Saito: Complete Genome Sequence of an Enterobacter roggenkampii Strain with Reduced Carbapenem Susceptibility Isolated from a Home-Visit Nursing Agency. Microbiol Resour Announc. 2022.08; e0035322. ( PubMed , DOI )

  64. TP53 ‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis 2022.08; 97 (8): 1005-1012. ( PubMed , DOI )

  65. Yuasa S, Nakajima J, Takatsuki Y, Takahashi Y, Tani-Sassa C, Iwasaki Y, Nagano K, Sonobe K, Yoshimoto T, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Ichimura N, Tohda S.: Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity Journal of Medical Virology. 2022.07; 94 (11): 5543-5546. ( PubMed , DOI )

  66. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. 2022.07; 97 (7): 885-894. ( PubMed , DOI )

  67. Prediction of survival with intensive chemotherapy in acute myeloid leukemia 2022.07; 97 (7): 865-876. ( PubMed , DOI )

  68. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. 2022.06; 40 (16): E19029. ( DOI )

  69. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia 2022.06; 98 (1): E11-E14-E14. ( PubMed , DOI )

  70. Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission. 2022.06; 40 (16): E19018.

  71. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy 2022.06; 97 (9): 1127-1134. ( PubMed , DOI )

  72. A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL). 2022.06; 40 (16):

  73. A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). 2022.06; 40 (16):

  74. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality. 2022.06; 40 (16):

  75. Hamada Satomi, Sasaki Kanae, Kito Hotaka, Tooyama Yui, Ihara Kensuke, Aoyagi Eiko, Ichimura Naoya, Tohda Shuji, Sasano Tetsuo: Effect of the recording condition on the quality of a single-lead electrocardiogram(和訳中) Heart and Vessels. 2022.06; 37 (6): 1010-1026. ( 医中誌 )

  76. Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors. 2022.06; 40 (16):

  77. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 2022.06; 374 (33): 3848-3857. ( PubMed , DOI )

  78. Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10-4 and Higher. 2022.06; 97 (9): 1135-1141. ( PubMed , DOI )

  79. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after >= 2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. 2022.06; 40 (16):

  80. Ryo Iwase, Tadashi Kanouchi, Toshitaka Yoshii, Taro Ishiguro, Takashi Hirai, Atsushi Okawa, Takanori Yokota, Nobuo Sanjo: Diverging pathophysiology in superficial siderosis with proximal upper limb amyotrophy. J Neurol Sci. 2022.05; 436 120248. ( PubMed , DOI )

  81. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. 2022.05; 12 (5): 77. ( PubMed , DOI )

  82. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. 2022.05; 9 (5): e350-e360-e360. ( PubMed , DOI )

  83. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. 2022.05; 14 (10): ( PubMed , DOI )

  84. Improved survival of patients with myelofibrosis in the last decade: Single‐center experience 2022.04; 128 (8): 1658-1665. ( PubMed , DOI )

  85. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia 2022.04; 63 (7): 1-4. ( PubMed , DOI )

  86. Saito Tatsuya, Itoh M. A. I., Tohda Shuji: TYRO3 Knockdown Suppresses the Growth of Myeloid Leukaemia Cells ANTICANCER RESEARCH. 2022.04; 42 (4): 1757-1761. ( PubMed , DOI )

  87. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Osamu Miura, Norihiko Kawamata: A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells. International Journal of Molecular Medicine. 2022.04; 49 (4): ( PubMed , DOI )

  88. Tani-Sassa C, Iwasaki Y, Ichimura N, Nagano K, Takatsuki Y, Yuasa S, Takahashi Y, Nakajima J, Sonobe K, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Tohda S.: Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo Journal of Medical Virology. 2022.04; 94 (4): 1707-1710. ( PubMed , DOI )

  89. Ryoichi Saito, Jun Nakajima, Isaac Prah, Masatomo Morita, Samiratu Mahazu, Yusuke Ota, Ayuka Kobayashi, Shuji Tohda, Hajime Kamiya, Hideyuki Takahashi, Makoto Ohnishi: Penicillin- and Ciprofloxacin-Resistant Invasive Neisseria meningitidis Isolates from Japan. Microbiol Spectr. 2022.04; e0062722. ( PubMed , DOI )

  90. Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification 2022.03; 97 (3): 329-337. ( PubMed , DOI )

  91. Major and minor complications of the pancreas after transcatheter arterial embolization using n-butyl-2-cyanoacrylate for acute bleeding from pancreatic arteries. 2022.03; 40 (3): 308-317. ( PubMed , DOI )

  92. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab 2022.03; 97 (6): E201-E204-E204. ( PubMed , DOI )

  93. Treatment‐Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors 2022.03; 97 (7): 856-864. ( PubMed , DOI )

  94. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib 2022.02; 36 (5): 1253-1260. ( PubMed , DOI )

  95. Kawahara Tomoki, Ueki Yutaka, Nawa Nobutoshi, Miyamae Shigeru, Hanafusa Mariko, Goto Yuki, Tohda Shuji, Fujiwara Takeo: Characteristics of SARS-CoV-2 super-spreaders in Japan JOURNAL OF INFECTION. 2022.02; 84 (2): e6-e9. ( PubMed , DOI )

  96. Kameda Takahiro, Horiuchi Yuna, Shimano Shitsuko, Yano Kouji, Lai Shao-Jui, Ichimura Naoya, Tohda Shuji, Kurihara Yuriko, Tozuka Minoru, Ohkawa Ryunosuke: Effect of myeloperoxidase oxidation and N-homocysteinylation of high-density lipoprotein on endothelial repair function BIOLOGICAL CHEMISTRY. 2022.02; 403 (3): 265-277. ( PubMed , DOI )

  97. Yamada Toru, Suzuki Risa, Ichimura Naoya, Mabuchi Suguru, Nagamine Yuiko, Sassa Chihiro, Tohda Shuji: Clinical Evaluation of Reverse Transcription-Polymerase Chain Reaction and Rapid Antigen Tests of Tongue Swabs for Detecting COVID-19(和訳中) Journal of Hospital General Medicine. 2022.01; 4 (1): 12-20. ( 医中誌 )

  98. Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy 2022.01; 97 (1): 68-78. ( PubMed , DOI )

  99. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD 2022.01; 6 (10): 3027-3035. ( PubMed , DOI )

  100. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) 2022.01; 12 (1): 5. ( PubMed , DOI )

  1. Yusuke Ota, Natsune Hongou, Yoko Nukui, Ryuji Koike, Shuji Tohda, Ryoichi Saito: Evaluation of polymerase chain reaction-based open reading frame typing method for the clonality investigation of Clostridioides difficile isolates. Anaerobe. 2021.12; 72 102462. ( PubMed , DOI )

  2. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. 2021.12; 35 (12): 3421-3429. ( PubMed , DOI )

  3. Prediction for sustained deep molecular response for treatment-free remission. 2021.12; 63 (1): 5-6. ( PubMed , DOI )

  4. Efficacy of superselective transcatheter arterial embolization for intractable postpartum hemorrhage due to genital tract trauma after vaginal delivery. 2021.12; 28 (6): 1127-1133. ( PubMed , DOI )

  5. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents 2021.11; 138 ( DOI )

  6. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First -in -Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after >= 2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks 2021.11; 138 ( DOI )

  7. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML 2021.11; 138 ( DOI )

  8. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2021.11; 138 ( DOI )

  9. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

  10. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission 2021.11; 138 ( DOI )

  11. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

  12. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study 2021.11; 138 ( DOI )

  13. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) 2021.11; 138 ( DOI )

  14. Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors 2021.11; 138 ( DOI )

  15. Disease Characteristics of Multiple Myeloma Involving BRAF Mutations 2021.11; 138 ( DOI )

  16. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVADBased Chemotherapy 2021.11; 138 ( DOI )

  17. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study 2021.11; 138 ( DOI )

  18. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups 2021.11; 138 ( DOI )

  19. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2021.11; 138 ( DOI )

  20. General Characteristics and Association of Myeloid Neoplasm with Thyroid Cancer 2021.11; 138 ( DOI )

  21. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML 2021.11; 138 ( DOI )

  22. Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy 2021.11; 138 ( DOI )

  23. Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study 2021.11; 138 ( DOI )

  24. Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations 2021.11; 138 ( DOI )

  25. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. 2021.11; 106 (11): 2853-2858. ( PubMed , DOI )

  26. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial 2021.11; 138 ( DOI )

  27. The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors 2021.11; 138 ( DOI )

  28. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. 2021.11; 138 (18): 1733-1739. ( PubMed , DOI )

  29. Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML 2021.11; 138 ( DOI )

  30. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 2021.11; 138 ( DOI )

  31. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. 2021.10; 127 (19): 3552-3565. ( PubMed , DOI )

  32. Takayuki Kuroda, Miho Akaza, Kazunori Miki, Shoko Fujii, Yousuke Yagi, Tadashi Kanouchi, Nobuo Sanjo, Kazutaka Sumita, Takanori Yokota: Sacral dural arteriovenous fistula mimicking multiple mononeuropathy. Clin Neurol Neurosurg. 2021.10; 210 106993. ( PubMed , DOI )

  33. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. 2021.10; 127 (19): 3541-3551. ( PubMed , DOI )

  34. Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center 2021.09; 21 S361.

  35. A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R) 2021.09; 21 S351.

  36. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. 2021.09; 11 (9): 162. ( PubMed , DOI )

  37. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. 2021.09; 62 (14): 3501-3505. ( PubMed , DOI )

  38. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. 2021.09; 39 (25): 2768-2778. ( PubMed , DOI )

  39. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia 2021.09; 21 S291.

  40. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. 2021.09; 127 (18): 3381-3389. ( PubMed , DOI )

  41. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. 2021.09; 127 (17): 3113-3124. ( PubMed , DOI )

  42. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. 2021.08; 138 (21): 2031-2041. ( PubMed , DOI )

  43. Ibrutinib plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial 2021.08; 7 (8): 1213-1219. ( PubMed , DOI )

  44. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. 2021.08; 127 (15): 2641-2647. ( PubMed , DOI )

  45. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. 2021.08; 127 (15): 2648-2656. ( PubMed , DOI )

  46. Takahiro Kameda, Yuna Horiuchi, Shitsuko Shimano, Kouji Yano, Shao-Jui Lai, Naoya Ichimura, Shuji Tohda, Yuriko Kurihara, Minoru Tozuka, Ryunosuke Ohkawa: N-homocysteinylation of high-density lipoprotein on endothelial repair function. Biol Chem. 2021.08; ( PubMed , DOI )

  47. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia 2021.08; 62 (14): 3402-3410. ( PubMed , DOI )

  48. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. 2021.07; 127 (20): 3772-3781. ( PubMed , DOI )

  49. Nagano K, Tani-Sassa C, Iwasaki Y, Takatsuki Y, Yuasa S, Takahashi Y, Nakajima J, Sonobe K, Ichimura N, Nukui Y, Takeuchi H, Tanimoto K, Tanaka Y, Kimura A, Tohda S: SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021. Journal of medical virology. 2021.07; 93 (12): 6833-6836. ( PubMed , DOI )

  50. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. 2021.07; 194 (2): 414-422. ( PubMed , DOI )

  51. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. 2021.07; 127 (14): 2489-2499. ( PubMed , DOI )

  52. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. 2021.07; 194 (1): 61-68. ( PubMed , DOI )

  53. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). 2021.07; 96 (7): E246-E249-E249. ( PubMed , DOI )

  54. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. 2021.06; 127 (12): 2025-2038. ( PubMed , DOI )

  55. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. 2021.06; 96 (6): 650-658. ( PubMed , DOI )

  56. Mitsumura Takahiro, Okamoto Tsukasa, Shirai Tsuyoshi, Iijima Yuki, Sakakibara Rie, Honda Takayuki, Ishizuka Masahiro, Aiboshi Junichi, Tateishi Tomoya, Tamaoka Meiyo, Shigemitsu Hidenobu, Arai Hirokuni, Otomo Yasuhiro, Tohda Shuji, Anzai Tatsuhiko, Takahashi Kunihiko, Yasuda Shinsuke, Miyazaki Yasunari: Predictors associated with clinical improvement of SARS-CoV-2 pneumonia(和訳中) Journal of Infection and Chemotherapy. 2021.06; 27 (6): 857-863. ( 医中誌 )

  57. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. 2021.06; 127 (12): 2049-2061. ( PubMed , DOI )

  58. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. 2021.06; 14 (1): 94. ( PubMed , DOI )

  59. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. 2021.05; 35 (5): 1494-1499. ( PubMed , DOI )

  60. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. 2021.05; 39 (15): ( DOI )

  61. Current status and novel strategy of CML. 2021.05; 113 (5): 624-631. ( PubMed , DOI )

  62. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. 2021.05; 96 (5): E154-E157-E157. ( PubMed , DOI )

  63. Samra, B; Kantarjian, HM; Sasaki, K; Alotaibi, AS; Konopleva, M; O'Brien, S; Ferrajoli, A; Garris, R; Nunez, CA; Kadia, TM; Short, NJ; Jabbour, E: Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant ACTA HAEMATOLOGICA. 2021.05; 144 (3): 285-292. ( PubMed , DOI )

  64. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. 2021.05; 96 (5): 589-598. ( PubMed , DOI )

  65. Azusa Yamazaki, Ryunosuke Ohkawa, Yuka Yamagata, Yuna Horiuchi, Shao-Jui Lai, Takahiro Kameda, Naoya Ichimura, Shuji Tohda, Minoru Tozuka: Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL). Biol Chem. 2021.05; 402 (4): 439-449. ( PubMed , DOI )

  66. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. 2021.05; 21 (5): 338-344. ( PubMed , DOI )

  67. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). 2021.05; 39 (15): ( DOI )

  68. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. 2021.04; 5 (8): 2173-2183. ( PubMed , DOI )

  69. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. 2021.04; 106 (4): 1097-1105. ( PubMed , DOI )

  70. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. 2021.04; 5 (7): 1876-1883. ( PubMed , DOI )

  71. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. 2021.03; 106 (3): 894-898. ( PubMed , DOI )

  72. Yamazaki Azusa, Ohkawa Ryunosuke, Yamagata Yuka, Horiuchi Yuna, Lai Shao-Jui, Kameda Takahiro, Ichimura Naoya, Tohda Shuji, Tozuka Minoru: Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)(2) and the larger HDL3 from very low-density lipoprotein (VLDL) BIOLOGICAL CHEMISTRY. 2021.03; 402 (4): 439-449. ( PubMed , DOI )

  73. Maiti, A; Qiao, W; Sasaki, K; Ravandi, F; Kadia, TM; Jabbour, EJ; Daver, NG; Borthakur, G; Garcia-Manero, G; Pierce, SA; Montalbano, KS; Pemmaraju, N; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Takahashi, K; Yilmaz, M; Jain, N; Kornblau, SM; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Masarova, L; Thompson, PA; Rausch, CR; Ning, J; Kantarjian, HM; DiNardo, CD; Konopleva, MY: Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality AMERICAN JOURNAL OF HEMATOLOGY. 2021.03; 96 (3): 282-291. ( PubMed , DOI )

  74. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. 2021.03; 11 (3): 52. ( PubMed , DOI )

  75. Shoukier, M; Kadia, T; Konopleva, M; Alotaibi, AS; Alfayez, M; Loghavi, S; Patel, KP; Kanagal-Shamanna, R; Cortes, J; Samra, B; Jabbour, E; Garcia-Manero, G; Takahashi, K; Pierce, S; Short, NJ; Yilmaz, M; Sasaki, K; Masarova, L; Pemmaraju, N; Borthakur, G; Kantarjian, HM; Ravandi, F; DiNardo, CD; Daver, N: Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations CANCER. 2021.02; 127 (3): 381-390. ( PubMed , DOI )

  76. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. 2021.02; 101 106511. ( PubMed , DOI )

  77. Mitsumura T, Okamoto T, Shirai T, Iijima Y, Sakakibara R, Honda T, Ishizuka M, Aiboshi J, Tateishi T, Tamaoka M, Shigemitsu H, Arai H, Otomo Y, Tohda S, Anzai T, Takahashi K, Yasuda S, Miyazaki Y: Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2021.02; 27 (6): 857-863. ( PubMed , DOI )

  78. Montalban-Bravo, G; Kanagal-Shamanna, R; Guerra, V; Ramos-Perez, J; Hammond, D; Shilpa, P; Naqvi, K; Sasaki, K; Jabbour, E; DiNardo, C; Takahashi, K; Konopleva, M; Pemmaraju, N; Kadia, T; Ravandi, F; Daver, N; Borthakur, G; Estrov, Z; Khoury, JD; Loghavi, S; Pierce, S; Bueso-Ramos, C; Patel, K; Kantarjian, H; Garcia-Manero, G: Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia AMERICAN JOURNAL OF HEMATOLOGY. 2021.02; 96 (2): E52-E55. ( PubMed , DOI )

  79. Sasaki, K; Jabbour, EJ; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, N; Takahashi, K; Naqvi, K; DiNardo, C; Montalban-Bravo, G; Kanagal-Shamanna, R; Issa, G; Jain, P; Skinner, J; Rios, MB; Pierce, S; Soltysiak, KA; Sato, J; Garcia-Manero, G; Cortes, JE: The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes AMERICAN JOURNAL OF HEMATOLOGY. 2021.02; 96 (2): 241-250. ( PubMed , DOI )

  80. Yilmaz, M; Kantarjian, HM; Toruner, G; Yin, CC; Kanagal-Shamanna, R; Cortes, JE; Issa, G; Short, NJ; Khoury, JD; Garcia-Manero, G; Ravandi, F; Kadia, T; Konopleva, M; Wierda, WG; Jain, N; Estrov, Z; Sasaki, K; Pierce, S; O'Brien, SM; Jabbour, EJ: Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis LEUKEMIA & LYMPHOMA. 2021.01; 62 (1): 224-228. ( PubMed , DOI )

  81. Fumi Nakamura, Honoka Arai, Yasuhito Nannya, Motoshi Ichikawa, Shiho Furuichi, Fusako Nagasawa, Wataru Takahashi, Tomoyuki Handa, Yuko Nakamura, Hiroko Tanaka, Yuka Nakamura, Ko Sasaki, Satoru Miyano, Seishi Ogawa, Kinuko Mitani: Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy. Int J Hematol. 2021.01; Online ahead of print (6): 936-940. ( PubMed , DOI )

  82. Jang, JH; Tomiyama, Y; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Enokitani, K; Matsuda, A; Ozawa, K; Mitani, K; Lee, JW; Nakao, S: Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study BRITISH JOURNAL OF HAEMATOLOGY. 2021.01; 192 (1): 190-199. ( PubMed , DOI )

  83. Sasaki, K; Nannya, Y; Nakamura, Y; Ichikawa, M; Ogawa, S; Mitani, K: Essential thrombocythaemia with aggressive megakaryocytosis after myelofibrotic transformation HEMATOLOGY. 2021.01; 26 (1): 594-600. ( PubMed , DOI )

  84. Nakamura, F; Arai, H; Tokita, K; Furuichi, S; Sugita-Nagasawa, F; Takahashi, W; Handa, T; Iso, H; Tadokoro, J; Tsurumi, S; Nakamura, Y; Nakamura, Y; Sasaki, K; Seo, S; Ichikawa, M; Mitani, K: PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma LEUKEMIA & LYMPHOMA. 2021.01; 62 (1): 239-242. ( PubMed , DOI )

  85. Sonoda Yuri, Itoh Mai, Tohda Shuji: Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells ANTICANCER RESEARCH. 2021; 41 (4): 1841-1847. ( PubMed , DOI )

  86. Shitsuko Shimano, Ryunosuke Ohkawa, Mayu Nambu, Mai Sasaoka, Azusa Yamazaki, Yuki Fujii, Yuna Horiuchi, Shao-Jui Lai, Takahiro Kameda, Naoya Ichimura, Koji Fujita, Shuji Tohda, Minoru Tozuka: Marked Changes in Serum Amyloid A Distribution and High-Density Lipoprotein Structure during Acute Inflammation. Biomed Res Int. 2021; 2021 9241259. ( PubMed , DOI )

  87. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S: Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Frontiers in cardiovascular medicine. 2021; 8 767074. ( PubMed , DOI )

  88. Kuboki Mai, Umezawa Yoshihiro, Motomura Yotaro, Okada Keigo, Nogami Ayako, Nagao Toshikage, Miura Osamu, Yamamoto Masahide: Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment IN VIVO. 2021; 35 (6): 3407-3411. ( PubMed , DOI )

  1. Maiti, A; Franquiz, MJ; Ravandi, F; Cortes, JE; Jabbour, EJ; Sasaki, K; Marx, K; Daver, NG; Kadia, TM; Konopleva, MY; Masarova, L; Borthakur, G; DiNardo, CD; Naqvi, K; Pierce, S; Kantarjian, HM; Short, NJ: Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias ACTA HAEMATOLOGICA. 2020.12; 143 (6): 567-573. ( PubMed , DOI )

  2. Sasaki, K; Montalban-Bravo, G; Kanagal-Shamanna, R; Jabbour, E; Ravandi, F; Kadia, T; Daver, N; Pemmaraju, N; Konopleva, M; Borthakur, G; Takahashi, K; Patel, K; Soltysiak, KA; Chien, KS; Sakurai, K; Pierce, S; Kantarjian, HM; Garcia-Manero, G: Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3) AMERICAN JOURNAL OF HEMATOLOGY. 2020.12; 95 (12): E326-E329. ( PubMed , DOI )

  3. Guerra, V; Perez, JMR; Hammond, D; Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Paul, S; Kadia, TM; DiNardo, CD; Konopleva, M; Daver, N; Ravandi, F; Pemmaraju, N; Short, NJ; Issa, GC; Takahashi, K; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Bravo, GM: Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure BLOOD. 2020.11; 136 ( DOI )

  4. Bravo, GM; Jabbour, E; Kadia, TM; Ravandi, F; Estrov, ZE; Naqvi, K; Sasaki, K; Chien, KS; González, GMN; Dong, XQ; Faderl, S; Schneider, H; John, RB; Kantarjian, HM; Garcia-Manero, G: Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents BLOOD. 2020.11; 136 ( DOI )

  5. Sasaki, K; Jabbour, E; Issa, GC; Garcia-Manero, G; Kadia, TM; Wierda, WG; Yilmaz, M; DiNardo, CD; Skinner, J; Khouri, M; Pemmaraju, N; Nasnas, P; Pierce, SA; Cortes, JE; Kantarjian, HM: Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors BLOOD. 2020.11; 136 ( DOI )

  6. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia 2020.11; 136 ( DOI )

  7. Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML 2020.11; 136 ( DOI )

  8. Morita, K; Bravo, GM; Sasaki, K; Bodden, KR; Wang, F; Bose, P; Alvarado, Y; Daver, N; Borthakur, G; Ravandi, F; Takahashi, K; Jabbour, E; DiNardo, CD; Pemmaraju, N; Kadia, TM; Ohanian, M; Pierce, SA; Azab, M; Kantarjian, HM; Garcia-Manero, G: Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) BLOOD. 2020.11; 136 ( DOI )

  9. Perez, JMR; Kadia, TM; Montalban-Bravo, G; Faderl, S; Sasaki, K; Daver, N; DiNardo, CD; Masarova, L; Ferrajoli, A; Jabbour, E; Borthakur, G; Al Azzawi, H; Pemmaraju, N; Konopleva, M; Pierce, SA; Garcia-Manero, G; Andreeff, M; Kantarjian, HM; Ravandi, F; Alvarado, Y: Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) BLOOD. 2020.11; 136 ( DOI )

  10. Sasaki, K; Jabbour, E; Bravo, GM; Short, NJ; Kanagal-Shamanna, R; Kadia, TM; Borthakur, G; Pemmaraju, N; Cortes, JE; Ravandi, F; Alvarado, Y; Chien, KS; Yang, H; Kantarjian, HM; Garcia-Manero, G: Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

  11. Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Jain, N; Konopleva, M; Garcia-Manero, G; Champlin, RE; Kadia, TM; Takahashi, K; Daver, N; Rafei, H; Khoury, JD; Jorgensen, JL; Wang, SA; Khouri, MR: Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial BLOOD. 2020.11; 136 ( DOI )

  12. Morita, K; Kantarjian, HM; Bravo, GM; Sasaki, K; Daver, N; Jabbour, E; Alvarado, Y; Chien, KS; DiNardo, CD; Ravandi, F; Borthakur, G; Bose, P; Pemmaraju, N; Naqvi, K; Cortes, JE; Kadia, TM; Konopleva, M; Rausch, CR; Gasior, Y; Garcia-Manero, G: A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) BLOOD. 2020.11; 136 ( DOI )

  13. A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab 2020.11; 136 ( DOI )

  14. Kanagal-Shamanna, R; Bravo, GM; Sasaki, K; Bueso-Ramos, CE; Jabbour, E; Wei, Y; Darbaniyan, F; Routbort, M; Pierce, SA; Soltysiak, KA; Patel, K; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G: Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes BLOOD. 2020.11; 136 ( DOI )

  15. Hammond, D; DiNardo, CD; Konopleva, M; Borthakur, G; Perez, JMR; Guerra, VA; Kanagal-Shamanna, R; Paul, S; Naqvi, K; Sasaki, K; Jabbour, E; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G: Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation BLOOD. 2020.11; 136 ( DOI )

  16. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response 2020.11; 136 ( DOI )

  17. Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, G; Takahashi, K; Estrov, ZE; Sasaki, K; Fowler, NH; Kadia, TM; Konopleva, M; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Kanagal-Shamanna, R; Patel, K; Wang, W; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Cruz, N; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG: Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results BLOOD. 2020.11; 136 ( DOI )

  18. Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis 2020.11; 136 ( DOI )

  19. Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression 2020.11; 136 ( DOI )

  20. Morita, K; Kantarjian, HM; Ravandi, F; Sasaki, K; Jain, N; Konopleva, M; Short, NJ; Takahashi, K; Khouri, R; Nasnas, P; DiNardo, CD; Kadia, TM; Garcia-Manero, G; Daver, N; Bravo, GM; Issa, GC; Cortes, JE; Jabbour, E: Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib BLOOD. 2020.11; 136 ( DOI )

  21. Rafei, H; Kantarjian, HM; Sasaki, K; Short, NJ; Ravandi, F; Huang, XL; Khoury, JD; Wang, SA; Jorgensen, JL; Yin, CC; Khouri, IF; Kebriaei, P; Jain, N; Takahashi, K; Dabaja, BS; Verstovsek, S; Kadia, TM; Paul, S; Rausch, CR; Garcia-Manero, G; Wierda, WG; DiNardo, CD; Daver, N; Montalban-Bravo, G; Yilmaz, M; Nasnas, P; Khouri, R; Kwari, M; Jacob, J; Rostykus, M; Garris, R; Konopleva, M; O'Brien, SM; Jabbour, E: Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

  22. Sasaki, K; Kantarjian, HM; Issa, GC; Garcia-Manero, G; Kadia, TM; Wierda, WG; Yilmaz, M; DiNardo, CD; Skinner, J; Khouri, R; Pemmaraju, N; Nasnas, P; Dellasala, SE; Pierce, SA; Cortes, JE; Jabbour, E: Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors BLOOD. 2020.11; 136 ( DOI )

  23. Darbaniyan, F; Bravo, GM; Wei, Y; Kanagal-Shamanna, R; Sasaki, K; Yang, H; Soltysiak, KA; Chien, KS; Do, KA: Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R BLOOD. 2020.11; 136 ( DOI )

  24. Reville, PK; González, GMN; Ravandi, F; Sasaki, K; Borthakur, G; Garcia-Manero, G; Daver, N; DiNardo, CD; Jabbour, E; Pemmaraju, N; Andreeff, M; Verstovsek, S; Ferrajoli, A; Jain, N; Ohanian, M; Pierce, SA; Estrov, ZE; Konopleva, M; Kantarjian, HM; Kadia, TM: Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort BLOOD. 2020.11; 136 ( DOI )

  25. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study 2020.11; 136 ( DOI )

  26. Hochhaus, A; Boquimpani, C; Rea, D; Minami, Y; Lomaia, E; Voloshin, S; Turkina, AG; Kim, DW; Apperley, J; Cortes, JE; Abdo, A; Fogliatto, LM; Kim, DDH; Le Coutre, PD; Saussele, S; Annunziata, M; Hughes, TP; Chaudhri, NA; Chee, LCY; Gutierrez, VG; Sasaki, K; Aimone, P; Allepuz, A; Quenet, S; Bédoucha, V; Mauro, MJ: Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs BLOOD. 2020.11; 136 ( DOI )

  27. Kanagal-Shamanna, R; Bravo, GM; Katsonis, P; Sasaki, K; Class, C; Benton, CB; Jabbour, E; Chien, KS; Luthra, R; Bueso-Ramos, CE; Kadia, TM; Andreeff, M; Short, NJ; Daver, N; Routbort, M; Khoury, JD; Patel, K; Ganan-Gomez, I; Wei, Y; Borthakur, G; Ravandi, F; Do, KA; Soltysiak, KA; Lichtarge, O; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G: Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis BLOOD. 2020.11; 136 ( DOI )

  28. Cherng, HJJ; Jammal, N; Paul, S; Wang, XM; Sasaki, K; Thompson, PA; Burger, JA; Ferrajoli, A; Estrov, ZE; O'Brien, SM; Keating, MJ; Wierda, WG; Jain, N: Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

  29. Bravo, GM; Kanagal-Shamanna, R; Darbaniyan, F; Ganan-Gomez, I; Sasaki, K; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, KS; Bueso-Ramos, CE; Kantarjian, HM; Garcia-Manero, G: Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) BLOOD. 2020.11; 136 ( DOI )

  30. Major, CK; Kantarjian, H; Sasaki, K; Borthakur, G; Kadia, T; Pemmaraju, N; DiNardo, C; Short, NJ; Daver, N; Jabbour, E; Champlin, R; Garcia-Manero, G; Konopleva, M; Andreeff, M; Kornblau, S; Wierda, W; Pierce, S; Ravandi, F; Cortes, J: Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years LEUKEMIA & LYMPHOMA. 2020.11; 61 (13): 3120-3127. ( PubMed , DOI )

  31. Maiti, A; DiNardo, CD; Wang, SA; Jorgensen, JL; Kadia, TM; Daver, N; Short, NJ; Yilmaz, M; Pemmaraju, N; Borthakur, G; Bose, P; Issa, GC; Ferrajoli, A; Jabbour, E; Jain, N; Garcia-Manero, G; Ohanian, M; Takahashi, K; Montalban-Bravo, G; Masarova, L; Burger, JA; Thompson, PA; Verstovsek, S; Sasaki, K; Andreeff, M; Rausch, CR; Montalbano, K; Pierce, SA; Kantarjian, HM; Konopleva, M; Ravandi, F: Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

  32. Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib 2020.11; 136 ( DOI )

  33. Guerra, VA; Alwash, Y; Yan, YQ; Perez, JMR; Richard-Carpentier, G; Alotaibi, AS; Ahaneku, HO; Samra, B; Raghunath, A; Jain, N; Short, NJ; Ravandi, F; Borthakur, G; Ferrajoli, A; Sasaki, K; Kornblau, SM; Estrov, ZE; Cortes, JE; Kantarjian, HM; Garcia-Manero, G; Jabbour, E; Kadia, TM: Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL) BLOOD. 2020.11; 136 ( DOI )

  34. Perez, JMR; Guerra, VA; Hammond, D; Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Paul, S; Kadia, TM; DiNardo, CD; Konopleva, M; Daver, N; Ravandi, F; Pemmaraju, N; Short, NJ; Takahashi, K; Estrov, ZE; Pierce, SA; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G: Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories BLOOD. 2020.11; 136 ( DOI )

  35. Rafei, H; Kantarjian, HM; Sasaki, K; Short, NJ; Ravandi, F; Huang, XL; Khoury, JD; Wang, SA; Jorgensen, JL; Khouri, IF; Kebriaei, P; Champlin, RE; Jain, N; Dabaja, BS; Issa, GC; Pemmaraju, N; Kadia, TM; Paul, S; Jammal, N; Garcia-Manero, G; Wierda, WG; DiNardo, CD; Daver, N; Montalban-Bravo, G; Khouri, R; Nasnas, P; Thompson, PA; Jacob, J; Rostykus, M; Garris, R; Konopleva, M; O'Brien, SM; Jabbour, E: Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study BLOOD. 2020.11; 136 ( DOI )

  36. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse 2020.11; 136 ( DOI )

  37. Bravo, GM; Kanagal-Shamanna, R; Guerra, V; Perez, JMR; Hammond, D; Paul, S; Naqvi, K; Sasaki, K; Jabbour, E; DiNardo, CD; Takahashi, K; Konopleva, M; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Estrov, ZE; Khoury, JD; Loghavi, S; Pierce, SA; Bueso-Ramos, CE; Patel, K; Kantarjian, HM: Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

  38. Bravo, GM; Kanagal-Shamanna, R; Sasaki, K; Masarova, L; Naqvi, K; Jabbour, E; DiNardo, CD; Takahashi, K; Konopleva, M; Pemmaraju, N; Short, NJ; Issa, GC; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Estrov, ZE; Khoury, JD; Loghavi, S; Pierce, SA; Bueso-Ramos, CE; Patel, K; Verstovsek, S; Kantarjian, HM; Bose, P; Garcia-Manero, G: Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

  39. Sasaki, K; Jabbour, E; Naqvi, K; Skinner, J; Anderson, K; Dellasala, SE; Yilmaz, M; Ferrajoli, A; Bose, P; Thompson, PA; Alvarado, Y; Jain, N; Garcia-Manero, G; Takahashi, K; Burger, JA; Borthakur, G; Pemmaraju, N; Khouri, R; Paul, S; Pierce, SA; Cortes, JE; Kantarjian, HM: The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis BLOOD. 2020.11; 136 ( DOI )

  40. Siddiqui, MT; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Masarova, L; Jabbour, E; Pemmaraju, N; Kadia, TM; Ravandi, F; Daver, N; Borthakur, G; Pierce, SA; Verstovsek, S; Bose, P; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G: Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series BLOOD. 2020.11; 136 ( DOI )

  41. Phase II Study of Venetoclax Added to Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 2020.11; 136 ( DOI )

  42. Bravo, GM; Darbaniyan, F; Kanagal-Shamanna, R; Ganan-Gomez, I; Sasaki, K; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, KS; Bueso-Ramos, CE; Kantarjian, HM; Garcia-Manero, G: Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia BLOOD. 2020.11; 136 ( DOI )

  43. DiNardo, CD; Maiti, A; Rausch, CR; Pemmaraju, N; Naqvi, K; Daver, NG; Kadia, TM; Borthakur, G; Ohanian, M; Alvarado, Y; Issa, GC; Montalban-Bravo, G; Short, NJ; Yilmaz, M; Bose, P; Jabbour, EJ; Takahashi, K; Burger, JA; Garcia-Manero, G; Jain, N; Kornblau, SM; Thompson, PA; Estrov, Z; Masarova, L; Sasaki, K; Verstovsek, S; Ferrajoli, A; Weirda, WG; Wang, SA; Konoplev, S; Chen, ZN; Pierce, SA; Ning, J; Qiao, W; Ravandi, F; Andreeff, M; Welch, JS; Kantarjian, HM; Konopleva, MY: 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial LANCET HAEMATOLOGY. 2020.10; 7 (10): E724-E736. ( PubMed , DOI )

  44. Masarova, L; Bose, P; Pemmaraju, N; Daver, NG; Zhou, LS; Pierce, S; Sasaki, K; Kantarjian, HM; Estrov, Z; Verstovsek, S: Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era CANCER. 2020.10; 126 (19): 4322-4331. ( PubMed , DOI )

  45. Quesada, AE; Montalban-Bravo, G; Luthra, R; Patel, KP; Sasaki, K; Bueso-Ramos, CE; Khoury, JD; Routbort, MJ; Bassett, R; Hidalgo-Lopez, JE; Zhao, C; Lin, P; Loghavi, S; Ok, CY; Kadia, T; DiNardo, CD; Kantarjian, H; Garcia-Manero, G; Kanagal-Shamanna, R: Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 MODERN PATHOLOGY. 2020.09; 33 (9): 1678-1689. ( PubMed , DOI )

  46. Predictors of Outcomes in AML with MLL Rearrangement 2020.09; 20 S202-S203.

  47. Sasaki, K; Jabbour, E; Naqvi, K; Skinner, J; Anderson, K; Dellasala, S; Yilmaz, M; Ferrajoli, A; Bose, P; Thompson, P; Alvarado, Y; Jain, N; Takahashi, K; Burger, J; Estrov, Z; Borthakur, G; Pemmaraju, N; Paul, S; Pierce, S; Cortes, J; Kantarjian, H: Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S237.

  48. Sasaki, K; Kantarjian, H; Samra, B; Short, N; Khoury, J; Kanagal, R; Konopleva, M; Jain, N; DiNardo, C; Khouri, R; Garcia-Manero, G; Kadia, T; Wierda, W; Tippett, N; Garris, R; Jeanis, V; Daver, N; Thompson, P; Yilmaz, M; Cortes, J; O'Brien, S; Ravandi, F; Jabbour, E: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S164-S165.

  49. Issa, G; Zarka, J; Sasaki, K; Short, N; Jabbour, E; Kadia, T; Borthakur, G; Garcia-Manero, G; Kantarjian, H; Ravandi, F: Predictors of Outcomes in AML with MLL Rearrangement CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020.09; 20 S202-S203.

  50. Jabbour, E; Richard-Carpentier, G; Sasaki, Y; Konopleva, M; Patel, K; Roberts, K; Gu, ZH; Wang, F; Huang, XL; Sasaki, K; Short, NJ; Jain, N; Ravandi, F; Daver, NG; Kadia, TM; Alvarado, Y; DiNardo, CD; Issa, GC; Pemmaraju, N; Garcia-Manero, G; Verstovsek, S; Wang, S; Khoury, JD; Jorgensen, J; Champlin, R; Khouri, I; Kebriaei, P; Schroeder, H; Khouri, M; Mullighan, CG; Takahashi, K; O'Brien, SM; Kantarjian, H: Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial LANCET HAEMATOLOGY. 2020.07; 7 (7): E523-E533. ( PubMed , DOI )

  51. Sasaki, K; Kantarjian, H; Wierda, W; Ravandi-Kashani, F; Jorgensen, J; Wang, SA; Khoury, J; Daver, N; Burger, J; Di Nardo, CD; Jain, N; Short, NJ; Estrov, Z; Konopleva, M; Ohanian, M; Garcia-Manero, G; Kadia, T; Alvarado-Valero, Y; Yilmaz, M; Pierce, S; Garris, R; Ingram, A; Cortes, J; O'Brian, S; Jabbour, E: Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia AMERICAN JOURNAL OF HEMATOLOGY. 2020.07; 95 (7): 734-739. ( PubMed , DOI )

  52. Salwa M Okasha, Mai Itoh, Shuji Tohda: Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-κB Pathways. Anticancer Res. 2020.06; 40 (6): 3155-3161. ( PubMed , DOI )

  53. Zhou, J; Huang, X; Endou, H; Sasaki, K; Hooshangnejad, H; Han, D; Ding, K: Feasibility Study of a Curved Flexible Probe for Abdominal Imaging During Radiation Therapy MEDICAL PHYSICS. 2020.06; 47 (6): E620.

  54. Montalban-Bravo, G; Kanagal-Shamanna, R; Class, CA; Sasaki, K; Ravandi, F; Cortes, JE; Daver, N; Takahashi, K; Short, NJ; DiNardo, CD; Jabbour, E; Borthakur, G; Naqvi, K; Issa, GC; Konopleva, M; Khoury, JD; Routbort, M; Pierce, S; Do, KA; Bueso-Ramos, C; Patel, K; Kantarjian, H; Garcia-Manero, G; Kadia, TM: Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy AMERICAN JOURNAL OF HEMATOLOGY. 2020.06; 95 (6): 612-622. ( PubMed , DOI )

  55. Tatsuya Saito, Mai Itoh, Shuji Tohda: Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase. Leuk Res. 2020.05; 94 106383. ( PubMed , DOI )

  56. Short, NJ; Kantarjian, H; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, J; Konopleva, M; Issa, GC; Kornblau, SM; Garcia-Manero, G; Garris, R; Higgins, J; Pratt, G; Williams, LN; Valentine, CC; Rivera, VM; Pritchard, J; Salk, JJ; Radich, J; Jabbour, E: Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph plus ALL BLOOD CANCER JOURNAL. 2020.05; 10 (5): 61. ( PubMed , DOI )

  57. Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. 2020.05; 38 (15):

  58. Sakurai, K; Kantarjian, HM; Sasaki, K; Jabbour, E; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, NG; Takahashi, K; Naqvi, K; Dinardo, CD; Bravo, GM; Issa, GC; Jain, P; Pierce, SA; Soltysiak, KA; Garcia-Manero, G; Tingen, MS; Cortes, JE: Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. JOURNAL OF CLINICAL ONCOLOGY. 2020.05; 38 (15):

  59. Dalle, IA; Ghorab, A; Patel, K; Wang, XM; Hwang, H; Cortes, J; Issa, GC; Yalniz, F; Sasaki, K; Chihara, D; Price, A; Kadia, T; Pemmaraju, N; Daver, N; DiNardo, C; Ravandi, F; Kantarjian, HM; Borthakur, G: Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia BLOOD CANCER JOURNAL. 2020.05; 10 (5): 48. ( PubMed , DOI )

  60. Chien, KS; Class, CA; Montalban-Bravo, G; Wei, Y; Sasaki, K; Naqvi, K; Ganan-Gomez, I; Yang, H; Soltysiak, KA; Kanagal-Shamanna, R; Do, KA; Kantarjian, HM; Garcia-Manero, G: LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents LEUKEMIA & LYMPHOMA. 2020.05; 61 (6): 1493-1499. ( PubMed , DOI )

  61. Yukino Usui, Alafate Ayibieke, Yuko Kamiichi, Shu Okugawa, Kyoji Moriya, Shuji Tohda, Ryoichi Saito: Impact of deoxycholate on Clostridioides difficile growth, toxin production, and sporulation. Heliyon. 2020.04; 6 (4): e03717. ( PubMed , DOI )

  62. Yukino Usui, Yoko Nukui, Ryuji Koike, Shuji Tohda, Ryoichi Saito: Draft Genome Sequence of a Clostridioides difficile Sequence Type 97 Strain Belonging to Hypervirulent Clade 2. Microbiol Resour Announc. 2020.04; 9 (14): e00245-20. ( PubMed , DOI )

  63. Lachowiez, CA; Loghavi, S; Kadia, TM; Daver, N; Borthakur, G; Pemmaraju, N; Naqvi, K; Alvarado, Y; Yilmaz, M; Short, N; Ohanian, M; Pierce, SR; Patel, KP; Qiao, W; Ning, J; Sasaki, K; Takahashi, K; Jabbour, E; Andreeff, M; Ravandi, F; Kantarjian, HM; Konopleva, M; DiNardo, CD: Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens BLOOD ADVANCES. 2020.04; 4 (7): 1311-1320. ( PubMed , DOI )

  64. Montalban-Bravo, G; Class, CA; Ganan-Gomez, I; Kanagal-Shamanna, R; Sasaki, K; Richard-Carpentier, G; Naqvi, K; Wei, Y; Yang, H; Soltysiak, KA; Chien, K; Bueso-Ramos, C; Do, KA; Kantarjian, H; Garcia-Manero, G: Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes LEUKEMIA. 2020.03; 34 (3): 872-881. ( PubMed , DOI )

  65. Yilmaz, M; Kantarjian, H; Wang, XM; Khoury, JD; Ravandi, F; Jorgensen, J; Short, NJ; Loghavi, S; Cortes, J; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Wierda, W; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, S; Jabbour, E: The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival AMERICAN JOURNAL OF HEMATOLOGY. 2020.02; 95 (2): 144-150. ( PubMed , DOI )

  66. Montalban-Bravo, G; Kanagal-Shamanna, R; Benton, CB; Class, CA; Chien, KS; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Daver, N; Takahashi, K; Jabbour, E; Borthakur, G; Pemmaraju, N; Konopleva, M; Soltysiak, KA; Pierce, SR; Bueso-Ramos, CE; Patel, KP; Kantarjian, H; Garcia-Manero, G: Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes BLOOD ADVANCES. 2020.02; 4 (3): 482-495. ( PubMed , DOI )

  67. Sasaki, K; Kanagal-Shamanna, R; Montalban-Bravo, G; Assi, R; Jabbour, E; Ravandi, F; Kadia, T; Pierce, S; Takahashi, K; Gonzalez, GN; Patel, K; Soltysiak, KA; Cortes, J; Kantarjian, H; Garcia-Manero, G: Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia CANCER. 2020.02; 126 (4): 765-774. ( PubMed , DOI )

  68. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. 2020; 10 582213. ( PubMed , DOI )

  1. Akaza Miho, Kawabata Shigenori, Watanabe Taishi, Hasegawa Yuki, Iida Shintaro, Sasaki Toru, Adachi Yoshiaki, Sekihara Kensuke, Kanouchi Tadashi, Sumi Yuki, Okawa Atsushi, Yokota Takanori: Diagnosis of C8 radiculopathy by magnetospinogram(和訳中) 臨床神経学. 2019.11; 59 (Suppl.): S406. ( 医中誌 )

  2. Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y, Miura O: FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Cancers. 2019.11; 11 (12): ( PubMed , DOI )

  3. Yagi Yohsuke, Iida Shintaro, Kanouchi Tadashi, Kusunoki Susumu, Sobue Gen, Kaji Ryuji, Kuwabara Satoshi, Yokota Takanori, Glovenin-I CIDP Study Group: IVIg維持療法はCIDPの進行を抑制する(Maintenance treatment with IVIg for CIDP can prevent disease progression) 臨床神経学. 2019.11; 59 (Suppl.): S384. ( 医中誌 )

  4. Short, NJ; Kantarjian, HM; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Konopleva, MY; Issa, GC; Kornblau, SM; Garcia-Manero, G; Rivera, V; Garris, R; Higgins, J; Pratt, G; Williams, LN; Valentine, CC; Salk, JJ; Prichard, J; Radich, JP; Jabbour, E: Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Using Duplex Sequencing (DS) BLOOD. 2019.11; 134 ( DOI )

  5. Montalban-Bravo, G; Class, C; Ganan-Gomez, I; Kanagal-Shamanna, R; Sasaki, K; Richard-Carpentier, G; Naqvi, K; Wei, Y; Yang, H; Soltysiak, K; Chien, KS; Bueso-Ramos, CE; Do, KA; Kantarjian, HM; Garcia-Manero, G: Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

  6. Short, NJ; Kantarjian, HM; Ravandi, F; Huang, XL; Jain, N; Sasaki, K; Khouri, R; Daver, NG; Pemmaraju, N; Khoury, JD; Jorgensen, JL; Alvarado, Y; Konopleva, MY; Garcia-Manero, G; Kadia, TM; Yilmaz, ME; Borthakur, GM; Burger, JA; Kornblau, SM; Wierda, WG; DiNardo, CD; Ferrajoli, A; Jacob, J; Rostykus, M; Garris, R; Ward, M; Huang, BR; Encarnacion, C; Loiselle, C; O'Brien, SM; Jabbour, E: Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia BLOOD. 2019.11; 134 ( DOI )

  7. Richard-Carpentier, G; Kantarjian, HM; Short, NJ; Ravandi, F; Ferrajoli, A; Schroeder, HM; Garcia-Manero, G; Bravo, GM; Cortes, JE; Kwari, M; Loiselle, C; Garris, R; Volter, N; Jain, N; Konopleva, MY; Takahashi, K; Sasaki, K; Wierda, WG; Jabbour, E: Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2019.11; 134 ( DOI )

  8. Kadia, TM; Cortes, JE; Konopleva, MY; Borthakur, GM; Pemmaraju, N; Daver, NG; Bravo, GM; Issa, GC; Naqvi, K; Short, NJ; DiNardo, CD; Bhalla, KN; Jabbour, E; Takahashi, K; Sasaki, K; Kornblau, SM; Malla, R; Pierce, SA; Wang, XM; Estrov, ZE; Andreeff, M; Garcia-Manero, G; Ravandi, F; Kantarjian, HM: Venetoclax Combined with Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) BLOOD. 2019.11; 134 ( DOI )

  9. Rausch, CR; DiNardo, CD; Maiti, A; Jammal, N; Kadia, TM; Marx, K; Borthakur, GM; Savoy, JM; Pemmaraju, N; Dipippo, A; Daver, NG; Chew, S; Sasaki, K; Issa, GC; Naqvi, K; Ravandi, F; Kantarjian, HM; Konopleva, MY: Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

  10. Guerra, VA; Kantarjian, HM; Cortes, JE; Garcia-Manero, G; Masarova, L; Pemmaraju, N; Jabbour, E; Kadia, TM; DiNardo, CD; Zhou, LS; Pierce, SA; Borthakur, GM; Wierda, WG; Ferrajoli, A; Sasaki, K; Takahashi, K; Naqvi, K; Alvarado, Y; Ohanian, MN; Jain, N; Bose, P; Ravandi, F; Konopleva, MY; Estrov, ZE; Verstovsek, S; Daver, NG: A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs) BLOOD. 2019.11; 134 ( DOI )

  11. Cortes, J; Garcia-Manero, G; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; Jabbour, E; Borthakur, GM; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Bravo, GM: Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) BLOOD. 2019.11; 134 ( DOI )

  12. Cortes, J; Alfayez, M; Kadia, TM; Konopleva, MY; Ravandi, F; Cortes, JE; Jabbour, E; Garcia-Manero, G; Pierce, SA; Yilmaz, ME; Short, NJ; Sasaki, K; Masarova, L; Pemmaraju, N; Borthakur, GM; Kantarjian, HM; DiNardo, CD; Daver, NG: Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm) BLOOD. 2019.11; 134 ( DOI )

  13. Daver, NG; Garcia-Manero, G; Konopleva, MY; Alfayez, M; Pemmaraju, N; Kadia, TM; DiNardo, CD; Cortes, JE; Ravandi, F; Abbas, H; Basu, S; Jabbour, E; Pierce, SA; Estrov, ZE; Takahashi, K; Ning, J; Kornblau, SM; Sasaki, K; Masarova, L; Flores, W; Allison, JP; Sharma, P; Kantarjian, HM: Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study BLOOD. 2019.11; 134 ( DOI )

  14. Nogami Ayako, Watanabe Daisuke, Okada Keigo, Akiyama Hiroki, Umezawa Yoshihiro, Nagao Toshikage, Tohda Shuji, Miura Osamu: FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim BLOOD. 2019.11; 134 ( DOI )

  15. Jain, N; Keating, MJ; Thompson, PA; Burger, JA; Ferrajoli, A; Estrov, ZE; Borthakur, GM; Takahashi, K; Bose, P; Fowler, NH; Kadia, TM; Daver, NG; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG: Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) BLOOD. 2019.11; 134 ( DOI )

  16. Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, GM; Takahashi, K; Estrov, ZE; Fowler, NH; Kadia, TM; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG: Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) BLOOD. 2019.11; 134 ( DOI )

  17. Samra, B; Kantarjian, HM; Sasaki, K; Konopleva, MY; Khouri, R; O'Brien, SM; Ferrajoli, A; Nunez, C; Kadia, TM; Jabbour, E: Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

  18. The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group 2019.11; 134 ( DOI )

  19. Alfayez, M; Richard-Carpentier, G; Jabbour, E; Vishnu, P; Naqvi, K; Sasaki, K; Cortes, J; Pemmaraju, N: Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY. 2019.11; 187 (4): 543-545. ( PubMed , DOI )

  20. Sasaki, K; Kantarjian, HM; Kadia, T; Patel, K; Loghavi, S; Garcia-Manero, G; Jabbour, EJ; DiNardo, C; Pemmaraju, N; Daver, N; Abou Dalle, I; Short, N; Yilmaz, M; Bose, P; Naqvi, K; Pierce, S; Yalniz, F; Cortes, JE; Ravandi, F: Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia CANCER. 2019.11; 125 (21): 3755-3766. ( PubMed , DOI )

  21. Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Rytting, ME; Jain, N; Konopleva, MY; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Estrov, ZE; Takahashi, K; Loiselle, C; Encarnacion, C; Rostykus, M; Khouri, R; Nasnas, P; Jacob, J; Kwari, M; Garris, R; Jabbour, E: Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse BLOOD. 2019.11; 134 ( DOI )

  22. Sasaki, K; Kantarjian, HM; Jabbour, EJ: Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? CANCER. 2019.11; 125 (21): 3891-3892. ( PubMed , DOI )

  23. Maiti, A; DiNardo, CD; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, MN; Short, NJ; Alvarado, Y; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, ME; Jain, N; Kornblau, SM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY: Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial BLOOD. 2019.11; 134 ( DOI )

  24. Sasaki, K; Ribera, JM; Figueroa, M; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Estrov, ZE; Garris, R; Khouri, R; Nasnas, P; DiNardo, CD; Naqvi, K; Kornblau, SM; Montalban-Bravo, G; Pemmaraju, N; Cortes, JE; O'Brien, SM; Chandra, J; Kantarjian, HM; Jabbour, E: The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) BLOOD. 2019.11; 134 ( DOI )

  25. Chien, KS; Kanagal-Shamanna, R; Naqvi, K; Sasaki, K; Alvarado, Y; Takahashi, K; Kadia, TM; Borthakur, GM; Jabbour, E; Routbort, M; Pierce, SA; Soltysiak, K; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G: The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

  26. Yilmaz, M; Kantarjian, HM; Wang, XM; Khoury, JD; Ravandi, F; Jorgensen, JL; Short, NJ; Loghavi, S; Cortes, JE; Garcia-Manero, G; Kadia, TM; Sasaki, K; Konopleva, MY; Takahashi, K; Wierda, WG; Jain, N; Verstovsek, S; Estrov, ZE; Bose, P; Pierce, SA; Garris, R; O'Brien, SM; Jabbour, E: The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival BLOOD. 2019.11; 134 ( DOI )

  27. Paul, S; Sasaki, K; Savoy, JM; Dipippo, A; Jammal, N; Marx, K; Kadia, TM; Garcia-Manero, G; Ravandi, F; Kantarjian, HM; Jabbour, E: Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia ( Ph)-Positive Acute Lymphocytic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

  28. Sasaki, K; Kantarjian, HM; Jabbour, E; Ravandi, F; Konopleva, MY; Borthakur, GM; Wierda, WG; Daver, NG; Takahashi, K; Naqvi, K; DiNardo, CD; Bravo, GM; Kanagal-Shamanna, R; Pemmaraju, N; Issa, GC; Jain, P; Skinner, J; Rios, MB; Pierce, SA; Soltysiak, K; Sato, J; Garcia-Manero, G; Cortes, JE: The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) BLOOD. 2019.11; 134 ( DOI )

  29. Kanagal-Shamanna, R; Montalban-Bravo, G; Class, C; Sasaki, K; Benton, CB; Soltysiak, K; Jabbour, E; Kadia, TM; Bueso-Ramos, CE; Patel, KP; Routbort, M; Ganan-Gomez, I; Wei, Y; Borthakur, GM; Ravandi, F; Do, KA; Medeiros, LJ; Kantarjian, HM; Garcia-Manero, G: Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

  30. Cortes, J; Kantarjian, HM; Richard-Carpentier, G; Borthakur, GM; Ravandi, F; Naqvi, K; Sasaki, K; Kadia, TM; Verstovsek, S; Garcia-Manero, G; DiNardo, CD; Pemmaraju, N; Daver, NG; Bose, P; Pierce, SA; Dara, S; Jabbour, E; Cortes, JE: Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs) BLOOD. 2019.11; 134 ( DOI )

  31. Kanagal-Shamanna, R; Montalban-Bravo, G; Sasaki, K; Luthra, R; Phdmd, HY; Toruner, GA; Patel, KP; Mallampati, S; Kantarjian, HM; Bueso-Ramos, CE; Medeiros, LJ; Garcia-Manero, G: High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

  32. Montalban-Bravo, G; Kanagal-Shamanna, R; Benton, CB; Class, C; Chien, KS; Sasaki, K; Naqvi, K; Alvarado, Y; Kadia, TM; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Andreeff, M; Patel, KP; Kantarjian, HM; Garcia-Manero, G: Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

  33. Jain, N; Thompson, PA; Burger, JA; Ferrajoli, A; Takahashi, K; Estrov, ZE; Borthakur, GM; Bose, P; Kadia, TM; Pemmaraju, N; Sasaki, K; Garg, N; Wang, XM; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Wang, SA; Lopez, W; Ayala, A; Plunkett, W; Gandhi, V; Kantarjian, HM; O'Brien, S; Keating, MJ; Wierda, WG: Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53 BLOOD. 2019.11; 134 ( DOI )

  34. Jabbour, E; Roberts, KG; Sasaki, K; Zhao, YQ; Qu, CX; Gu, ZH; Jain, N; Patel, KP; Ravandi, F; Short, NJ; Garcia-Manero, G; Garris, R; Kornblau, S; Konopleva, MY; Mullighan, CG; Kantarjian, HM: Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2019.11; 134 ( DOI )

  35. Perez, JMR; Kadia, TM; Montalban-Bravo, G; Benton, CB; Faderl, S; Sasaki, K; Naqvi, K; Cortes, JE; Daver, NG; DiNardo, CD; Jabbour, E; Borthakur, GM; Al Azzawi, H; Pemmaraju, N; Konopleva, MY; Pierce, SA; Jain, N; Ohanian, M; Garcia-Manero, G; Andreeff, M; Kantarjian, HM; Ravandi, F; Alvarado, Y: Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) BLOOD. 2019.11; 134 ( DOI )

  36. Sasaki, K; Bravo, GM; Kanagal-Shamanna, R; Jabbour, E; Ravandi, F; Kadia, TM; Naqvi, K; Daver, NG; Pierce, SA; Takahashi, K; DiNardo, CD; González, GMN; Patel, K; Soltysiak, K; Sato, J; Cortes, JE; Kantarjian, HM; Garcia-Manero, G: Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome BLOOD. 2019.11; 134 ( DOI )

  37. Sakhdari, A; Class, C; Montalban-Bravo, G; Sasaki, K; Bueso-Ramos, CE; Patel, KP; Khoury, JD; Kantarjian, HM; Garcia-Manero, G; Medeiros, LJ; Kanagal-Shamanna, R: Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome BLOOD. 2019.11; 134 ( DOI )

  38. Short, NJ; Kantarjian, HM; Ravandi, F; Huang, XL; Daver, NG; DiNardo, CD; Konopleva, MY; Pemmaraju, N; Wierda, WG; Garcia-Manero, G; Sasaki, K; Cortes, JE; Garris, R; Ward, M; Huang, BR; Encarnacion, C; Loiselle, C; Khoury, JD; Jorgensen, JL; Jain, N; Alvarez, J; Tippett, N; O'Brien, SM; Jabbour, E: Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2019.11; 134 ( DOI )

  39. Montalban-Bravo, G; Jabbour, E; Class, C; Short, NJ; Kanagal-Shamanna, R; Kadia, TM; Borthakur, GM; Pemmaraju, N; Sasaki, K; Estrov, ZE; Cortes, JE; Ravandi, F; Alvarado, Y; Komrokji, RS; Sekeres, MA; Steensma, DP; DeZern, AE; Roboz, GJ; Yang, H; Kantarjian, HM; Garcia-Manero, G: Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes BLOOD. 2019.11; 134 ( DOI )

  40. Maiti, A; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, M; Jain, N; Kornblau, SM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Patel, KP; Kantarjian, HM; Konopleva, MY; DiNardo, CD: Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia BLOOD. 2019.11; 134 ( DOI )

  41. Samra, B; Kantarjian, HM; Sasaki, K; Short, NJ; Khouri, R; Khoury, JD; Champlin, RE; Kebriaei, P; Cortes, JE; Jorgensen, JL; Wang, SA; Garcia-Manero, G; Kadia, TM; Borthakur, GM; Verstovsek, S; Daver, NG; Montalban-Bravo, G; Jain, N; Konopleva, MY; Yilmaz, ME; Naqvi, K; O'Brien, SM; Ravandi, F; Jabbour, E: Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR) BLOOD. 2019.11; 134 ( DOI )

  42. Bravo, GM; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Garcia-Manero, G; Kadia, TM: Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy BLOOD. 2019.11; 134 ( DOI )

  43. Montalban-Bravo, G; Kanagal-Shamanna, R; Sasaki, K; Ravandi, F; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, E; Borthakur, GM; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, KP; Kantarjian, HM; Garcia-Manero, G; Kadia, TM: Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy BLOOD. 2019.11; 134 ( DOI )

  44. Masarova, L; Verstovsek, S; Bose, P; Pemmaraju, N; Cortes, JE; Jabbour, E; Ohanian, M; Zhou, LS; Pierce, SA; Gergis, R; Borthakur, GM; Kadia, TM; DiNardo, CD; Ravandi, F; Konopleva, MY; Naqvi, K; Sasaki, K; Estrov, ZE; Garcia-Manero, G; Bueso-Ramos, CE; Kantarjian, HM; Daver, NG: Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis BLOOD. 2019.11; 134 ( DOI )

  45. Maiti, A; Rausch, CR; Cortes, JE; Pemmaraju, N; Daver, NG; Ravandi, F; Garcia-Manero, G; Borthakur, GM; Naqvi, K; Ohanian, M; Short, NJ; Alvarado, Y; Benton, CB; Benton, CB; Kadia, TM; Takahashi, K; Yilmaz, ME; Jain, N; Kornblau, SM; Bravo, GM; Sasaki, K; Andreeff, M; Bose, P; Ferrajoli, A; Issa, GC; Jabbour, E; Masarova, L; Rytting, ME; Thompson, PA; Wang, SA; Konoplev, S; Chen, ZN; Goswami, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Bivins, CA; Wade, A; Adewale, SL; Tse, S; Thomas, R; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY; DiNardo, CD: Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens BLOOD. 2019.11; 134 ( DOI )

  46. Ahaneku, HO; Kantarjian, HM; González, GMN; Borthakur, GM; Verstovsek, S; Kadia, TM; Pemmaraju, N; Garcia-Manero, G; Konopleva, MY; DiNardo, CD; Naqvi, K; Sasaki, K; Issa, GC; Jabbour, E; Cortes, JE: Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet BLOOD. 2019.11; 134 2930. ( DOI )

  47. Nukui Y, Chino T, Tani C, Sonobe K, Aiso Y, Tohda S, Koike R, Saito R: Molecular epidemiologic and clinical analysis of Helicobacter cinaedi bacteremia in Japan. Helicobacter. 2019.11; e12675. ( PubMed , DOI )

  48. Richard-Carpentier, G; Kantarjian, HM; Konopleva, MY; Patel, KP; Roberts, KG; Gu, ZH; Ravandi, F; Jain, N; Short, NJ; Garcia-Manero, G; Schroeder, HM; Kwari, M; Garris, R; Khouri, R; Jones, M; Loiselle, C; Cortes, JE; Sasaki, K; Issa, GC; Kadia, TM; DiNardo, CD; Verstovsek, S; Daver, NG; Mullighan, CG; O'Brien, SM; Jabbour, E: Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2019.11; 134 ( DOI )

  49. Richard-Carpentier, G; DeZern, AE; Takahashi, K; Konopleva, MY; Loghavi, S; Masarova, L; Alvarado, Y; Ravandi, F; Bravo, GM; Naqvi, K; Sasaki, K; Delumpa, R; Kwari, M; Sekeres, MA; Nazha, A; Roboz, GJ; Kantarjian, HM; Garcia-Manero, G; DiNardo, CD: Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) BLOOD. 2019.11; 134 ( DOI )

  50. Ryoichi Saito, Yukino Usui, Alafate Ayibieke, Jun Nakajima, Isaac Prah, Kazunari Sonobe, Yoshibumi Aiso, Shiori Ito, Yasuhiro Itsui, Yoshiro Hadano, Yoko Nukui, Ryuji Koike, Shuji Tohda: Hypervirulent clade 2, ribotype 019/sequence type 67 Clostridioides difficile strain from Japan. Gut Pathog. 2019.11; 11 54. ( PubMed , DOI )

  51. Sasaki, K; Kantarjian, HM; Samra, B; Short, NJ; Khoury, JD; Kanagal-Shamanna, R; Konopleva, MY; Jain, N; DiNardo, CD; Khouri, R; Garcia-Manero, G; Kadia, TM; Wierda, WG; Tippett, N; Garris, R; Jeanis, V; Daver, NG; Thompson, PA; Yilmaz, M; Cortes, JE; O'Brien, SM; Ravandi, F; Jabbour, E: Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs) BLOOD. 2019.11; 134 ( DOI )

  52. Sasaki, Y; Short, NJ; Kantarjian, HM; Garris, R; Jain, N; Sasaki, K; Ravandi, F; Konopleva, MY; Rytting, ME; Garcia-Manero, G; Little, L; Gumbs, C; Zhao, L; Futreal, PA; Wang, F; Takahashi, K; Jabbour, E: Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib BLOOD. 2019.11; 134 ( DOI )

  53. Kaminaka S., Akaza M., Kawabata S., Watanabe T., Miyano Y., Iida S., Sasaki T., Adachi Y., Sekihara K., Kanouchi T., Sumi Y., Okawa A., Yokota T.: Diagnosis of C8 radiculopathy by magnetospinogram JOURNAL OF THE NEUROLOGICAL SCIENCES. 2019.10; 405 ( DOI )

  54. Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Ravandi, F; Short, N; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Jeanis, V; Alvarez, J; Khouri, M; Nasnas, P; Garris, R; Wierda, W; Thompson, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E: Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S180-S181.

  55. Short, N; Kantarjian, H; Sasaki, K; Kanagal-Shamanna, R; Ravandi, F; Cortes, J; Konopleva, M; Issa, G; Kornblau, S; Garcia-Manero, G; Rivera, V; Garris, R; Salk, J; Prichard, J; Radich, J; Jabbour, E: Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S186.

  56. Short, N; Jabbour, E; Sasaki, K; Ravandi, F; Huang, XL; Kebriaei, P; Jain, N; Garcia-Manero, G; Kadia, T; Konopleva, M; Jacob, J; Garris, R; Cortes, J; O'Brien, S; Kantarjian, H: Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S186-S187.

  57. Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Ravandi, F; Short, N; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Estrov, Z; Garris, R; Khouri, M; Nasnas, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E: The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S180.

  58. Yilmaz, M; Kantarjian, H; Wang, XM; Loghavi, S; Khoury, J; Jorgensen, J; Ravandi, F; Short, N; Cortes, J; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Wierda, W; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, S; Jabbour, E: The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S193-S194. ( DOI )

  59. Yilmaz, M; Kantarjian, H; Ravandi, F; Thomas, D; Khouri, M; Garcia-Manero, G; Garris, R; Cortes, J; Short, N; Sasaki, K; Issa, G; Koller, P; Schroeder, H; Kadia, T; Verstovsek, S; Daver, N; Jain, N; Konopleva, M; O'Brien, S; Jabbour, E: Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S185. ( DOI )

  60. Sasaki, K; Kantarjian, H; Richard-Carpentier, G; Short, N; Ravandi, F; Khouri, M; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Issa, G; Jacob, J; Garris, R; Yilmaz, M; Thompson, P; Nasnas, P; Pemmaraju, N; Cortes, J; O'Brien, S; Jabbour, E: Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S181. ( DOI )

  61. Chien, K; Class, C; Bravo, GM; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Kanagal-Shamanna, R; Soltysiak, K; Kantarjian, H; Garcia-Manero, G: LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019.09; 19 S341. ( DOI )

  62. Yalniz, F; Abou Dalle, I; Kantarjian, H; Borthakur, G; Kadia, T; Patel, K; Loghavi, S; Garcia-Manero, G; Sasaki, K; Daver, N; DiNardo, C; Pemmaraju, N; Short, NJ; Yilmaz, M; Bose, P; Naqvi, K; Pierce, S; Gonzalez, GMN; Konopleva, M; Andreeff, M; Cortes, J; Ravandi, F: Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib AMERICAN JOURNAL OF HEMATOLOGY. 2019.09; 94 (9): 984-991. ( PubMed , DOI )

  63. Yoko Nukui, Alafate Ayibieke, Makoto Taniguchi, Yoshibumi Aiso, Yuka Shibuya, Kazunari Sonobe, Jun Nakajima, Saki Kanehira, Yoshiro Hadano, Shuji Tohda, Ryuji Koike, Ryoichi Saito: Whole-genome analysis of EC129, an NDM-5-, CTX-M-14-, OXA-10- and MCR-1-co-producing Escherichia coli ST167 strain isolated from Japan. J Glob Antimicrob Resist. 2019.09; 18 148-150. ( PubMed , DOI )

  64. Itoh M, Okuhashi Y, Takahashi Y, Sonoda Y, Mohammad S, Saito T, Shiratori E, Tohda S: Hypoxia Up-regulates HIF Expression While Suppressing Cell Growth and NOTCH Activity in Leukaemia Cells. Anticancer research. 2019.08; 39 (8): 4165-4170. ( PubMed , DOI )

  65. Jabbour, EJ; Sasaki, K; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, N; Kadia, T; Konopleva, M; Jain, N; Cortes, J; Issa, GC; Jacob, J; Kwari, M; Thompson, P; Garris, R; Pemmaraju, N; Yilmaz, M; O'Brien, SM; Kantarjian, HM: Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis CANCER. 2019.08; 125 (15): 2579-2586. ( PubMed , DOI )

  66. Naqvi, K; Sasaki, K; Montalban-Bravo, G; Pierola, AA; Yilmaz, M; Short, N; Assi, R; Jabbour, E; Ravandi, F; Kadia, T; Pierce, S; Takahashi, K; Gonzalez, GN; Kanagal-Shamanna, R; Patel, K; Soltysiak, KA; Kantarjian, HM; Garcia-Manero, G: Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome CANCER. 2019.07; 125 (13): 2233-2241. ( PubMed , DOI )

  67. Horiuchi Y., Ohkawa R., Lai S., Shimano S., Hagihara M., Tohda S., Tozuka M.: Availability of ApoB-depleted serum in clinical assay for cholesterol efflux capacity using immobilized liposome-bound gel beads CLINICA CHIMICA ACTA. 2019.06; 493 S78-S79. ( DOI )

  68. LILRB4 expression in CMML and MDS based on response to hypomethylating agents. 2019.05; 37 (15):

  69. Alfayez, M; Abou Dalle, I; Abou Richard-Carpentier, G; Pak, D; Ning, J; Pierce, SA; Sasaki, K; Naqvi, K; Daver, NG; Cortes, JE; Ravandi, F; Pemmaraju, N; Ferrajoli, A; Garcia-Manero, G; Konopleva, M; Borthakur, G; Kantarjian, HM; Kadia, T; Dinardo, CD: Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

  70. Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. 2019.05; 37 (15):

  71. Jain, N; Keating, M; Thompson, P; Ferrajoli, A; Burger, J; Borthakur, G; Takahashi, K; Estrov, Z; Fowler, N; Kadia, T; Konopleva, M; Alvarado, Y; Yilmaz, M; DiNardo, C; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, J; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, H; Gandhi, V; Wierda, W: Ibrutinib and Venetoclax for First-Line Treatment of CLL NEW ENGLAND JOURNAL OF MEDICINE. 2019.05; 380 (22): 2095-2103. ( PubMed , DOI )

  72. Sasaki, K; Kantarjian, HM; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, SA; Jabbour, EJ; Cortes, JE: Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors INTERNATIONAL JOURNAL OF HEMATOLOGY. 2019.05; 109 (5): 545-552. ( PubMed , DOI )

  73. Chien, KS; Class, CA; Montalban-Bravo, G; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Kanagal-Shamanna, R; Kantarjian, HM; Garcia-Manero, G: LILRB4 expression in CMML and MDS based on response to hypomethylating agents. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

  74. Chien, KS; Benton, CB; Class, CA; Kadia, TM; Dinardo, CD; Konopleva, M; Andreeff, M; Sasaki, K; Naqvi, K; Gomez, IG; Wei, Y; Yang, H; Pierce, SA; Patel, KP; Kanagal-Shamanna, R; Kantarjian, HM; Garcia-Manero, G; Montalban-Bravo, G: Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

  75. Montalban-Bravo, G; Kanagal-Shamanna, R; Sasaki, K; Patel, K; Ganan-Gomez, I; Jabbour, E; Kadia, T; Ravandi, F; Dinardo, C; Borthakur, G; Takahashi, K; Konopleva, M; Komrokji, RS; DeZern, A; Kuzmanovic, T; Maciejewski, J; Pierce, S; Colla, S; Sekeres, MA; Kantarjian, H; Bueso-Ramos, C; Garcia-Manero, G: NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy BLOOD ADVANCES. 2019.03; 3 (6): 922-933. ( PubMed , DOI )

  76. Jain, P; Kantarjian, H; Boddu, PC; Nogueras-González, GM; Verstovsek, S; Garcia-Manero, G; Borthakur, G; Sasaki, K; Kadia, TM; Sam, P; Ahaneku, H; O'Brien, S; Estrov, Z; Ravandi, F; Jabbour, E; Cortes, JE: Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs BLOOD ADVANCES. 2019.03; 3 (6): 851-861. ( PubMed , DOI )

  77. Yuna Horiuchi, Ryunosuke Ohkawa, Shao-Jui Lai, Shitsuko Shimano, Michio Hagihara, Shuji Tohda, Takahiro Kameda, Minoru Tozuka: Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads. Biosci. Rep.. 2019.03; ( PubMed , DOI )

  78. Hamada S, Hasegawa Y, Oono A, Suzuki A, Takahashi N, Nishimura T, Koyama T, Hagihara M, Tohda S, Furukawa T, Hirao K, Sasano T: Author Correction: Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry. Scientific reports. 2019.03; 9 (1): 4957. ( PubMed , DOI )

  79. Nogami Ayako, Okada Keigo, Ishida Shinya, Akiyama Hiroki, Umezawa Yoshihiro, Miura Osamu: Inhibition of the STAT5/Pim Kinase Axis Enhanecs Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway TRANSLATIONAL ONCOLOGY. 2019.02; 12 (2): 336-349. ( PubMed , DOI )

  80. Short, NJ; Jabbour, E; Naqvi, K; Patel, A; Ning, J; Sasaki, K; Nogueras-Gonzalez, GM; Bose, P; Kornblau, SM; Takahashi, K; Andreeff, M; Sanchez-Petitto, G; Estrov, Z; Dinardo, CD; Montalban-Bravo, G; Konopleva, M; Alvarado, Y; Bhalla, KN; Fiskus, W; Khouri, M; Islam, R; Kantarjian, H; Garcia-Manero, G: A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents AMERICAN JOURNAL OF HEMATOLOGY. 2019.01; 94 (1): 74-79. ( PubMed , DOI )

  81. Hu, B; Thall, P; Milton, DR; Sasaki, K; Bashir, Q; Shah, N; Patel, K; Popat, U; Hosing, C; Nieto, Y; Lin, P; Delgado, R; Jorgensen, J; Manasanch, E; Weber, D; Thomas, S; Orlowski, RZ; Champlin, R; Qazilbash, MH: High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes LEUKEMIA & LYMPHOMA. 2019.01; 60 (2): 442-452. ( PubMed , DOI )

  82. Kawaguchi-Ihara Noriko, Zhao Yan, Nakamura Suzune, Suzuki Keiko, Zhang Yi, Tohda Shuji, Murohashi Ikuo: Chloroquine Inhibits Self-Renewal of Blast Progenitors Synergistically With Phytochemicals or Nonsteroidal Anti-inflammatory Drugs in Hematological Malignant Cell Lines ANTICANCER RESEARCH. 2019.01; 39 (1): 87-98. ( PubMed , DOI )

  83. Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Okada Keigo, Nogami Ayako, Miura Osamu: Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed , DOI )

  1. Jabbour, E; Short, NJ; Ravandi, F; Huang, XL; Daver, N; DiNardo, CD; Konopleva, M; Pemmaraju, N; Wierda, W; Garcia-Manero, G; Sasaki, K; Cortes, J; Garris, R; Khoury, JD; Jorgensen, J; Jain, N; Alvarez, J; O'Brien, S; Kantarjian, H: Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study LANCET HAEMATOLOGY. 2018.12; 5 (12): E618-E627. ( PubMed , DOI )

  2. Akaza Miho, Akaza Itaru, Kanouchi Tadashi, Sasano Tetsuo, Sumi Yuki, Yokota Takanori: Study for association between glycemic variability and diabetic neuropathy assessed by NCS(和訳中) 臨床神経学. 2018.12; 58 (Suppl.): S419. ( 医中誌 )

  3. Sasaki, K; Jabbour, EJ; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Jeanis, V; Alvarez, J; Khouri, M; Nasnas, P; Garris, RE; Wierda, WG; Thompson, PA; Pemmaraju, N; Cortes, JE; O'Brien, SM; Kantarjian, HM: Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 ( DOI )

  4. Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Cortes, JE; Konopleva, MY; Issa, GC; Kanagal-Shamanna, R; Kornblau, SM; Garcia-Manero, G; Rivera, V; Garris, RE; Salk, J; Prichard, J; Radich, JP; Jabbour, EJ: Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 ( DOI )

  5. Rausch, CR; Paul, S; Kantarjian, HM; Ravandi, F; Short, NJ; Sasaki, K; Khouri, M; Jacob, J; Montalbano, KS; Thompson, PA; Jain, N; Yilmaz, M; Naqvi, K; Ohanian, MN; Nasnas, P; Estrov, ZE; O'Brien, SM; Jabbour, EJ: Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen BLOOD. 2018.11; 132 ( DOI )

  6. Richard-Carpentier, G; Kantarjian, HM; Short, NJ; Ravandi, F; Ferrajoli, A; Schroeder, HM; Khouri, M; Garcia-Manero, G; Bravo, GM; Cortes, JE; Jain, N; Konopleva, MY; Takahashi, K; Sasaki, K; Garris, RE; Jabbour, EJ: A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2018.11; 132 ( DOI )

  7. Garcia-Manero, G; Sasaki, K; Montalban-Bravo, G; Daver, NG; Jabbour, EJ; Alvarado, Y; DiNardo, CD; Ravandi, F; Borthakur, G; Bose, P; Pemmaraju, N; Naqvi, K; Cortes, JE; Kadia, TM; Konopleva, MY; Colla, S; Yang, H; Rausch, CR; Gasior, Y; Bueso-Ramos, CE; Kanagal-Shamanna, R; Patel, KP; Kantarjian, HM: A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS) BLOOD. 2018.11; 132 ( DOI )

  8. Short, NJ; Jabbour, EJ; Ravandi, F; Huang, XL; Jain, N; Sasaki, K; Pemmaraju, N; Daver, NG; Khoury, JD; Jorgensen, JL; Alvarado, Y; Konopleva, MY; Garcia-Manero, G; Kadia, TM; Yilmaz, M; Borthakur, G; Burger, JA; Kornblau, SM; Wierda, WG; DiNardo, CD; Ferrajoli, A; Nasnas, P; Jacob, J; Garris, RE; O'Brien, SM; Kantarjian, HM: Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study BLOOD. 2018.11; 132 ( DOI )

  9. Naqvi, K; Sasaki, K; Montalban-Bravo, G; Teach, MS; Pierce, SA; Kantarjian, HM; Garcia-Manero, G: Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis BLOOD. 2018.11; 132 ( DOI )

  10. Jain, N; Keating, MJ; Thompson, PA; Ferrajoli, A; Burger, JA; Borthakur, G; Takahashi, K; Estrov, ZE; Fowler, NH; Kadia, TM; Konopleva, MY; Alvarado, Y; Yilmaz, M; DiNardo, CD; Bose, P; Ohanian, MN; Pemmaraju, N; Jabbour, EJ; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, JL; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, HM; Gandhi, V; Wierda, WG: Combined Ibrutinib and Venetoclax in Patients with Treatment-Naive High-Risk Chronic Lymphocytic Leukemia (CLL) BLOOD. 2018.11; 132 ( DOI )

  11. Nakamura, Y; Ichikawa, M; Oda, H; Yamazaki, I; Sasaki, K; Mitani, K: RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice LEUKEMIA RESEARCH. 2018.11; 74 14-20. ( PubMed , DOI )

  12. Jabbour, EJ; Sasaki, K; Ravandi, F; Short, NJ; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Estrov, ZE; Garris, RE; Khouri, M; Nasnas, P; Pemmaraju, N; Cortes, JE; O'Brien, SM; Kantarjian, HM: Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) BLOOD. 2018.11; 132 ( DOI )

  13. Sasaki, K; Kantarjian, HM; Ravandi, F; Short, NJ; Kebriaei, P; Huang, XL; Rytting, ME; Jain, N; Konopleva, MY; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Estrov, ZE; Takahashi, K; Mace, M; Khouri, M; Nasnas, P; Jacob, J; Garris, RE; Jabbour, EJ: Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial BLOOD. 2018.11; 132 ( DOI )

  14. Sasaki, K; Kanagal-Shamanna, R; Montalban-Bravo, G; Assi, R; Naqvi, K; Pierola, AA; Yilmaz, M; Short, NJ; Jabbour, EJ; Ravandi, F; Kadia, TM; Pierce, SA; Takahashi, K; DiNardo, CD; González, GMN; Abaza, Y; Devendra, KC; Chamoun, K; Sakurai, K; Patel, KP; Cortes, JE; Kantarjian, HM; Garcia-Manero, G: The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

  15. Garcia-Manero, G; Sasaki, K; Montalban-Bravo, G; Bodden, KR; Bose, P; Alvarado, Y; Daver, NG; Borthakur, G; Ravandi, F; Takahashi, K; Cortes, JE; Jabbour, EJ; Naqvi, K; DiNardo, CD; Benton, CB; Pemmaraju, N; Kadia, TM; Ohanian, MN; Pierce, SA; Kantarjian, HM: Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) BLOOD. 2018.11; 132 ( DOI )

  16. Kanagal-Shamanna, R; Sasaki, K; Bravo, GM; Benton, CB; Jabbour, EJ; Borthakur, G; Kadia, TM; Bueso-Ramos, CE; Patel, K; Ravandi, F; Kantarjian, HM; Garcia-Manero, G: Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

  17. Swaminathan, M; Kantarjian, HM; Sasaki, K; Ravandi, F; Borthakur, G; Kadia, TM; Garcia-Manero, G; DiNardo, CD; Konopleva, MY; Estrov, ZE; Pemmaraju, N; Daver, NG; Wierda, WG; Ferrajoli, A; Pierce, SA; Dellasala, MDE; Jabbour, EJ; Cortes, JE: Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

  18. Naqvi, K; Sasaki, K; Montalban-Bravo, G; Alfonso, A; Yilmaz, M; Short, NJ; Assi, R; Jabbour, EJ; Ravandi, F; Kadia, TM; Pierce, SA; Takahashi, K; González, GMN; Kanagal-Shamanna, R; Patel, KP; Kantarjian, HM; Garcia-Manero, G: Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome BLOOD. 2018.11; 132 ( DOI )

  19. Sasaki, K; Kantarjian, HM; Short, NJ; Ravandi, F; Khouri, M; Garcia-Manero, G; Daver, NG; Kadia, TM; Konopleva, MY; Jain, N; Issa, GC; Jacob, J; Garris, RE; Yilmaz, M; Thompson, PA; Nasnas, P; Pemmaraju, N; Cortes, JE; O'Brien, SM; Jabbour, EJ: Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis BLOOD. 2018.11; 132 ( DOI )

  20. Montalban-Bravo, G; Benton, CB; Kanagal-Shamanna, R; Sasaki, K; Assi, R; Kadia, TM; Ravandi, F; Ganan-Gomez, I; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, EJ; Borthakur, G; Pemmaraju, N; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Kornblau, SM; Patel, K; Colla, S; Kantarjian, HM; Andreeff, M; Garcia-Manero, G: Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia BLOOD. 2018.11; 132 ( DOI )

  21. Bose, P; McCue, D; Wiederhold, NP; Kadia, TM; Borthakur, G; Ravandi, F; Yilmaz, M; Takahashi, K; Thompson, PA; Pemmaraju, N; Daver, NG; Burger, JA; Cortes, JE; Garcia-Manero, G; Verstovsek, S; Konopleva, MY; Jain, N; DiNardo, CD; Alvarado, Y; Naqvi, K; Kornblau, SM; Ferrajoli, A; Wierda, WG; Estrov, ZE; Benton, CB; Masarova, L; Montalban-Bravo, G; Sasaki, K; Rausch, CR; Marx, K; Qiao, W; Huang, X; Bivins, CA; Pierce, SA; Kantarjian, HM; Kontoyiannis, DP: Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label Prospective Study BLOOD. 2018.11; 132 ( DOI )

  22. Maiti, A; DiNardo, CD; Cortes, JE; Borthakur, G; Pemmaraju, N; Benton, CB; Kadia, TM; Takahashi, K; Naqvi, K; Ravandi, F; Alvarado, Y; Short, NJ; Daver, NG; Sasaki, K; Ohanian, MN; Garcia-Manero, G; Thompson, PA; Kornblau, SM; Masarova, L; Jain, N; Jabbour, EJ; Andreeff, M; Maduike, R; Guerrero, JA; Zhang, Q; Cavazos, A; Ma, H; Rausch, CR; Bivins, CA; Vaughan, K; Pierce, SA; Ning, J; Qiao, W; Welch, JS; Kantarjian, HM; Konopleva, MY: Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome BLOOD. 2018.11; 132 ( DOI )

  23. Aboudalle, I; Kantarjian, HM; Short, NJ; Ravandi, F; Sasaki, K; Garcia-Manero, G; Montalban-Bravo, G; Cortes, JE; Benton, CB; Issa, GC; Khouri, M; Nasnas, P; O'Brien, SM; Jabbour, EJ: Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia BLOOD. 2018.11; 132 4017. ( DOI )

  24. Bravo, GM; Kanagal-Shamanna, R; Benton, CB; Colla, S; Ganan-Gomez, I; Sasaki, K; Ravandi, F; Kadia, TM; Cortes, JE; Daver, NG; Takahashi, K; DiNardo, CD; Jabbour, EJ; Borthakur, G; Naqvi, K; Konopleva, MY; Pierce, SA; Bueso-Ramos, CE; Patel, K; Kantarjian, HM; Garcia-Manero, G: Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes BLOOD. 2018.11; 132 ( DOI )

  25. Okuhashi Yuki, Itoh Mai, Tohda Shuji: GLI1 and CTNNB1 Knockdown Activates NOTCH and mTOR Signalling in NB4 Myeloid Leukaemia Cells ANTICANCER RESEARCH. 2018.11; 38 (11): 6329-6332. ( PubMed , DOI )

  26. Yalniz, F; Kantarjian, HM; Kadia, TM; Garcia-Manero, G; Patel, K; Loghavi, S; Sasaki, K; Daver, NG; DiNardo, CD; Pemmaraju, N; Short, NJ; Yilmaz, M; Bose, P; Naqvi, K; Pierce, SA; Cortes, JE; Ravandi, F: Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib BLOOD. 2018.11; 132 ( DOI )

  27. Hamada Satomi, Hasegawa Yuki, Oono Ai, Suzuki Anna, Takahashi Naomi, Nishimura Takuro, Koyama Takatoshi, Hagihara Michio, Tohda Shuji, Furukawa Tetsushi, Hirao Kenzo, Sasano Tetsuo: Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry SCIENTIFIC REPORTS. 2018.10; 8 (1): 16129. ( PubMed , DOI )

  28. Jabbour, E; Sasaki, K; Ravandi, F; Huang, XL; Short, NJ; Khouri, M; Kebriaei, P; Burger, J; Khoury, J; Jorgensen, J; Jain, N; Konopleva, M; Garcia-Manero, G; Kadia, T; Cortes, J; Jacob, J; Montalbano, K; Garris, R; O'Brien, S; Kantarjian, HM: Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage CANCER. 2018.10; 124 (20): 4044-4055. ( PubMed , DOI )

  29. Kosho, T; Yue, F; Era, T; Nakayama, J; Yamaguchi, T; Miyake, N; Mizumoto, S; Yamada, S; Kawamura, R; Wakui, K; Yoshizawa, T; Takahashi, Y; Matsumoto, K; Hirose, T; Minaguchi, J; Takehana, K; Uehara, M; Takahashi, J; Ishikawa, M; Masuda, C; Shimazu, S; Nitahara-Kasahara, Y; Watanabe, A; Okada, T; Matsumoto, K; Hashimoto, A; Nomura, Y; Kakuta, Y; Hatamochi, A; Fukushima, Y; Sasaki, K: Pathophysiology of large subcutaneous hematomas in Musculocontractural EDS-CHST14: an iPS cells-based comprehensive investigation EUROPEAN JOURNAL OF HUMAN GENETICS. 2018.10; 26 237-238.

  30. Miho Akaza, Itaru Akaza, Tadashi Kanouchi, Tetsuo Sasano, Yuki Sumi, Takanori Yokota: Nerve conduction study of the association between glycemic variability and diabetes neuropathy. Diabetol Metab Syndr. 2018.09; 10 69. ( PubMed , DOI )

  31. Kadia, TM; Cortes, J; Ravandi, F; Jabbour, E; Konopleva, M; Benton, CB; Burger, J; Sasaki, K; Borthakur, G; DiNardo, CD; Pemmaraju, N; Daver, N; Ferrajoli, A; Wang, XM; Patel, K; Jorgensen, JL; Wang, S; O'Brien, S; Pierce, S; Tuttle, C; Estrov, Z; Verstovsek, S; Garcia-Manero, G; Kantarjian, H: Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial LANCET HAEMATOLOGY. 2018.09; 5 (9): E411-E421. ( PubMed , DOI )

  32. Wang S, Itoh M, Shiratori E, Ohtaka M, Tohda S: NOTCH activation promotes glycosyltransferase expression in human myeloid leukemia cells. Hematology reports. 2018.09; 10 (3): 7576. ( PubMed , DOI )

  33. Yonekura S, Itoh M, Shiratori E, Ohtaka M, Tohda S: FOXP3 knockdown inhibits the proliferation and reduces NOTCH1 expression of T cell acute lymphoblastic leukemia cells. BMC research notes. 2018.08; 11 (1): 582. ( PubMed , DOI )

  34. Ishida S, Akiyama H, Umezawa Y, Okada K, Nogami A, Oshikawa G, Nagao T, Miura O: Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed , DOI )

  35. Morita, K; Kantarjian, HM; Wang, F; Yan, YQ; Bueso-Ramos, C; Sasaki, K; Issa, GC; Wang, S; Jorgensen, J; Song, XZ; Zhang, JH; Tippen, S; Thornton, R; Coyle, M; Little, L; Gumbs, C; Pemmaraju, N; Daver, N; DiNardo, CD; Konopleva, M; Andreeff, M; Ravandi, F; Cortes, JE; Kadia, T; Jabbour, E; Garcia-Manero, G; Patel, KP; Futreal, PA; Takahashi, K: Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia JOURNAL OF CLINICAL ONCOLOGY. 2018.06; 36 (18): 1788-+. ( PubMed , DOI )

  36. Horiuchi Yuna, Lai Shao-Jui, Yamazaki Azusa, Nakamura Ayaka, Ohkawa Ryunosuke, Yano Kouji, Kameda Takahiro, Okubo Shigeo, Shimano Shitsuko, Hagihara Michio, Tohda Shuji, Tozuka Minoru: VALIDATION AND APPLICATION OF A NOVEL CHOLESTEROL EFFLUX ASSAY USING IMMOBILIZED LIPOSOMES AS A SUBSTITUTE FOR CULTURED CELLS ATHEROSCLEROSIS SUPPLEMENTS. 2018.06; 32 59.

  37. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida KI, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Japanese Eculizumab Trial for GBS (JET-GBS) Study Group.: Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet. Neurology. 2018.06; 17 (6): 519-529. ( PubMed , DOI )

  38. Bazarbachi, AH; Yilmaz, M; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Issa, GC; Koller, PB; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E; Kantarjian, HM: A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15): ( DOI )

  39. Ghorab, A; Kantarjian, HM; Jain, P; Kanagal-Shamanna, R; Jabbour, E; Sasaki, K; Kadia, TM; Garcia-Manero, G; Bose, P; Yilmaz, M; Naqvi, K; Wierda, WG; Verstovsek, S; Jain, N; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE: Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15): ( DOI )

  40. Yuna Horiuchi, Shao-Jui Lai, Azusa Yamazaki, Ayaka Nakamura, Ryunosuke Ohkawa, Kouji Yano, Takahiro Kameda, Shigeo Okubo, Shitsuko Shimano, Michio Hagihara, Shuji Tohda, Minoru Tozuka: Validation and application of a novel cholesterol efflux assay using immobilized liposomes as a substitute for cultured cells. Biosci. Rep.. 2018.04; 38 (2): ( PubMed , DOI )

  41. Ogihara Shinji, Saito Ryoichi, Sawabe Etsuko, Kozakai Takahiro, Shima Mari, Aiso Yoshibumi, Fujie Toshihide, Nukui Yoko, Koike Ryuji, Hagihara Michio, Tohda Shuji: Molecular typing of methicillin-resistant Staphylococcus aureus: Comparison of PCR-based open reading frame typing, multilocus sequence typing, and Staphylococcus protein A gene typing Journal of Infection and Chemotherapy. 2018.04; 24 (3-4): 312-314. ( 医中誌 )

  42. Shinji Ogihara, Ryoichi Saito, Etsuko Sawabe, Takahiro Kozakai, Mari Shima, Yoshibumi Aiso, Toshihide Fujie, Yoko Nukui, Ryuji Koike, Michio Hagihara, Shuji Tohda: Molecular typing of methicillin-resistant Staphylococcus aureus: Comparison of PCR-based open reading frame typing, multilocus sequence typing, and Staphylococcus protein A gene typing. J. Infect. Chemother.. 2018.04; 24 (4): 312-314. ( PubMed , DOI )

  43. Sasaki, K; Kantarjian, H; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, W; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, E; Cortes, JE: Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase CANCER. 2018.03; 124 (6): 1160-1168. ( PubMed , DOI )

  44. Jabbour, E; Ravandi, F; Kebriaei, P; Huang, XL; Short, NJ; Thomas, D; Sasaki, K; Rytting, M; Jain, N; Konopleva, M; Garcia-Manero, G; Champlin, R; Marin, D; Kadia, T; Cortes, J; Estrov, Z; Takahashi, K; Patel, Y; Khouri, MR; Jacob, J; Garris, R; O'Brien, S; Kantarjian, H: Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial JAMA ONCOLOGY. 2018.02; 4 (2): 230-234. ( PubMed , DOI )

  45. Kantarjian, H; Ravandi, F; Short, NJ; Huang, XL; Jain, N; Sasaki, K; Daver, N; Pemmaraju, N; Khoury, JD; Jorgensen, J; Alvarado, Y; Konopleva, M; Garcia-Manero, G; Kadia, T; Yilmaz, M; Bortakhur, G; Burger, J; Kornblau, S; Wierda, W; DiNardo, C; Ferrajoli, A; Jacob, J; Garris, R; O'Brien, S; Jabbour, E: Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study LANCET ONCOLOGY. 2018.02; 19 (2): 240-248. ( PubMed , DOI )

  46. Yuki Koda, Mai Itoh, Shuji Tohda: Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells. Anticancer Res.. 2018; 38 (1): 199-204. ( PubMed , DOI )

  47. Short, NJ; Kantarjian, H; Ravandi, F; Huang, XL; Xiao, LC; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, NG; Borthakur, G; Jain, N; Konopleva, M; Estrov, Z; Kadia, TM; Wierda, WG; DiNardo, CD; Brandt, M; O'Brien, SM; Cortes, JE; Jabbour, E: A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia LEUKEMIA & LYMPHOMA. 2018; 59 (4): 813-820. ( PubMed , DOI )

  1. Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) 2017.12; 130

  2. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes 2017.12; 130

  3. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

  4. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia 2017.12; 130

  5. Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa and Osamu Miura: FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway Oncotarget. 2017.12; 9 8870-8886.

  6. Assi, R; Kantarjian, HM; Khouri, R; Ravandi, F; Kebriaei, P; Short, NJ; Thomas, DA; Garcia-Manero, G; Champlin, RE; Kadia, T; Cortes, JE; Jain, N; Konopleva, M; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Manzoor, A; Garris, R; O'Brien, SM; Jabbour, EJ: Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) BLOOD. 2017.12; 130

  7. Short, NJ; Kantarjian, HM; Ravandi, F; Huang, X; Jain, N; Daver, N; Thomas, DA; Pemmaraju, N; Khouri, R; Khoury, JD; Jorgensen, JL; Alvarado, Y; Sasaki, K; Konopleva, M; Garcia-Manero, G; Kadia, T; Cortes, JE; Benton, CB; Borthakur, G; Burger, JA; Ohanian, M; Wierda, WG; Estrov, Z; Kornblau, S; DiNardo, CD; Ferrajoli, A; Jacob, J; Manzoor, A; Garris, R; O'Brien, SM; Jabbour, EJ: A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia BLOOD. 2017.12; 130

  8. Naqvi, K; Bravo, GM; Pierola, AA; Yilmaz, M; Sasaki, K; Short, NJ; Assi, R; Jabbour, EJ; Ravandi, F; Benton, CB; Kadia, T; Pierce, S; Borthakur, G; Daver, N; DiNardo, CD; Takahashi, K; Jain, N; Pemmaraju, N; González, GN; Kantarjian, HM; Garcia-Manero, G: Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome BLOOD. 2017.12; 130

  9. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML 2017.12; 130

  10. Sasaki, K; Nagasawa, F; Yoshida, K; Takeda, J; Shiraishi, Y; Chiba, K; Tanaka, H; Okada, A; Miyano, S; Ichikawa, M; Ogawa, S; Mitani, K: Contribution of MIR9 on Disease Progression of Chronic Myelogenous Leukemia BLOOD. 2017.12; 130

  11. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

  12. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial 2017.12; 130

  13. Alqam, HM; Kantarjian, HM; Chihara, D; Sasaki, K; Jabbour, EJ; Cortes, JE: Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia BLOOD. 2017.12; 130

  14. Yilmaz, M; Devendra, KC; Akosile, MA; Khoury, JD; Short, NJ; Cortes, JE; Garcia-Manero, G; Ravandi, F; Kadia, T; Sasaki, K; Konopleva, M; Wierda, WG; Jain, N; Verstovsek, S; Estrov, Z; Pierce, S; O'Brien, SM; Jabbour, EJ; Kantarjian, HM: The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

  15. Yilmaz, M; Jabbour, EJ; Wang, XM; Loghavi, S; Khoury, JD; Jorgensen, JL; Ravandi, F; Short, NJ; Cortes, JE; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Takahashi, K; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, SM; Kantarjian, HM: Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

  16. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura: Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Journal of Biological Chemistry. 2017.12; 292 (48): 19639-19655.

  17. Maiti, A; Kantarjian, HM; Ravandi, F; Khouri, M; Thomas, DA; Garcia-Manero, G; Garris, R; Cortes, JE; Short, NJ; Jain, N; Bose, P; Verstovsek, S; Konopleva, M; Sasaki, K; Issa, GC; Ghosn, M; Schroeder, HM; Kadia, T; Daver, N; O'Brien, SM; Jabbour, EJ: Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial BLOOD. 2017.12; 130

  18. Sasaki, K; Kantarjian, HM; O'Brien, SM; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, EJ; Cortes, JE: Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) BLOOD. 2017.12; 130

  19. Ghorab, A; Jain, P; Kantarjian, HM; Kanagal-Shamanna, R; Jabbour, EJ; Sasaki, K; Kadia, T; Garcia-Manero, G; Bose, P; Yilmaz, M; Naqvi, K; Wierda, WG; Verstovsek, S; Jain, N; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE: Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes BLOOD. 2017.12; 130

  20. Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Lucas, FAS; Ghorab, A; Jabbour, EJ; Ghayas, I; Sasaki, K; Kadia, T; Estrov, Z; Ravandi, F; Cortes, JE: Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML BLOOD. 2017.12; 130

  21. Sasaki, K; Jabbour, EJ; Khouri, M; Thomas, DA; Garcia-Manero, G; Ravandi, F; Borthakur, G; Short, NJ; Issa, GC; Kadia, T; Jones, E; Garris, R; Cortes, JE; O'Brien, SM; Kantarjian, HM: Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

  22. Yilmaz, M; Kantarjian, HM; Wang, XM; Devendra, KC; Khoury, JD; Ravandi, F; Short, NJ; Cortes, JE; Garcia-Manero, G; Kadia, T; Sasaki, K; Konopleva, M; Wierda, WG; Khouri, M; Jain, N; Verstovsek, S; Estrov, Z; Bose, P; Pierce, S; Garris, R; O'Brien, SM; Jabbour, EJ: Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) BLOOD. 2017.12; 130

  23. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

  24. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) 2017.12; 130

  25. Shuta Toru, Tadashi Kanouchi, Takanori Yokota, Yosuke Yagi, Akira Machida, Takayoshi Kobayashi: Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease. Eur. Neurol.. 2017.11; 79 (1-2): 27-32. ( PubMed , DOI )

  26. Jabbour, E; Short, NJ; Ravandi, F; Huang, XL; Xiao, LC; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, NG; Borthakur, G; Jain, NT; Konopleva, M; Estrov, Z; Kadia, TM; Wierda, WG; DiNardo, CD; Brandt, M; O'Brien, SM; Cortes, JE; Kantarjian, H: A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia CANCER. 2017.11; 123 (22): 4430-4439. ( PubMed , DOI )

  27. Issa, GC; Kantarjian, HM; Gonzalez, GN; Borthakur, G; Tang, GL; Wierda, W; Sasaki, K; Short, NJ; Ravandi, F; Kadia, T; Patel, K; Luthra, R; Ferrajoli, A; Garcia-Manero, G; Rios, MB; Dellasala, S; Jabbour, E; Cortes, JE: Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment BLOOD. 2017.11; 130 (19): 2084-2091. ( PubMed , DOI )

  28. Jain, P; Kantarjian, HM; Ghorab, A; Sasaki, K; Jabbour, EJ; Nogueras Gonzalez, G; Kanagal-Shamanna, R; Issa, GC; Garcia-Manero, G; Devendra, KC; Dellasala, S; Pierce, S; Konopleva, M; Wierda, WG; Verstovsek, S; Daver, NG; Kadia, TM; Borthakur, G; O'Brien, S; Estrov, Z; Ravandi, F; Cortes, JE: Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients CANCER. 2017.11; 123 (22): 4391-4402. ( PubMed , DOI )

  29. Kanouchi T., Sekiguchi T., Iida S., Akaza M., Yokota T.: Temporal relation between local disease progression in the onset site and regional spread of motor symptoms in amyotrophic lateral sclerosis JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017.10; 381 558-559. ( DOI )

  30. Kanai K., Yokota T., Shibuya K., Nakazato T., Kanouchi T., Iwai Y., Oyama G., Shimo Y., Shimizu T., Hattori N., Kuwabara S.: Increased motor axonal persistent sodium currents is associated with rapid regional spreading in amyotrophic lateral sclerosis JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017.10; 381 558. ( DOI )

  31. Arai, H; Ichikawa, M; Furuichi, S; Nagasawa, F; Takahashi, W; Handa, T; Nakamura, Y; Nakamura, Y; Sasaki, K; Mitani, K: Non-Hodgkin's lymphoma of the breast: a review of 6 cases including 3 patients with a history of autoimmune diseases ANNALS OF ONCOLOGY. 2017.10; 28

  32. Kanagal-Shamanna, R; Jain, P; Takahashi, K; Short, NJ; Tang, GL; Issa, GC; Ravandi, F; Garcia-Manero, G; Yin, CC; Luthra, R; Patel, KP; Khoury, JD; Montalban-Bravo, G; Sasaki, K; Kadia, TM; Borthakur, G; Konopleva, M; Jain, N; Garris, R; Pierce, S; Wierda, W; Estrov, Z; Cortes, J; O'Brien, S; Kantarjian, HM; Jabbour, E: TP53 Mutation Does Not Confer a Poor Outcome in Adult Patients With Acute Lymphoblastic Leukemia Who Are Treated With Frontline Hyper-CVAD-Based Regimens CANCER. 2017.10; 123 (19): 3717-3724. ( PubMed , DOI )

  33. Yamada A., Numasawa Y., Hattori T., Ozaki K., Ishibashi S., Nishida Y., Kanouchi T., Sanjo N., Takanori Y.: Signal changes of skeletal muscle MRI in peripheral nerve disorders JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017.10; 381 1068. ( DOI )

  34. Jain, P; Kantarjian, H; Jain, N; Short, NJ; Yin, CC; Kanagal-Shamanna, R; Khoury, J; Konopleva, M; Sasaki, K; Kadia, TM; Garris, R; Pierce, S; Estrov, Z; Wierda, W; Cortes, J; O'Brien, S; Ravandi, F; Jabbour, E: Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens AMERICAN JOURNAL OF HEMATOLOGY. 2017.10; 92 (10): E595-E597. ( PubMed , DOI )

  35. Murakawa Miyako, Asahina Yasuhiro, Nagata Hiroko, Nakagawa Mina, Kakinuma Sei, Nitta Sayuri, Kawai-Kitahata Fukiko, Otani Satoshi, Kaneko Shun, Miyoshi Masato, Tsunoda Tomoyuki, Asano Yu, Sato Ayako, Itsui Yasuhiro, Azuma Seishin, Nouchi Toshihiko, Furumoto Yohei, Asano Tooru, Chuganji Yoshimichi, Tohda Shuji, Watanabe Mamoru: ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin Hepatology Research. 2017.10; 47 (11): 1212-1218. ( 医中誌 )

  36. Assi, R; Kantarjian, H; Ravandi, F; O'Brien, SM; Kebriaei, P; Short, NJ; Thomas, DA; Garcia-Manero, G; Champlin, RE; Kadia, TM; Cortes, JE; Jain, N; Konopleva, M; Khouri, R; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Garris, R; Jabbour, E: A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S264-S265. ( DOI )

  37. Yoshimoto Ryoto, Watanabe Ken, Uchida Emi, Suwa Shihoko, Tohda Shuji, Hatano Masahiko, Miura Osamu, Fukuda Tetsuya: IVNS1ABP/Nd1は新規治療標的分子として難治性リンパ腫に強発現する(IVNS1ABP/Nd1 is highly expressed in refractory lymphoma as a novel therapeutic target molecule) 臨床血液. 2017.09; 58 (9): 1655. ( 医中誌 )

  38. Jabbour, E; Short, NJ; Montalban-Bravo, G; Huang, XL; Bueso-Ramos, C; Qiao, W; Yang, H; Zhao, C; Kadia, T; Borthakur, G; Pemmaraju, N; Sasaki, K; Estrov, Z; Cortes, J; Ravandi, F; Alvarado, Y; Komrokji, R; Sekeres, MA; Steensma, DP; DeZern, A; Roboz, G; Kantarjian, H; Garcia-Manero, G: Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN BLOOD. 2017.09; 130 (13): 1514-1522. ( PubMed , DOI )

  39. Maiti, A; Kantarjian, H; Ravandi, F; Thomas, D; Khouri, M; Garcia-Manero, G; Garris, R; Cortes, J; Short, N; Sasaki, K; Issa, G; Koller, P; Schroeder, H; Kadia, T; Verstovsek, S; Daver, N; Jain, N; Konopleva, M; O'Brien, S; Jabbour, E: Frontline Ofatumumab with Hyper-CVAD in CD20+Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S256-S257. ( DOI )

  40. Maiti, A; Kantarjian, H; O'Brien, S; Ravandi, F; Short, N; Thomas, D; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, P; Cortes, J; Jabbour, E: Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S255-S256. ( DOI )

  41. Maiti, A; Kantarjian, H; Ravandi, F; Short, N; Daver, N; Pemmaraju, N; Thomas, D; Yilmaz, M; Kadia, T; Sasaki, K; Garris, R; Garcia-Manero, G; DiNardo, C; Konopleva, M; Estrov, Z; Jain, N; Weirda, W; Jeanis, V; Cortes, J; O'Brien, S; Jabbour, E: Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S257-S258. ( DOI )

  42. Sasaki, K; Jabbour, E; O'Brien, S; Thomas, D; Garcia-Manero, G; Ravandi, F; Borthakur, G; Short, N; Issa, G; Gachimova, E; Garris, R; Cortes, J; Kantarjian, H: Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017.09; 17 S266. ( DOI )

  43. Mika Ohtaka, Mai Itoh, Shuji Tohda: BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells. Anticancer Res.. 2017.08; 37 (11): 6047-6053. ( PubMed , DOI )

  44. Erika Shiratori, Mai Itoh, Shuji Tohda: MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells. Anticancer Res.. 2017.07; 37 (11): 6203-6209. ( PubMed , DOI )

  45. Short, N; Kantarjian, H; Ravandi, F; Daver, N; Pemmaraju, N; Thomas, D; Yilmaz, M; Kadia, T; Sasaki, K; Garris, R; Garcia-Manero, G; DiNardo, C; Konopleva, M; Estrov, Z; Jain, N; Wierda, W; Jeanis, V; Cortes, J; O'Brien, S; Jabbour, E: UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA HAEMATOLOGICA. 2017.06; 102 198.

  46. Short, N; Kantarjian, H; Ravandi, F; Huang, X; Xiao, L; Garcia-Manero, G; Plunkett, W; Gandhi, V; Sasaki, K; Pemmaraju, N; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Estrov, Z; Kadia, T; Wierda, W; DiNardo, C; Brandt, M; O'Brien, S; Cortes, J; Jabbour, E: A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE OR FLUDARABINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HAEMATOLOGICA. 2017.06; 102 53.

  47. Short, N; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, D; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, P; Cortes, J; Jabbour, E: INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL HAEMATOLOGICA. 2017.06; 102 34-35.

  48. Short, NJ; Kantarjian, HM; O'Brien, SM; Ravandi, F; Thomas, DA; Garcia-Manero, G; Daver, NG; Borthakur, G; Jain, N; Konopleva, M; Sasaki, K; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, PA; Cortes, JE; Jabbour, E: Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  49. Maiti, A; Kantarjian, HM; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Issa, GC; Koller, PB; Schroeder, HM; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E: Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+acute lymphoblastic leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  50. Short, NJ; Kantarjian, HM; Ravandi, F; Daver, NG; Pemmaraju, N; Thomas, DA; Yilmaz, M; Kadia, TM; Sasaki, K; Garris, R; Garcia-Manero, G; Dinardo, CD; Konopleva, M; Estrov, Z; Jain, N; Wierda, WG; Jeanis, V; Cortes, JE; O'Brien, SM; Jabbour, E: Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Updated results of a phase II study. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  51. Assi, R; Kantarjian, HM; Ravandi, F; O'Brien, SM; Kebriaei, P; Thomas, DA; Garcia-Manero, G; Khouri, IF; Champlin, RE; Kadia, TM; Cortes, JE; Jain, N; Konopleva, M; Khouri, R; Estrov, Z; Takahashi, K; Sasaki, K; Jacob, J; Garris, R; Jabbour, E: Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  52. Yuki Okuhashi, Mai Itoh, Shuji Tohda: Hedgehog Stimulation Suppresses Clonogenicity and Activates NOTCH Signalling in T-lymphoblastic Leukaemia Jurkat Cells. Anticancer Res.. 2017.05; 37 (9): 5005-5009. ( PubMed , DOI )

  53. S Nogami, N Kawaguchi-Ihara, E Shiratori, M Ohtaka, M Itoh, S Tohda: Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods. Int J Lab Hematol. 2017.04; 39 (2): 163-168. ( PubMed , DOI )

  54. Gettys, SC; Gulbis, A; Wilhelm, K; Sasaki, K; Dinh, Y; Rondon, G; Qazilbash, MH: Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma EUROPEAN JOURNAL OF HAEMATOLOGY. 2017.04; 98 (4): 388-392. ( PubMed , DOI )

  55. Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Ko, H; Yin, CC; Garcia-Manero, G; Cortes, JE; Garris, R; O'Brien, SM; Patel, K; Khouri, M; Thomas, D; Jain, N; Kadia, TM; Daver, NG; Benton, CB; Issa, GC; Konopleva, M; Jabbour, E: Poor outcomes associated with+1der(22) t(9;22) and-9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor AMERICAN JOURNAL OF HEMATOLOGY. 2017.03; 92 (3): 238-243. ( PubMed , DOI )

  56. Jabbour, E; Faderl, S; Sasaki, K; Kadia, T; Daver, N; Pemmaraju, N; Patel, K; Khoury, JD; Bueso-Ramos, C; Bohannan, Z; Ravandi, F; Borthakur, G; Verstovsek, S; Miller, D; Maduike, R; Hosing, C; Kantarjian, HM; Garcia-Manero, G: Phase 2 Study of Low-Dose Clofarabine Plus Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome Who Have Relapsed or Are Refractory to Hypomethylating Agents CANCER. 2017.02; 123 (4): 629-637. ( PubMed , DOI )

  57. Issa, GC; Kantarjian, HM; Yin, CC; Qiao, W; Ravandi, F; Thomas, D; Short, NJ; Sasaki, K; Garcia-Manero, G; Kadia, TM; Cortes, JE; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Khouri, I; Kebriaei, P; Champlin, RE; Pierce, S; O'Brien, SM; Jabbour, E: Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease CANCER. 2017.02; 123 (3): 459-467. ( PubMed , DOI )

  58. Jabbour, E; Short, NJ; Jorgensen, JL; Yilmaz, M; Ravandi, F; Wang, SA; Thomas, DA; Khoury, J; Champlin, RE; Khouri, I; Kebriaei, P; O'Brien, SM; Garcia-Manero, G; Cortes, JE; Sasaki, K; Dinardo, CD; Kadia, TM; Jain, N; Konopleva, M; Garris, R; Kantarjian, HM: Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CANCER. 2017.01; 123 (2): 294-302. ( PubMed , DOI )

  59. Miyako Murakawa, Yasuhiro Asahina, Hiroko Nagata, Mina Nakagawa, Sei Kakinuma, Sayuri Nitta, Fukiko Kawai-Kitahata, Satoshi Otani, Shun Kaneko, Masato Miyoshi, Tomoyuki Tsunoda, Yu Asano, Ayako Sato, Yasuhiro Itsui, Seishin Azuma, Toshihiko Nouchi, Yohei Furumoto, Tooru Asano, Yoshimichi Chuganji, Shuji Tohda, Mamoru Watanabe: ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin. Hepatol. Res.. 2017.01; ( PubMed , DOI )

  60. Iwasawa Eri, Ohkubo Takuya, Kanouchi Tadashi, Kanda Takashi, Mizusawa Hidehiro, Yokota Takanori: Long-term Effects of Intravenous Cyclophosphamide in Combination with Mesna Provided Intravenously and via Bladder Perfusion in a Patient with Severe Multifocal Motor Neuropathy INTERNAL MEDICINE. 2017; 56 (14): 1893-1896. ( PubMed , DOI )

  1. Short, NJ; Jabbour, EJ; Sasaki, K; Ko, HD; Ravandi, F; Yin, CC; Khouri, MR; Cortes, JE; Garris, R; O'Brien, SM; Patel, KP; Garcia-Manero, G; Thomas, DA; Daver, N; Naqvi, K; Bose, P; Jain, N; Konopleva, M; Kantarjian, HM: Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality BLOOD. 2016.12; 128 (22): ( DOI )

  2. Short, NJ; Kantarjian, HM; Jorgensen, JL; Ravandi, F; Yilmaz, M; Khouri, MR; Wang, S; Thomas, DA; Khoury, JD; Champlin, RE; Khouri, IF; Kebriaei, P; Marin, D; O'Brien, SM; Garcia-Manero, G; Cortes, JE; Sasaki, K; DiNardo, CD; Kadia, TM; Jain, N; Konopleva, M; Garris, R; Jabbour, EJ: Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment BLOOD. 2016.12; 128 (22): ( DOI )

  3. Jabbour, EJ; Short, NJ; Huang, X; Maiti, A; Kadia, TM; Daver, N; Borthakur, G; DiNardo, CD; Pemmaraju, N; Sasaki, K; Estrov, Z; Verstovsek, S; Ravandi, F; Alvarado, Y; Sekeres, MA; Komrokji, RS; Steensma, DP; DeZern, AE; Roboz, GJ; Miller, D; Dong, X; Kantarjian, HM; Garcia-Manero, G: A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium BLOOD. 2016.12; 128 (22): ( DOI )

  4. Sasaki, K; Kantarjian, HM; Jabbour, EJ; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Wierda, WG; Daver, N; Takahashi, K; Jain, P; Skinner, J; Rios, MB; Pierce, S; Garcia-Manero, G; Cortes, JE: Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase BLOOD. 2016.12; 128 (22): ( DOI )

  5. Kanagal-Shamanna, R; Jain, P; Luthra, R; Patel, KP; Garcia-Manero, G; Takahashi, K; Ravandi, F; Sasaki, K; Kadia, TM; Borthakur, G; Konopleva, M; Jain, N; Garris, R; Pierce, S; Estrov, Z; Wierda, WG; O'Brien, SM; Cortes, JE; Kantarjian, HM; Jabbour, EJ: Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens BLOOD. 2016.12; 128 (22): ( DOI )

  6. Jain, P; Kantarjian, HM; Ravandi, F; Kanagal-Shamanna, R; Khoury, JD; Patel, KP; Garcia-Manero, G; Konopleva, M; Jain, N; Sasaki, K; Kadia, TM; Borthakur, G; Garris, R; Pierce, S; Estrov, Z; Wierda, WG; Cortes, JE; O'Brien, SM; Jabbour, EJ: Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens BLOOD. 2016.12; 128 (22): ( DOI )

  7. Jabbour, EJ; Kantarjian, HM; Sasaki, K; Kadia, TM; Ravandi, F; Cortes, JE; Khoury, JD; Patel, KP; Bueso-Ramos, CE; Daver, NG; Borthakur, G; Jain, N; DiNardo, CD; Konopleva, M; Verstovsek, S; Pemmaraju, N; Estrov, Z; Miller, D; Maduike, R; Faderl, S; Garcia-Manero, G: Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy BLOOD. 2016.12; 128 (22): ( DOI )

  8. Miyako Murakawa, Yasuhiro Asahina, Fukiko Kawai-Kitahata, Mina Nakagawa, Sayuri Nitta, Satoshi Otani, Hiroko Nagata, Shun Kaneko, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhito Tanaka, Sayuki Iijima, Kaoru Tsuchiya, Namiki Izumi, Shuji Tohda, Mamoru Watanabe: Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. [Epub ahead of print] J. Med. Virol.. 2016.12; ( PubMed , DOI )

  9. Gene Igawa, Mika Casey, Etsuko Sawabe, Yoko Nukui, Shu Okugawa, Kyoji Moriya, Ryuji Koike, Shuji Tohda, Ryoichi Saito: Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing. J Glob Antimicrob Resist. 2016.12; 43-45. ( PubMed , DOI )

  10. Koji Sasaki, Elias J Jabbour, Farhad Ravandi, Nicholas J Short, Deborah A Thomas, Guillermo Garcia-Manero, Naval G Daver, Tapan M Kadia, Marina Y Konopleva, Nitin Jain, Ghayas C Issa, Vicki Jeanis, Haim G Moore, Rebecca S Garris, Naveen Pemmaraju, Jorge E Cortes, Susan M O'Brien, Hagop M Kantarjian: Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016.12; 122 (23): 3650-3656. ( PubMed , DOI )

  11. Jain, P; Kantarjian, HM; Jabbour, EJ; Gonzalez, GN; Garcia-Manero, G; Kanagal-Shamanna, R; Patel, KP; Hu, SM; DellaSala, SE; Pierce, S; Sasaki, K; Konopleva, M; Wierda, WG; Daver, N; Kadia, TM; Borthakur, G; Estrov, Z; Ravandi, F; O'Brien, SM; Cortes, JE: Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients BLOOD. 2016.12; 128 (22): ( DOI )

  12. Sasaki, K; Kantarjian, HM; Ravandi, F; Daver, N; Kadia, TM; Khouri, RB; Alvarado, Y; Burger, JA; Thomas, DA; Garcia-Manero, G; DiNardo, CD; Pemmaraju, N; Short, NJ; Schroeder, H; Garris, R; Bose, P; Jain, N; Naqvi, K; Wierda, WG; Verstovsek, S; Cortes, JE; Konopleva, M; O'Brien, SM; Jabbour, EJ: Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial BLOOD. 2016.12; 128 (22): ( DOI )

  13. Sasaki, K; Jabbour, EJ; O'Brien, SM; Ravandi, F; Thomas, DA; Garcia-Manero, G; Daver, N; Borthakur, G; Jain, N; Konopleva, M; Short, NJ; Pemmaraju, N; Alvarado, Y; Jacob, J; Garris, R; Thompson, PA; Cortes, JE; Kantarjian, HM: Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial BLOOD. 2016.12; 128 (22): ( DOI )

  14. Patel, YB; Voit, KN; Sasaki, K; Ravandi, F; Thomas, DA; O'Brien, SM; Borthakur, G; Garcia-Manero, G; Cortes, JE; Konopleva, M; Jain, N; Ohanian, M; Garris, R; Jacob, J; Kantarjian, HM; Jabbour, EJ: Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen BLOOD. 2016.12; 128 (22):

  15. Sasaki, K; Jabbour, EJ; O'Brien, SM; Thomas, DA; Ravandi, F; Garcia-Manero, G; Cortes, JE; Short, NJ; Verstovsek, S; Yilmaz, M; Wierda, WG; Borthakur, G; Kadia, TM; Konopleva, M; Khouri, MR; Ferrajoli, A; Daver, NG; Pemmaraju, N; DiNardo, CD; Jain, N; Benton, CB; Takahashi, K; Naqvi, K; Bose, P; Kornblau, SM; Andreeff, M; Keating, MJ; Freireich, EJ; Kantarjian, HM: Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience BLOOD. 2016.12; 128 (22): ( DOI )

  16. Sasaki, K; Jabbour, EJ; Ravandi, F; Daver, NG; Pemmaraju, N; Thomas, DA; Khouri, RB; Yilmaz, M; Kadia, TM; Short, NJ; Garris, R; Garcia-Manero, G; DiNardo, CD; Konopleva, M; Estrov, Z; Jain, N; Wierda, WG; Jeanis, TV; Cortes, JE; O'Brien, SM; Kantarjian, HM: Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia BLOOD. 2016.12; 128 (22): ( DOI )

  17. Sasaki, K; Kantarjian, HM; O'Brien, S; Ravandi, F; Konopleva, M; Borthakur, G; Garcia-Manero, G; Wierda, WG; Daver, N; Ferrajoli, A; Takahashi, K; Jain, P; Rios, MB; Pierce, S; Jabbour, EJ; Cortes, JE: Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) BLOOD. 2016.12; 128 (22): ( DOI )

  18. Sasaki, K; Jabbour, EJ; O'Brien, SM; Ravandi, F; Thomas, DA; Kadia, TM; Garcia-Manero, G; Burger, JA; Pemmaraju, N; Alvarado, Y; Daver, NG; Jain, N; Konopleva, M; Champlin, RE; Khouri, IF; Kebriaei, P; Marin, D; DiNardo, CD; Estrov, Z; Takahashi, K; Short, NJ; Khouri, MR; Jacob, J; Garris, R; Cortes, JE; Kantarjian, HM: Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) BLOOD. 2016.12; 128 (22): ( DOI )

  19. Short, NJ; Kantarjian, HM; Sasaki, K; Cortes, JE; Ravandi, F; Thomas, DA; Garcia-Manero, G; Khouri, I; Kebriaei, P; Champlin, RE; Pierce, S; Issa, GC; Konopleva, M; Kadia, TM; Bueso-Ramos, C; Khoury, JD; Jain, N; O'Brien, SM; Jabbour, E: Prognostic Significance of Day 14 Bone Marrow Evaluation in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia CANCER. 2016.12; 122 (24): 3812-3820. ( PubMed , DOI )

  20. Takahashi, K; Kantarjian, HM; Yang, YL; Sasaki, K; Jain, P; DellaSala, S; Ravandi, F; Kadia, T; Pemmaraju, N; Daver, N; Borthakur, G; Garcia-Manero, G; Jabbour, E; Cortes, JE: A Propensity Score Matching Analysis of Dasatinib and Nilotinib as a Frontline Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase CANCER. 2016.11; 122 (21): 3336-3343. ( PubMed , DOI )

  21. Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O'Brien, Hagop Kantarjian, Farhad Ravandi: Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016.11; 16 (11): 616-624. ( PubMed , DOI )

  22. Shinji Ogihara, Ryoichi Saito, Etsuko Sawabe, Michio Hagihara, Shuji Tohda: First Japanese case of infectious endocarditis due to Enterococcus faecalis small-colony variants. J. Infect. Chemother. 2016.10; 22 (10): 716-719. ( PubMed , DOI )

  23. Tamamyan, GN; Kantarjian, HM; Ning, J; Jain, P; Sasaki, K; McClain, KL; Allen, CE; Pierce, SA; Cortes, JE; Ravandi, F; Konopleva, MY; Garcia-Manero, G; Benton, CB; Chihara, D; Rytting, ME; Wang, S; Abdelall, W; Konoplev, SN; Daver, NG: Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes CANCER. 2016.09; 122 (18): 2857-2866. ( PubMed , DOI )

  24. Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E Cortes: Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016.08; 101 (8): e324-e327. ( PubMed , DOI )

  25. Hiroko Nagata, Mina Nakagawa, Yuki Nishimura-Sakurai, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Fumio Goto, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Naoko Tojo, Shuji Tohda, Yasuhiro Asahina, Mamoru Watanabe, : Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.[Epub ahead of print] Hepatol Int. 2016.07; ( PubMed , DOI )

  26. Short, NJ; Jabbour, E; Sasaki, K; Patel, K; O'Brien, SM; Cortes, JE; Garris, R; Issa, GC; Garcia-Manero, G; Luthra, R; Thomas, D; Kantarjian, H; Ravandi, F: Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia BLOOD. 2016.07; 128 (4): 504-507. ( PubMed , DOI )

  27. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa: Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  28. Issa, GC; Kantarjian, HM; Ravandi, F; Thomas, DA; Khouri, M; Garcia-Manero, G; Garris, RS; Cortes, JE; Short, NJ; Sasaki, K; Schroeder, HM; Kadia, TM; Verstovsek, S; Daver, NG; Jain, N; Konopleva, M; O'Brien, SM; Jabbour, E: Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  29. Sasaki, K; Kantarjian, HM; Ravandi, F; Thomas, DA; Cortes, JE; Pemmaraju, N; Kadia, TM; Short, NJ; Issa, GC; Garris, RS; Jeanis, V; Moore, HG; Garcia-Manero, G; Borthakur, G; Wierda, WG; Gachimova, E; O'Brien, SM; Jabbour, E: Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  30. Short, NJ; Kantarjian, HM; Sasaki, K; Ravandi, F; Garcia-Manero, G; Thomas, DA; Pierce, S; Issa, GC; Cortes, JE; Kadia, TM; Jain, N; O'Brien, SM; Jabbour, E: xPrognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  31. Hu, B; Sasaki, K; Bashir, Q; Shah, N; Patel, KK; Popat, UR; Hosing, C; Nieto, Y; Lin, P; Delgado, R; Jorgensen, JL; Shah, JJ; Manasanch, EE; Weber, DM; Thomas, SK; Orlowski, RZ; Champlin, RE; Qazilbash, MH: Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  32. Short, NJ; Jabbour, E; Cortes, JE; Garris, R; O'Brien, SM; Patel, K; Sasaki, K; Issa, GC; Garcia-Manero, G; Thomas, DA; Kantarjian, HM; Ravandi, F: Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  33. Issa, GC; Kantarjian, HM; Yin, CC; Ravandi, F; Garcia-Manero, G; Thomas, DA; Cortes, JE; Short, NJ; Sasaki, K; Qiao, W; Takahashi, K; Pierce, S; Verstovsek, S; Kadia, TM; Borthakur, G; O'Brien, SM; Jabbour, E: Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  34. Sasaki, K; Kantarjian, HM; Ravandi, F; Thomas, DA; Daver, NG; Kadia, TM; Konopleva, M; Jain, N; Short, NJ; Issa, GC; Jeanis, V; Moore, HG; Garris, RS; Garcia-Manero, G; Cortes, JE; O'Brien, SM; Jabbour, E: Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  35. Jain, P; Kantarjian, H; Sasaki, K; Jabbour, E; Dasarathula, J; Gonzalez, GN; Verstovsek, S; Borthakur, G; Wierda, W; Kadia, T; Dellasala, S; Pierce, S; Ravandi, F; O'Brien, S; Cortes, J: Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes BRITISH JOURNAL OF HAEMATOLOGY. 2016.04; 173 (1): 114-126. ( PubMed , DOI )

  36. Noriko Kawaguchi-Ihara, Mai Itoh, Ikuo Murohashi, Shuji Tohda: Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells. Oncol Lett. 2016.04; 11 (4): 2429-2432. ( PubMed , DOI )

  37. Ramlal, R; Sasaki, K; Cerrada, SL; Srour, SA; Chen, JLN; Rondon, RG; Rezvani, K; Oran, B; Olson, A; Shpall, EJ; Champlin, RE; Ciurea, SO: Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide - a Single Institution Experience BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S375-S376. ( DOI )

  38. Sasaki, K; Lahoti, A; Jabbour, E; Jain, P; Pierce, S; Borthakur, G; Daver, N; Kadia, T; Pemmaraju, N; Ferrajoli, A; O'Brien, S; Kantarjian, H; Cortes, J: Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2016.03; 16 (3): 152-162. ( PubMed , DOI )

  39. Jain, P; Kantarjian, H; Patel, KP; Gonzalez, GN; Luthra, R; Shamanna, RK; Sasaki, K; Jabbour, E; Romo, CG; Kadia, TM; Pemmaraju, N; Daver, N; Borthakur, G; Estrov, Z; Ravandi, F; O'Brien, S; Cortes, J: Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors BLOOD. 2016.03; 127 (10): 1269-1275. ( PubMed , DOI )

  40. Qazilbash, MH; Chen, J; Valdez, BC; Sasaki, K; Kawedia, JD; Bashir, Q; Hosing, C; Kebriaei, P; Nieto, Y; Shah, N; Patel, K; Shpall, EJ; Andersson, BS; Champlin, RE; Popat, U: Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S228-S229. ( DOI )

  41. Sasaki, K; Bashir, Q; Shah, N; Hosing, C; Popat, UR; Nieto, Y; Parmar, S; Shah, J; Weber, D; Thomas, S; Orlowski, RZ; Champlin, RE; Qazilbash, MH: Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016.03; 22 (3): S231-S232. ( DOI )

  42. Koji Sasaki, Hagop M Kantarjian, Preetesh Jain, Elias J Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Koichi Takahashi, Naveen Pemmaraju, Naval Daver, Sherry A Pierce, Susan M O'Brien, Jorge E Cortes: Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016.01; 122 (2): 238-248. ( PubMed , DOI )

  43. Jacobs, RW; Saliba, RM; Sasaki, K; Farhan, S; Armas, A; Shah, ND; Bashir, Q; Qureshi, S; Rondon, G; Hosing, C; Popat, U; Parmar, S; Shah, JJ; Wang, M; Weber, DM; Thomas, SK; Orlowski, RZ; Champlin, RE; Qazilbashi, MH: Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2016.01; 16 (1): 36-42. ( PubMed , DOI )

  44. Mari Kamiya, Peter Y Shane, Makoto Soejima, Shuji Tohda, Nobuyuki Miyasaka, Hitoshi Kohsaka: IgG4-Related Sialoadenitis with a Skin Lesion and Multiple Mononeuropathies Suggesting Coexistent Cryoglobulinemic Vasculitis. Intern. Med.. 2016; 55 (10): 1355-1361. ( PubMed , DOI )

  1. Koji Sasaki, Sara S Strom, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Preetesh Jain, Sherry Pierce, Hagop Kantarjian, Jorge E Cortes: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015.05; 2 (5): e186-e193. ( PubMed , DOI )

  2. Nogami Ayako, Oshikawa Gaku, Okada Keigo, Fukutake Shusaku, Umezawa Yoshihiro, Nagao Toshikage, Kurosu Tetsuya, Miura Osamu: FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget. 2015.04; 6 (11): 9189-9205. ( PubMed )

  3. Mitsuma S, Van den Bergh P, Rajabally YA, Van Parijs V, Martin-Lamb D, Sonoo M, Inaba A, Shimizu T, Isose S, Sato Y, Komori T, Misawa S, Kuwabara S, The Tokyo Metropolitan Neuromuscular Electrodiagnosis Study Group(including Kanouchi T): Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese-European multicenter prospective study. Clinical Neurophysiology. 2015; 126 1805-1810.

  1. Saito R, Takahashi R, Sawabe E, Koyano S, Takahashi Y, Shima M, Ushizawa H, Fujie T, Tosaka N, Kato Y, Moriya K, Tohda S, Tojo N, Koike R, Kubota T: First Report of KPC-2 Carbapenemase-Producing Klebsiella pneumoniae in Japan. Antimicrob Agents Chemother. 2014.05; 58 (5): 2961-2963. ( PubMed , DOI )

  2. Takebe I, Sawabe E, Ohkusu K, Tojo N, Tohda S: Catheter-related Bloodstream Infection by Tsukamurella inchonensis in an Immunocompromised Patient. J Clin Microbiol. 2014.03; 52 (6): 2251-2253. ( PubMed , DOI )

  3. Mizuno N, Kanamori E, Saito H, Murakami N, Tojo N, Tohda S: A Case of Gray Platelet Syndrome Masked by Immune Thrombocytopenia at Presentation. Acta Haematol. 2014.02; 132 (2): 163-165. ( PubMed , DOI )

  4. Teruhiko Sekiguchi, Tadashi Kanouchi, Kazumoto Shibuya, Yu-ichi Noto, Yohsuke Yagi, Akira Inaba, Keisuke Abe, Sonoko Misawa, Satoshi Orimo, Takayoshi Kobayashi, Tomoyuki Kamata, Masanori Nakagawa, Satoshi Kuwabara, Hidehiro Mizusawa, Takanori Yokota: Spreading of amyotrophic lateral sclerosis lesions--multifocal hits and local propagation? J. Neurol. Neurosurg. Psychiatr.. 2014.01; 85 (1): 85-91. ( PubMed , DOI )

  5. Tohda S: NOTCH signaling roles in acute myeloid leukemia cell growth and interaction with other stemness-related signals. Anticancer Research. 2014; 34 (11): 6259-6264. ( PubMed )

  6. Takahashi Y, Itoh M, Nara N, Tohda S: Effect of EPH-ephrin signaling on the growth of human leukemia cells. Anticancer Research. 2014; 34 2913-2918.

  7. Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O: Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS ONE. 2014; 9 (1): e84746. ( PubMed , DOI )

  1. Okuhashi Y, Itoh M, Nara N, Tohda S: NOTCH knockdown affects the proliferation and mTOR signaling of leukemia cells. Anticancer Res. 2013.10; 33 (10): 4293-4298. ( PubMed )

  2. Yonekura S, Itoh M, Okuhashi Y, Takahashi Y, Ono A, Nara N, Tohda S: Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells. Anticancer Res. 2013.08; 33 (8): 3099-3103. ( PubMed )

  3. Ono A, Oike R, Okuhashi Y, Takahashi Y, Itoh M, Nara N, Tohda S: Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells. Anticancer Research. 2013.03; 33 (3): 809-813. ( PubMed )

  1. Kanamori E, Itoh M, Tojo N, Koyama T, Nara N, Tohda S: Flow cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and leukemia cells. Exp Ther Med. 2012.09; 4 (3): 397-400. ( PubMed , DOI )

  2. Ono A, Okuhashi Y, Takahashi Y, Itoh M, Nara N, Tohda S: Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation. Oncol Lett. 2012.08; 4 (2): 205-208. ( PubMed , DOI )

  3. Takahashi Y, Ishigaki T, Okuhashi Y, Ono A, Itoh M, Nara N, Tohda S: Effect of BMP4 on the growth and clonogenicity of human leukemia and lymphoma cells. Anticancer Res. 2012.07; 32 (7): 2813-2817. ( PubMed )

  4. Kanouchi Tadashi, Ohkubo Takuya, Yokota Takanori: Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012.07; 83 (7): 739-745. ( PubMed , DOI )

  5. Kitamura Y, Sawabe E, Ohkusu K, Tojo N, Tohda S: First report of sepsis caused by Rhodococcus corynebacterioides in a patient with myelodysplastic syndrome. J Clin Microbiol. 2012.03; 50 (3): 1089-1091. ( PubMed , DOI )

  1. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, Medin JA, Tohda S, Schueler J, Fisch P, Keating A: Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy. 2011.07; 13 (6): 753-764. ( PubMed , DOI )

  2. Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Murohashi I, Nara N, Tohda S: Promotion of the self-renewal capacity of human leukemia cells by sonic hedgehog protein. Anticancer Res. 2011.03; 31 (3): 781-784. ( PubMed )

  3. Okuhashi Y, Itoh M, Nara N, Tohda S: Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res. 2011.03; 31 (3): 893-896. ( PubMed )

  4. Nara N, Suzuki T, Tohda S: The current medical education system in the world. J Med Dent Sci. 2011; 58 (2): 79-83. ( PubMed )

  1. Okuhashi Y, Itoh M, Arai A, Nara N, Tohda S: Gamma-secretase inhibitors induce erythroid differentiation in erythroid leukemia cell lines. Anticancer Res. 2010.10; 30 (10): 4071-4074. ( PubMed )

  2. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S: Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet. 2010.08; 201 (1): 62-65. ( PubMed , DOI )

  3. Okuhashi Y, Nara N, Tohda S: Effects of gamma-secretase inhibitors on the growth of leukemia cells. Anticancer Res. 2010.02; 30 (2): 495-498. ( PubMed )

  1. Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N, Tohda S: Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res. 2009.11; 29 (11): 4629-4632. ( PubMed )

  2. Fu L, Katsube K, Tohda S: Transition of cleaved Notch1 and gene expression changes in myeloblastic leukemia cells stimulated with notch ligands. Anticancer Res. 2009.10; 29 (10): 3967-3970. ( PubMed )

  3. Itoh M, Fu L, Tohda S: NF-kappaB activation induced by Notch ligand stimulation in acute myeloid leukemia cells. Oncol Rep. 2009.09; 22 (3): 631-634. ( PubMed )

  4. Nara N, Beppu M, Tohda S, Suzuki T: The introduction and effectiveness of simulation-based learning in medical education. Intern Med. 2009; 48 (17): 1515-1519. ( PubMed )

  1. Nemoto Y, Kanai T, Tohda S, Totsuka T, Okamoto R, Tsuchiya K, Nakamura T, Sakamoto N, Fukuda T, Miura O, Yagita H, Watanabe M: Negative feedback regulation of colitogenic CD4+ T cells by increased granulopoiesis. Inflamm Bowel Dis. 2008.11; 14 (11): 1491-1503. ( PubMed , DOI )

  2. Kawaguchi-Ihara N, Murohashi I, Nara N, Tohda S: Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A. Anticancer Res. 2008.09; 28 (5A): 2701-2704. ( PubMed )

  3. Kobayashi T, Terada Y, Kuwana H, Tanaka H, Okado T, Kuwahara M, Tohda S, Sakano S, Sasaki S: Expression and function of the Delta-1/Notch-2/Hes-1 pathway during experimental acute kidney injury. Kidney Int. 2008.06; 73 (11): 1240-1250. ( PubMed , DOI )

  4. Morita-Hoshi Y, Tohda S, Miura O, Nara N: An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis. Int J Hematol. 2008.01; 87 (1): 69-74. ( PubMed , DOI )

  1. Fu L, Nara N, Tohda S: Involvement of Notch signaling in myelodysplastic syndrome. Leuk Res. 2007.08; 31 (8): 1160-1161. ( PubMed , DOI )

  2. Kogoshi H, Sato T, Koyama T, Nara N, Tohda S: Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells. Oncol Rep. 2007.07; 18 (1): 77-80. ( PubMed )

  1. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, Nara N: Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res. 2006.11; 30 (11): 1385-1390. ( PubMed , DOI )

  2. Fu L, Kogoshi H, Nara N, Tohda S: NOTCH1 mutations are rare in acute myeloid leukemia. Leuk Lymphoma. 2006.11; 47 (11): 2400-2403. ( PubMed , DOI )

  1. Kogoshi H, Tohda S, Fu L, Koyama T, Nara N: Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells. Oncol Rep. 2005.09; 14 (3): 723-726. ( PubMed )

  2. Tohda S, Kogoshi H, Murakami N, Sakano S, Nara N: Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Exp Hematol. 2005.05; 33 (5): 558-563. ( PubMed , DOI )

  3. Murata-Ohsawa M, Tohda S, Kogoshi H, Sakano S, Nara N: The Notch ligand, Delta-1, alters retinoic acid (RA)-induced neutrophilic differentiation into monocytic and reduces RA-induced apoptosis in NB4 cells. Leuk Res. 2005.02; 29 (2): 197-203. ( PubMed , DOI )

  1. Murata-Ohsawa M, Tohda S, Kogoshi H, Nara N: The Notch ligand, Delta-1, reduces TNF-alpha-induced growth suppression and apoptosis by decreasing activation of caspases in U937 cells. Int J Mol Med. 2004.11; 14 (5): 861-866. ( PubMed )

  2. Murata-Ohsawa M, Tohda S, Nara N: Cellular analysis of growth suppression induced by the Notch ligands, Delta-1 and Jagged-1 in two myeloid leukemia cell lines. Int J Mol Med. 2004.08; 14 (2): 223-226. ( PubMed )

  3. Murata-Ohsawa M, Tohda S, Sakano S, Nara N: The Notch ligand, Delta-1, partially inhibits GM-CSF-induced differentiation and apoptosis along with reducing the cleavage of PARP in U937 cells. Int J Mol Med. 2004.03; 13 (3): 419-423. ( PubMed )

  1. Tohda S, Murata-Ohsawa M, Sakano S, Nara N: Notch ligands, Delta-1 and Delta-4 suppress the self-renewal capacity and long-term growth of two myeloblastic leukemia cell lines. Int J Oncol. 2003.05; 22 (5): 1073-1079. ( PubMed )

  1. Tohda S, Sakano S, Ohsawa M, Murakami N, Nara N: A novel cell line derived from de novo acute myeloblastic leukaemia with trilineage myelodysplasia which proliferates in response to a Notch ligand, Delta-1 protein. Br J Haematol. 2002.05; 117 (2): 373-378. ( PubMed )

  1. Tohda S, Murakami N, Nara N: Human herpesvirus 8 DNA in HIV-negative Japanese patients with multicentric Castleman's disease and related diseases. Int J Mol Med. 2001.11; 8 (5): 549-551. ( PubMed )

  2. Tohda S, Nara N: Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001.07; 42 (3): 467-472. ( PubMed )

  1. Tohda S, Ohkusa T: Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Am J Hematol. 2000.12; 65 (4): 329-330. ( PubMed )

  2. Tohda S, Murakami N, Nara N: Polymerase chain reaction detection of rearranged immunoglobulin heavy chain DNA in plasma samples is useful in the diagnosis of B-cell lymphoma. Int J Hematol. 2000.07; 72 (1): 74-78. ( PubMed )

  1. Tohda S, Sakashita C, Fukuda T, Murakami N, Nara N: Establishment of a double Philadelphia chromosome-positive acute lymphoblastic leukemia-derived cell line, TMD5: effects of cytokines and differentiation inducers on growth of the cells. Leuk Res. 1999.03; 23 (3): 255-261. ( PubMed )

  1. Tohda S, Koyama N, Tanaka M, Kida Y, Murakami N, Nara N: A case of atypical chronic myeloid leukemia regarded as MDS with myeloproliferative features. Acta Haematol. 1998; 100 (4): 191-194. ( PubMed )

  1. Tohda S, Nara N: Phosphorylation of signaling proteins in factor-independent myeloid leukemia cell lines. Int J Oncol. 1997.10; 11 (4): 843-847. ( PubMed )

  2. Tohda S, Maruyama M, Nara N: Molecular typing of methicillin-resistant Staphylococcus aureus by polymerase chain reaction: distribution of the typed strains in hospitals. Intern Med. 1997.10; 36 (10): 694-699. ( PubMed )

  3. Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K, Tanikawa S: Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia. Exp Hematol. 1997.03; 25 (3): 199-204. ( PubMed )

  1. Imai Y, Yasuhara S, Hanafusa N, Ohsaka A, Enokihara H, Tomizuka H, Sonoyama M, Miura YS, Tohda S, Nara N, Takahashi A: Clonal involvement of eosinophils in therapy-related myelodysplastic syndrome with eosinophilia, translocation t(1;7) and lung cancer. Br J Haematol. 1996.12; 95 (4): 710-714. ( PubMed )

  2. Tohda S, Kurokawa H, Nara N: Relation of protein kinase A and protein kinase C to signaling pathways of hematopoietic factors in leukemia cell lines. Int J Oncol. 1996.03; 8 (3): 521-524. ( PubMed )

  1. Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K, Tanikawa S: The effect of basic and acidic fibroblast growth factors (bFGF and aFGF) on the growth of leukemic blast progenitors in acute myelogenous leukemia. Exp Hematol. 1995.08; 23 (9): 1030-1034. ( PubMed )

  2. Tohda S, Kurokawa H, Nara N: Diversity and similarity in signaling pathways of hematopoietic growth factors in human leukemia cell lines. Leukemia. 1995.05; 9 (5): 879-883. ( PubMed )

  1. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N: All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 1994.11; 84 (9): 3001-3009. ( PubMed )

  2. Tohda S, Shudo K, Minden M: The effects of retinoic Acid analogs on the blast cells of acute myeloblastic-leukemia in culture. Int J Oncol. 1994.06; 4 (6): 1311-1314. ( PubMed )

  3. Tohda S, Minden MD: Modulation of growth factor receptors on acute myeloblastic leukemia cells by retinoic acid. Jpn J Cancer Res. 1994.04; 85 (4): 378-383. ( PubMed )

  4. Nara N, Tohda S: Successful treatment of refractory pure red cell aplasia by buserelin acetate. Acta Haematol. 1994; 92 (1): 42-45. ( PubMed )

  1. Tohda S, Ashman L, Minden M: The role of stroma cells on the proliferation and C-kit expression of acute myeloblastic-leukemia cells. Int J Oncol. 1993.12; 3 (6): 1141-1147. ( PubMed )

  2. Murohashi I, Tohda S, Imai Y, Hirai Y, Nara N: Growth potentiating activity of endogenous production of interleukin-1 and tumor necrosis factor alpha in blast cells of acute myeloblastic leukemia. Exp Hematol. 1993.07; 21 (7): 846-851. ( PubMed )

  3. Tohda S, Yang GS, Ashman LK, McCulloch EA, Minden MD: Relationship between c-Kit expression and proliferation in acute myeloblastic leukemia cell lines. J Cell Physiol. 1993.02; 154 (2): 410-418. ( PubMed , DOI )

  1. Nara N, Chen GJ, Murohashi I, Tohda S, Imai Y, Tomiyama J, Nagata K, Suzuki T, Tanikawa S, Shiina S: The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia. Exp Hematol. 1992.08; 20 (7): 904-908. ( PubMed )

  2. Tohda S, Curtis JE, McCulloch EA, Minden MD: Comparison of the effects of all-trans and cis-retinoic acid on the blast stem cells of acute myeloblastic leukemia in culture. Leukemia. 1992.07; 6 (7): 656-661. ( PubMed )

  3. Kawamata N, Maruyama Y, Toda S, Takase K, Akiyama H, Sakamaki H, Onozawa Y: A case of chronic lymphocytic leukaemia with myeloid associated antigen. Br J Haematol. 1992.01; 80 (1): 129-130. ( PubMed )

  4. Suzuki T, Bessho M, Hirashma K, Tohda S, Nagata K, Imai Y, Nara N: Interleukin-6 reduces the optimal growth in vitro of leukemic blast progenitors from acute myeloblastic leukemia patients. Acta Haematol. 1992; 87 (1-2): 63-68. ( PubMed )

  5. Tohda S, Nara N, Tanikawa S, Imai Y, Murakami N, Aoki N: Pure red cell aplasia following autoimmune haemolytic anaemia. Cell-mediated suppression of erythropoiesis as a possible pathogenesis of pure red cell aplasia. Acta Haematol. 1992; 87 (1-2): 98-102. ( PubMed )

  6. Suzuki T, Tohda S, Nagata K, Imai Y, Murohashi I, Nara N: Enhanced effect of mutant granulocyte-colony-stimulating factor (KW-2228) on the growth of normal and leukemic hemopoietic progenitor cells in comparison with recombinant human granulocyte-colony-stimulating factor (G-CSF). Acta Haematol. 1992; 87 (4): 181-189. ( PubMed )

  7. Nara N, Tohda S, Suzuki T, Nagata K, Tanikawa S, Imai Y, Tomiyama J, Shiina S: Comparison of the proliferative activity and sensitivity to cytosine arabinoside of leukemic blast progenitors in acute myeloblastic leukemia at diagnosis and in relapse. Acta Haematol. 1992; 88 (1): 17-21. ( PubMed )

  1. Tohda S, Minden MD, McCulloch EA: Interactions between retinoic acid and colony-stimulating factors affecting the blast cells of acute myeloblastic leukemia. Leukemia. 1991.11; 5 (11): 951-957. ( PubMed )

  2. Tohda S, Nara N, Murohashi I, Aoki N: Establishment of an interleukin-3-dependent leukemic cell line from a patient with chronic lymphocytic leukemia in the acute phase. Blood. 1991.10; 78 (7): 1789-1794. ( PubMed )

  3. Suzuki T, Bessho M, Hirashima K, Tohda S, Nagata K, Morio T, Imai Y, Nara N: Enhancement by transforming growth factor-beta 1 (TGF-beta 1) of the proliferation of leukemic blast progenitors stimulated with IL-3. J Cell Physiol. 1991.09; 148 (3): 396-403. ( PubMed , DOI )

  4. Yamashita Y, Tohda S, Nagata K, Suzuki T, Imai Y, Nara N: The in vitro effect of vincristine on the blast cell renewal in acute myeloblastic leukemia. Jpn J Med. 1991.09; 30 (5): 412-419. ( PubMed )

  5. Tohda S, Nara N, Imai Y, Aoki N: Effect of protein kinase inhibitors on the proliferation of leukemic cells stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor or interleukin-3. Leukemia. 1991.09; 5 (9): 813-814. ( PubMed )

  6. Imai Y, Nara N, Tohda S, Nagata K, Suzuki T, Nagasawa M, Murohashi I, Aoki N: Antiproliferative and differentiative effects of recombinant interleukin-4 on a granulocyte colony-stimulating factor-dependent myeloblastic leukemic cell line. Blood. 1991.07; 78 (2): 471-478. ( PubMed )

  7. Imai Y, Tohda S, Nagata K, Suzuki T, Nara N, Aoki N: Effects of recombinant interleukin 4 on the growth and differentiation of blast progenitors stimulated with G-CSF, GM-CSF and IL-3 from acute myeloblastic leukaemia patients. Br J Haematol. 1991.06; 78 (2): 173-179. ( PubMed )

  1. Nara N, Tohda S, Suzuki T, Nagata K, Yamashita Y, Imai Y, Maruyama Y, Tomiyama J: Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia. Cancer Res. 1990.12; 50 (23): 7587-7592. ( PubMed )

  2. Suzuki T, Morio T, Tohda S, Nagata K, Yamashita Y, Imai Y, Aoki N, Hirashima K, Nara N: Effects of interleukin-6 and granulocyte colony-stimulating factor on the proliferation of leukemic blast progenitors from acute myeloblastic leukemia patients. Jpn J Cancer Res. 1990.10; 81 (10): 979-986. ( PubMed )

  3. Tohda S, Morio T, Suzuki T, Nagata K, Kamiyama T, Imai Y, Nara N, Aoki N: Richter syndrome with two B cell clones possessing different surface immunoglobulins and immunoglobulin gene rearrangements. Am J Hematol. 1990.09; 35 (1): 32-36. ( PubMed )

  4. Nara N, Suzuki T, Nagata K, Tohda S, Yamashita Y, Nakamura Y, Imai Y, Morio T, Minamihisamatsu M: Granulocyte colony-stimulating factor-dependent growth of an acute myeloblastic leukemia cell line. Jpn J Cancer Res. 1990.06; 81 (6-7): 625-631. ( PubMed )

  5. Tohda S, Suzuki T, Nagata K, Nara N, Aoki N: Successful treatment of a patient with posthepatitic severe aplastic anemia with bolus methylprednisolone. Jpn J Med. 1990.03; 29 (2): 191-194. ( PubMed )

  6. Murohashi I, Tohda S, Suzuki T, Nagata K, Yamashita Y, Nara N: Mechanism of action of interleukin 1 on the progenitors of blast cells in acute myeloblastic leukemia. Exp Hematol. 1990.02; 18 (2): 133-137. ( PubMed )

  7. Tohda S, Suzuki T, Nagata K, Nara N, Aoki N: Haematopoietic suppressing activity of gamma-interferon in serum and bone marrow of aplastic anaemia patients. Nippon Ketsueki Gakkai Zasshi. 1990.02; 53 (1): 14-20. ( PubMed )

  8. Nara N, Tohda S, Nagata K, Suzuki T, Yamashita Y, Imai Y: Effect of platelet-derived growth factor on the proliferation of blast progenitors from acute myeloblastic leukemia patients. Acta Haematol. 1990; 83 (4): 187-192. ( PubMed )

  9. Maruyama Y, Tohda S, Nagata K, Suzuki T, Murohashi I, Nara N: Role of humoral and cellular factors on the growth of blast progenitors of acute myeloblastic leukemia in serum-free culture. Hematol Pathol. 1990; 4 (3): 115-123. ( PubMed )

  10. Tohda S, Nagata K, Suzuki T, Nara N: Comparative effects of busulfan, cytosine arabinoside and adriamycin on different maturation stages of normal human bone marrow cells. Acta Haematol. 1990; 83 (1): 16-21. ( PubMed )

  11. Nara N, Tohda S, Suzuki T, Nagata K, Yamashita Y, Imai Y, Morio T, Bessho M, Shibuya A, Adachi Y: Terminal differentiation to mature neutrophils and eosinophils in suspension culture of the blast progenitors in acute myeloblastic leukemia. Hematol Pathol. 1990; 4 (3): 125-134. ( PubMed )

  1. Nagata K, Tohda S, Suzuki T, Nara N: Effects of recombinant human tumor necrosis factor on the self-renewal capacity of leukemia blast progenitors in acute myeloblastic leukemia. Leukemia. 1989.09; 3 (9): 626-630. ( PubMed )

  2. Nara N, Tohda S, Nagata K, Suzuki T, Yamashita Y: Inhibition of the in vitro growth of blast progenitors from acute myeloblastic leukemia patients by transforming growth factor-beta (TGF-beta). Leukemia. 1989.08; 3 (8): 572-577. ( PubMed )

  3. Murohashi I, Tohda S, Suzuki T, Nagata K, Yamashita Y, Nara N: Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia. Blood. 1989.07; 74 (1): 35-41. ( PubMed )

  4. Murohashi I, Tohda S, Suzuki T, Nagata K, Yamashita Y, Nara N, Aoki N: Expression of interleukin 1 beta receptors on blast cells in acute myeloblastic leukemia: comparison with interleukin 1 beta proliferative activity. Cancer Res. 1989.06; 49 (12): 3431-3435. ( PubMed )

  5. Murohashi I, Tohda S, Suzuki T, Nagata K, Yamashita Y, Nara N: Specific binding of radioiodinated human GM-CSF to the blast cells of acute myeloblastic leukemia. Leuk Res. 1989; 13 (7): 599-604. ( PubMed )

  1. 大谷 泰, 赤座 実穂, 夏井 洋和, 叶内 匡, 川端 茂徳: 【脊磁図,末梢神経磁図,筋磁図の臨床応用の可能性】磁場測定による筋活動の評価 臨床神経生理学. 2025.12; 53 (6): 687-693. ( 医中誌 )

  2. 安田 柊平, 小林 勇揮, 赤座 実穂, 叶内 匡, 西田 陽一郎, 三澤 園子: 三角筋導出の運動誘発電位によりC5神経根伝導ブロックを確認しえた21歳男性例 臨床神経生理学. 2025.10; 53 (5): 555. ( 医中誌 )

  3. 慕 健, 桑原 宏哉, 赤座 実穂, 叶内 匡, 西田 陽一郎, 三澤 園子: 日常的なサーフィンが発症の契機と考えた頸椎症性筋萎縮症の一例 臨床神経生理学. 2025.10; 53 (5): 630. ( 医中誌 )

  4. 山崎 あずさ, 貫井 陽子, 亀田 貴寛, 甲田 祐樹, 市村 直也, 齋藤 良一, 東田 修二, 大川 龍之介: COVID-19患者におけるプレセプシン測定の有用性および腎機能との関連 臨床化学. 2025.04; 54 (2): 112-118. ( 医中誌 )

  1. 赤座 実穂, 大谷 泰, 夏井 洋和, 叶内 匡, 横田 隆徳: 【生体磁界計測による脊髄・神経・筋活動の評価】磁場測定による運動単位の電気活動評価 臨床神経生理学. 2023.12; 51 (6): 674-681. ( 医中誌 )

  2. 叶内 匡: 治療法の再整理とアップデートのために　専門家による私の治療　圧迫性/絞扼性ニューロパチー(手根管症候群などの単ニューロパチー) 日本医事新報. 2023.12; (5200): 47-48. ( 医中誌 )

  3. 厚井 聡志, 野上 彩子, 藤原 煕基, 坂東 夏菜, 齊藤 真貴子, 長田 有生, 田中 圭祐, 坂下 千瑞子, 吉藤 康太, 岡田 啓五, 梅澤 佳央, 長尾 俊景, 山本 正英, 森 毅彦: 無症候性の脳出血を認めた急性前骨髄球性白血病 臨床血液. 2023.11; 64 (11): 1426-1430. ( 医中誌 )

  4. 鈴木 基弘, 三條 伸夫, 石黒 太郎, 吉濱 れい, 木塚 成美, 叶内 匡, 内山 由美子, 山田 正仁, 西田 陽一郎, 横田 隆徳: COVID-19感染に伴う脊髄炎の病態生理 NEUROINFECTION. 2023.10; 28 (2): 122. ( 医中誌 )

  5. 東田修二: 変異株スクリーニング 臨床検査. 2023.09; 67 (9): 954-958.

  6. 東田修二: T/NK細胞リンパ増殖性疾患とリンパ腫 臨床検査. 2023.07; 67 (7): 757-759.

  7. 福島 紘子, 渡部 芽以, 古城 京花, 阿部 広輝, 松本 大志, 大野 一彦, 市村 直也, 東田 修二: シカリキッドALP-IFCC改良試薬の基礎的性能及び酸性ホスファターゼの影響の評価 医療検査と自動化. 2023.06; 48 (3): 197-203. ( 医中誌 )

  8. Tanaka Keisuke, Ichikawa Ayako, Umezawa Natsuka, Yamamoto Kouhei, Yoshifuji Kota, Okada Keigo, Nogami Ayako, Umezawa Yoshihiro, Nagao Toshikage, Sakashita Chizuko, Mori Takehiko, Tohda Shuji, Koike Ryuji, Yasuda Shinsuke, Yamamoto Masahide: Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis CANCER SCIENCE. 2023.06; ( PubMed , DOI )

  9. 河合 ほなみ, 小野 大介, 八木 洋輔, 西田 陽一郎, 叶内 匡, 三條 伸夫, 横田 隆徳: 亜急性に進行する経静脈的免疫グロブリン療法に反応性の伝導遅延を伴わないニューロパチーを呈した88歳女性例 臨床神経学. 2023.04; 63 (4): 240. ( 医中誌 )

  10. 夏井 洋和, 叶内 匡, 横田 隆徳: 【しびれQ&A-ビビッとシビれるクリニカルパール付き!】しびれ診療のQに答えます!　small fiber neuropathyって、何? 総合診療. 2023.02; 33 (2): 181-184. ( 医中誌 )

  11. 甲田 祐樹, 東田 修二: 骨髄系疾患　反応性・腫瘍性の鑑別ポイント 日本検査血液学会雑誌. 2023.02; 24 (1): 180-187. ( 医中誌 )

  1. 小泉 綾沙, 甲田 祐樹, 市村 直也, 東田 修二: コーチングを活用した,臨床検査技師のためのパフォーマンスを最大限発揮する目標設定術 臨床検査. 2022.12; 66 (12): 1454-1459. ( 医中誌 )

  2. 大西 澪奈子, 本多 弘子, 市村 直也, 東田 修二: Atellica IM1600免疫自動分析装置による感染症5項目の基礎的検討 医療検査と自動化. 2022.11; 47 (5): 534-537. ( 医中誌 )

  3. 河合 ほなみ, 赤座 実穂, 夏井 洋和, 叶内 匡, 石黒 太郎, 西田 陽一郎, 横田 隆徳: TNFα阻害薬を使用中に片側の皮質脳炎と左顔面のミオクローヌスを来した60代男性例 神経治療学. 2022.10; 39 (6): S284. ( 医中誌 )

  4. 西田 陽一郎, 野中 一哉, 藤木 修子, 夏井 洋和, 岩瀬 遼, 石黒 太郎, 叶内 匡, 横田 隆徳: 肘で叩打誘発性の持続性間代を呈した非典型的原発性側索硬化症患者の検討 臨床神経学. 2022.10; 62 (Suppl.): S310. ( 医中誌 )

  5. Mitsumura Takahiro, Okamoto Tsukasa, Tosaka Mizuho, Yamana Takashi, Shimada Sho, Iijima Yuki, Sakakibara Rie, Shibata Sho, Honda Takayuki, Shirai Tsuyoshi, Ishizuka Masahiro, Aiboshi Junichi, Furusawa Haruhiko, Tateishi Tomoya, Tamaoka Meiyo, Shigemitsu Hidenobu, Arai Hirokuni, Otomo Yasuhiro, Tohda Shuji, Anzai Tatsuhiko, Takahashi Kunihiko, Yasuda Shinsuke, Miyazaki Yasunari: Association of SARS-CoV-2 RNA Copy Number with the COVID-19 Mortality Rate and Its Effect on the Predictive Performance of Mortality in Severe Cases JAPANESE JOURNAL OF INFECTIOUS DISEASES. 2022.09; 75 (5): 504-510. ( DOI )

  6. 叶内 匡: 【筋萎縮性側索硬化症】筋萎縮性側索硬化症　進展病態の基礎と臨床 脳神経内科. 2022.08; 97 (2): 194-198. ( 医中誌 )

  7. 赤座 実穂, 石黒 太郎, 西田 陽一郎, 叶内 匡, 横田 隆徳: 全身痙攣の既往がない良性成人型家族性ミオクローヌスてんかんが疑われる症例について パーキンソン病・運動障害疾患コングレスプログラム・抄録集. 2022.07; 16回 91. ( 医中誌 )

  8. Oba S., Hosoya T., Kawata D., Lee W., Kamiya M., Komiya Y., Iwai H., Nukui Y., Tohda S., Yasuda S.: SARS-COV-2 INFECTION CAUSED THROMBOSIS IN THE LUPUS MODEL WITH ANTIPHOSPHOLIPID ANTIBODY, WHEREAS COVID-19 ASSOCIATED THROMBOSIS WAS IRRELEVANT IN PATIENTS WITH POSITIVE ANTIPHOSPHOLIPID ANTIBODY ANNALS OF THE RHEUMATIC DISEASES. 2022.06; 81 331-332. ( DOI )

  9. Hamada Satomi, Sasaki Kanae, Kito Hotaka, Tooyama Yui, Ihara Kensuke, Aoyagi Eiko, Ichimura Naoya, Tohda Shuji, Sasano Tetsuo: Effect of the recording condition on the quality of a single-lead electrocardiogram HEART AND VESSELS. 2022.06; 37 (6): 1010-1026. ( PubMed , DOI )

  10. 大西 澪奈子, 本多 弘子, 市村 直也, 東田 修二: Atellica IM1600免疫自動分析装置による性腺/下垂体ホルモン4項目の基礎的検討 医療検査と自動化. 2022.06; 47 (3): 239-244. ( 医中誌 )

  11. Saito Ryoichi, Nakajima Jun, Prah Isaac, Morita Masatomo, Mahazu Samiratu, Ota Yusuke, Kobayashi Ayuka, Tohda Shuji, Kamiya Hajime, Takahashi Hideyuki, Ohnishi Makoto: Penicillin- and Ciprofloxacin-Resistant Invasive Neisseria meningitidis Isolates from Japan MICROBIOLOGY SPECTRUM. 2022.06; 10 (3): ( DOI )

  12. 福島 紘子, 大野 一彦, 市村 直也, 東田 修二: 血中薬物濃度測定における血清分離剤入り採血管の検討 医学検査. 2022.04; 71 (2): 263-269. ( 医中誌 )

  13. 木村 萌, 西山 優, 上田 浩樹, 北條 亜樹子, 有松 朋之, 久保木 麻衣, 高畑 篤, 斎藤 真貴子, 坂下 千瑞子, 岡田 啓五, 梅澤 佳央, 長尾 俊景, 山本 正英, 東田 修二, 田邉 稔, 森 毅彦, 野上 彩子: Ravulizumab投与下の発作性夜間ヘモグロビン尿症に対する腹腔鏡下胆嚢摘出術の周術期管理 臨床血液. 2022.04; 63 (4): 260-264. ( 医中誌 )

  14. 砂生 奈那美, 杉田 陽一郎, 飯田 真太朗, 赤座 実穂, 桑原 宏哉, 石黒 太郎, 叶内 匡, 石川 欽也, 横田 隆徳: 大腿四頭筋に目立つ筋萎縮を呈したLambert-Eaton筋無力症候群の73歳男性例 臨床神経学. 2022.04; 62 (4): 330. ( 医中誌 )

  15. 東田 修二: 新型コロナウイルス検査の現状と展望　変異株同定の実際とあり方 日本臨床検査医学会誌. 2022.03; 70 (3): 211-213. ( 医中誌 )

  16. 渡部 芽以，島野 志都子，亀田 貴寛，藤井 祐葵，平尾 裕子，大野 一彦，市村 直也，東田 修二，大川 龍之介: 生化学自動分析装置を用いたアポリポタンパクE含有高比重リポタンパクコレステロール測定試薬の性能評価 医療検査と自動化. 2022.02; 47 (1): 43-49.

  17. 上中 沙衿, 赤座 実穂, 川端 茂徳, 渡部 泰士, 宮野 由貴, 佐々木 亨, 叶内 匡, 足立 善昭, 関原 謙介, 角 勇樹, 大川 淳, 横田 隆徳: 超音波検査と誘発磁界計測による正中神経前腕部神経活動評価 脊髄機能診断学. 2022.01; 42 (1): 30-33. ( 医中誌 )

  18. 水口 隆介, 赤座 実穂, 川端 茂徳, 渡部 泰士, 宮野 由貴, 佐々木 亨, 叶内 匡, 足立 善昭, 関原 謙介, 角 勇樹, 大川 淳, 横田 隆徳: 磁場計測と神経超音波検査を組み合わせた正中神経肘部神経活動評価 脊髄機能診断学. 2022.01; 42 (1): 34-37. ( 医中誌 )

  19. 金 亮秀, 桑原 宏哉, 東出 理栄子, 赤座 実穂, 叶内 匡, 西田 陽一郎, 三條 伸夫, 横田 隆徳: 左大腿のミオキミア様不随意運動と錯感覚を呈し、脊柱管内左側に腫瘤を認めた49歳男性 臨床神経学. 2022.01; 62 (1): 87. ( 医中誌 )

  20. 朴 文英, 横手 裕明, 黒岩 伸明, 安達 彩織, 七枝 健太朗, 銭谷 怜史, 内原 俊記, 叶内 匡, 融 衆太: 呼吸不全を初発症状とした球脊髄性筋萎縮症(SBMA)の67歳男性例 臨床神経学. 2022.01; 62 (1): 83. ( 医中誌 )

  21. 木村萌、西山優、上田浩樹、北條亜樹子、有松朋之、久保木麻衣、髙畑篤、斎藤真貴子、坂下千瑞子、岡田啓五、梅澤佳央、長尾俊景、山本正英、東田修二、田邉稔、森毅彦 、野上彩子: Ravulizumab投与下の発作性夜間ヘモグロビン尿症の腹腔鏡下胆嚢摘出術の周術期管理 臨床血液. 2022; 63 (4): 260-264. ( PubMed , DOI )

  1. 叶内 匡: 治療法の再整理とアップデートのために　専門家による私の治療　ギラン・バレー症候群・フィッシャー症候群 日本医事新報. 2021.08; (5079): 34-35. ( 医中誌 )

  2. 柳原 克紀, 大塚 喜人, 東田 修二, 玉井 清子, 納富 継宣: 新型コロナウイルス感染症(COVID-19)について 日本臨床検査医学会誌. 2021.07; 69 (7): 505-515. ( 医中誌 )

  3. 東田 修二: 新型コロナウイルス検査の感度・特異度と結果報告の標準化 日本臨床検査医学会誌. 2021.06; 69 (6): 405-409. ( 医中誌 )

  4. 叶内 匡: 医学的基礎知識　神経生理学　神経伝導検査(その2) 日本臨床検査同学院通信. 2021.06; 46 (夏季): 105-110. ( 医中誌 )

  5. 小林 亜由香, 中島 淳, 大塚 武, 飯草 正実, 酒井 雄一郎, 佐多 章, 大城 健哉, 菊地 孝司, 菊池 俊, 松本 裕子, 宮原 聖奈, 宮平 勝人, 神谷 元, 高橋 英之, 東田 修二, 齋藤 良一: 市販輸送培地におけるNeisseria meningitidis生菌数の経時的変動 日本臨床微生物学会雑誌. 2021.03; 31 (2): 108-112. ( 医中誌 )

  6. 叶内 匡: 医学的基礎知識　神経生理学　神経伝導検査 日本臨床検査同学院通信. 2021.03; 46 (春季): 56-60. ( 医中誌 )

  7. 東田修二: 新型コロナウイルス検査の感度・特異度と検査結果の標準化 日本臨床検査医学会誌. 2021; 69 (6): 405-409.

  8. 山崎 あずさ, 糸井 彩子, 甲田 祐樹, 永野 勝稔, 市村 直也, 東田 修二: 全自動血液凝固測定装置CS-5100を用いた活性化部分トロンボプラスチン時間(APTT)測定試薬「レボヘムAPTT SLA」の基礎的性能評価およびループスアンチコアグラント感受性に着目した相関乖離検体の解析 医療検査と自動化. 2021; 46 (3): 208-214. ( 医中誌 )

  1. Horiuchi Y., Lai S. -J., Shimano S., Kameda T., Ichimura N., Tohda S., Tozuka M., Ohkawa R.: NOVEL CHOLESTEROL EFFLUX ASSAY USING IMMOBILIZED LIPOSOME-BOUND GEL BEADS: COMPARISON TO CONVENTIONAL METHOD ATHEROSCLEROSIS. 2020.12; 315 E155.

  2. 玉木 香菜, 三條 伸夫, 叶内 匡, 横田 隆徳: Sjogren症候群(SS)に伴う末梢神経障害の長期予後と運動神経障害を伴うsubtypeの特徴 臨床神経学. 2020.11; 60 (Suppl.): S331. ( 医中誌 )

  3. 叶内 匡, 夏井 洋和, 飯田 真太朗, 赤座 実穂, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳: 上肢発症のALSにおける手内筋の筋による進行パターン 臨床神経学. 2020.11; 60 (Suppl.): S409. ( 医中誌 )

  4. 上中 沙衿, 赤座 実穂, 川端 茂徳, 渡部 泰士, 宮野 由貴, 佐々木 亨, 叶内 匡, 足立 善昭, 関原 謙介, 角 勇樹, 大川 淳, 横田 隆徳: 磁場計測と神経超音波検査を組み合わせた正中神経前腕部神経活動評価 臨床神経学. 2020.11; 60 (Suppl.): S519. ( 医中誌 )

  5. 山本 雄彬, 市村 直也, 東田 修二: ディープラーニングを用いた尿中赤血球の形態分類 医療検査と自動化. 2020.11; 45 (5): 581-588. ( 医中誌 )

  6. 岩瀬 遼, 三條 伸夫, 叶内 匡, 横田 隆徳: 上肢近位筋の著明な萎縮を呈する脳表ヘモジデリン沈着症の病巣解析 臨床神経生理学. 2020.10; 48 (5): 587. ( 医中誌 )

  7. 黒田 隆之, 赤座 実穂, 叶内 匡, 八木 洋輔, 三條 伸夫, 横田 隆徳: 問題症例の神経筋診断　両下肢感覚障害、脛骨神経F波潜時延長が緩徐に進行した70歳男性の一例 臨床神経生理学. 2020.10; 48 (5): 493. ( 医中誌 )

  8. 玉木 香菜, 三條 伸夫, 叶内 匡, 横田 隆徳: シェーグレン症候群(SS)に伴う末梢神経障害の長期予後と運動神経障害を伴うサブタイプの特徴 神経免疫学. 2020.10; 25 (1): 117. ( 医中誌 )

  9. 叶内 匡: 筋萎縮性側索硬化症における神経生理学的検査の役割 臨床神経生理学. 2020.10; 48 (5): 343. ( 医中誌 )

  10. 野上　彩子、山本　正英、山本　浩平、伊藤　雅文、梅澤　佳央、東田　修二、三浦　修 、福田　哲也: 汎血球減少の長期経過後に明らかとなった辺縁帯リンパ腫様の骨髄原発リンパ腫 臨床血液. 2020.10; 61 (10): 1469-1475. ( PubMed , DOI )

  11. 野上 彩子, 山本 正英, 山本 浩平, 伊藤 雅文, 梅澤 佳央, 東田 修二, 三浦 修, 福田 哲也: 汎血球減少の長期経過後に明らかとなった辺縁帯リンパ腫様の骨髄原発リンパ腫 臨床血液. 2020.10; 61 (10): 1469-1475. ( 医中誌 )

  12. 東田 修二: 臨床検査のガイドライン2018の概要と活用法　血液・造血器分野 臨床病理. 2020.09; 68 (9): 785-787. ( 医中誌 )

  13. 佐々木 宏治: CML治療と予後の最前線 臨床血液. 2020.09; 61 (9): 1179-1186. ( 医中誌 )

  14. 市村 直也, 萩原 三千男, 東田 修二: 翼状採血針における製品別の溶血率調査 医療検査と自動化. 2020.06; 45 (3): 208-212. ( 医中誌 )

  15. 大西 澪奈子, 本多 弘子, 武部 功, 萩原 三千男, 東田 修二: ルミパルスPresto IIを用いた可溶性インターロイキン2レセプター(sIL-2R)測定試薬「ルミパルスプレストIL-2R」の基礎的検討 臨床病理. 2020.06; 68 (6): 513-519. ( 医中誌 )

  16. 松本 梨沙, 市村 直也, 青柳 栄子, 鳴海 純, 萩原 三千男, 東田 修二: 中央採血室における採血時の録画・録音システムの構築 医学検査. 2020.04; 69 (2): 224-228. ( 医中誌 )

  17. 島野 志都子, 大川 龍之介, 戸塚 実, 萩原 三千男, 東田 修二: Dimension EXL200によるタクロリムス測定の基礎的検討とTurn Around Timeの評価 医療検査と自動化. 2020.02; 45 (1): 53-58. ( 医中誌 )

  18. 阿部 広輝, 島野 志都子, 大川 龍之介, 戸塚 実, 萩原 三千男, 東田 修二: 尿中アルブミン測定試薬「LZテスト'栄研'U-ALB」の性能評価と検体前処理の検討 医療検査と自動化. 2020.02; 45 (1): 59-66. ( 医中誌 )

  19. [Chronic myeloid leukemia: update on treatment and survival prediction]. 2020; 61 (9): 1179-1186. ( PubMed , DOI )

  20. 東田　修二: がんの遺伝子検査とコンパニオン診断の現状 臨床病理. 2020; 67 1072-1074.

  21. 東田　修二, 市村　直也: 新型コロナウイルスRT-PCR検査の中間総括と第２波に備えた問題点の提起 臨床病理. 2020; 68 665-669.

  22. 東田　修二: 臨床検査のガイドライン 2018 の概要と活用法　血液・造血器分野 臨床病理. 2020; 68 800-803.

  23. Koi S, Arai K, Nogami A, Toma H, Yamamoto M, Miura O, Nagao T: [Impaired hematopoiesis due to copper deficiency in a hemodialysis patient supplemented with zinc]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2020; 61 (10): 1487-1491. ( PubMed , DOI )

  1. 飯田 真太朗, 叶内 匡, 金井 数明, 中里 朋子, 服部 信孝, 横田 隆徳: 上肢遠位筋発症ALSの領域間進展におけるpropagationメカニズムの検証 臨床神経学. 2019.11; 59 (Suppl.): S333. ( 医中誌 )

  2. 叶内 匡, 飯田 真太朗, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳: 上肢で発症したALS病変の左右進展におけるpropagation仮説の検証 臨床神経学. 2019.11; 59 (Suppl.): S333. ( 医中誌 )

  3. 赤座 実穂, 川端 茂徳, 渡部 泰士, 宮野 由貴, 佐々木 亨, 叶内 匡, 足立 善昭, 関原 謙介, 角 勇樹, 大川 淳, 横田 隆徳: 神経超音波検査と末梢神経磁界測定による神経活動評価 臨床神経生理学. 2019.10; 47 (5): 495. ( 医中誌 )

  4. 夏井 洋和, 叶内 匡, 飯田 真太郎, 赤座 実穂, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳: ALSのsplit handにおいて筋による神経脱落速度に違いはあるか 臨床神経生理学. 2019.10; 47 (5): 505. ( 医中誌 )

  5. 玉木 香菜, 三條 伸夫, 叶内 匡, 横田 隆徳: リツキシマブ(RTX)の有効性が示唆されたシェーグレン症候群に伴うneuropathyの1例 神経治療学. 2019.10; 36 (6): S252. ( 医中誌 )

  6. 東田 修二: がん診療における遺伝子検査の現状と将来展望　がんの遺伝子検査とコンパニオン診断の現状 臨床病理. 2019.10; 67 (10): 1072-1074. ( 医中誌 )

  7. 東田修二: がんの遺伝子検査とコンパニオン診断の現状 臨床病理. 2019.10; 67 (10): 1072-1074.

  8. 市村 直也, 萩原 三千男, 東田 修二: 採血担当者による品質指標の層別化と業務プロセスの改善 日本臨床検査自動化学会会誌. 2019.06; 44 (3): 218-223. ( 医中誌 )

  9. 東田 修二: 臨床検査アップデート　骨髄増殖性腫瘍の遺伝子検査 Modern Media. 2019.06; 65 (6): 119-122. ( 医中誌 )

  10. 東田 修二: 免疫電気泳動と免疫固定法の解釈のしかた 臨床病理. 2019.06; 67 (6): 609-613. ( 医中誌 )

  11. 平地 渉, 村川 美也子, 青柳 栄子, 齊木 有美, 鈴木 委久江, 宮崎 健太郎, 萩原 三千男, 叶内 匡, 朝比奈 靖浩, 東田 修二: 造影超音波検査が診断に有用であった肝血管肉腫の一例 超音波医学. 2019.04; 46 (Suppl.): S679. ( 医中誌 )

  12. 赤座 至, 赤座 実穂, 叶内 匡, 笹野 哲郎, 角 勇樹, 横田 隆徳: 血糖変動と糖尿病神経障害との関連についての検討 日本内分泌学会雑誌. 2019.04; 95 (1): 495. ( 医中誌 )

  13. 山内 泰輔, 水野 朋子, 鈴木 智典, 鹿島田 彩子, 今井 耕輔, 高木 正稔, 叶内 匡: SCN4A遺伝子変異が同定されたNaチャネルミオトニアの1例 脳と発達. 2019.03; 51 (2): 124. ( 医中誌 )

  14. 甲田 祐樹, 大久保 有希, 糸井 彩子, 金盛 英里子, 永野 勝稔, 西家 里奈, 萩原 三千男, 東田 修二: LPIAジェネシスDダイマー試薬の基礎的検討および採血管内凝固によるDダイマー測定値への影響に関する検討 日本検査血液学会雑誌. 2019.02; 20 (1): 43-51. ( 医中誌 )

  15. 永野 勝稔, 小山 祥美, 北村 優佳, 山本 雄彬, 佐藤 明日香, 町田 友美, 萩原 三千男, 東田 修二, 山本 貴信, 前嶋 康浩, 平尾 見三: Fabry病を疑う契機となった尿沈渣中のマルベリー細胞の意義 臨床病理. 2019.02; 67 (2): 112-116. ( 医中誌 )

  16. 渡邉 健, 吉藤 康太, 齋藤 達也, 山下 知子, 野上 彩子, 坂下 千瑞子, 福田 哲也, 新井 文子, 東田 修二, 川又 紀彦, 三浦 修, 山本 正英: 腫瘍随伴性天疱瘡と閉塞性細気管支炎を合併した濾胞性リンパ腫 臨床血液. 2019.01; 60 (1): 7-11. ( 医中誌 )

  1. 金井 数明, 横田 隆徳, 澁谷 和幹, 叶内 匡, 中里 朋子, 岩井 雄太, 三澤 園子, 大山 彦光, 下 泰司, 清水 俊夫, 服部 信孝, 桑原 聡: Latetnt addition法を用いたALSにおける持続性Na+電流上昇と病気進展についての検討 臨床神経学. 2018.12; 58 (Suppl.): S230. ( 医中誌 )

  2. 融 衆太, 内原 俊記, 叶内 匡, 齋藤 和幸, 片山 優希, 横手 裕明, 小林 高義, 北川 昌伸, 廣川 勝いく, 横田 隆徳: レヴィ小体型認知症と病理診断された症例の自律神経障害の検討 臨床神経学. 2018.12; 58 (Suppl.): S264. ( 医中誌 )

  3. 山本 雄彬, 岩崎 由美, 萩原 三千男, 東田 修二: 先進医療としての多項目迅速ウイルスPCR法によるウイルス感染症の早期診断 臨床病理. 2018.12; 66 (12): 1306-1313. ( 医中誌 )

  4. 齋藤 明日香, 服部 高明, 宮下 彰子, 飯田 真太朗, 小林 正樹, 赤座 美穂, 石橋 哲, 叶内 匡, 三條 伸夫, 石川 欽也, 横田 隆徳: 高CK血症を呈する筋萎縮性側索硬化症の筋生検所見の検討 臨床神経学. 2018.12; 58 (Suppl.): S291. ( 医中誌 )

  5. 赤座 実穂, 川端 茂徳, 渡部 泰士, 長谷川 由貴, 飯田 真太郎, 佐々木 亨, 足立 善昭, 関原 謙介, 叶内 匡, 角 勇樹, 大川 淳, 横田 隆徳: 脊磁計を用いたC8神経根障害の診断 臨床神経生理学. 2018.10; 46 (5): 509. ( 医中誌 )

  6. 飯田 真太朗, 叶内 匡, 澁谷 和幹, 能登 祐一, 木村 英紀, 赤座 美穂, 清水 俊夫, 桑原 聡, 横田 隆徳: ALS病変の左右病変進展におけるpropagation仮説の検証 臨床神経生理学. 2018.10; 46 (5): 549. ( 医中誌 )

  7. 叶内 匡: 片側上肢のしびれ、麻痺をきたす疾患〜鑑別診断と診療のポイント〜　神経内科の立場から　運動ニューロン疾患を中心に 臨床神経生理学. 2018.10; 46 (5): 371. ( 医中誌 )

  8. 柳平 貢, 赤座 実穂, 飯田 真太郎, 叶内 匡, 横田 隆徳: 抗neurofascin-155抗体陽性慢性炎症性脱髄性多発根ニューロパチーの神経エコー所見 臨床神経生理学. 2018.10; 46 (5): 472. ( 医中誌 )

  9. 市村 直也, 小山 祥美, 佐藤 明日香, 町田 友美, 萩原 三千男, 東田 修二: 尿沈渣目視法における内部精度管理システムの構築と技師間差に及ぼす効果の検証 医学検査. 2018.10; 67 (5): 708-715. ( 医中誌 )

  10. 佐々木 宏治: 【急性白血病の薬物療法のupdate ～最新の診断・治療戦略～】ポナチニブ　国内承認(治療抵抗性Ph陽性ALL) 医薬ジャーナル. 2018.05; 54 (5): 1229-1233. ( 医中誌 )

  11. 池田 朱里, 堤 大樹, 渡邉 健, 青山 慧, 齊藤 達也, 長尾 俊景, 坂下 千瑞子, 山本 正英, 福田 哲也, 東田 修二, 新井 文子, 川又 紀彦, 三浦 修: 二次性骨髄線維症による門脈圧亢進症性消化管出血に対しルキソリチニブが著効した1例 臨床血液. 2018.05; 59 (5): 626-627. ( 医中誌 )

  12. 貫井 陽子, 相曽 啓史, 齋藤 良一, 谷 千尋, 東田 修二, 小池 竜司: Clostridium difficileアウトブレイクの分子疫学解析 日本化学療法学会雑誌. 2018.04; 66 (Suppl.A): 249. ( 医中誌 )

  13. 東田 修二: リンパ腫診療におけるsIL-2Rの有用性と骨髄腫診療におけるM蛋白検査の進展 東京都医学検査. 2018.03; 46 (1): 45-46. ( 医中誌 )

  14. 加藤 優子, 市村 直也, 青柳 栄子, 萩原 三千男, 安藤 登, 明石 巧, 東田 修二, 角 勇樹, 沢辺 元司, 戸塚 実, 窪田 哲朗: つながりを創る特色ある臨床検査技師教育 大学院における臨床検査技師職能教育 臨床検査学教育. 2018.03; 10 (1): 113-117. ( 医中誌 )

  15. 山本雄彬、岩崎由美、萩原三千男、東田修二: 先進医療としての多項目迅速ウイルスPCR法によるウイルス感染症の早期診断 臨床病理. 2018; 66 1306-1313.

  1. 東田 修二: 【臨床検査の最前線-将来の検査を展望する】 血液　造血器腫瘍WHO分類2016を支える遺伝子検査 医学のあゆみ. 2017.12; 263 (13): 1153-1157. ( 医中誌 )

  2. 東田修二: 造血器腫瘍WHO分類2016を支える遺伝子検査 医学のあゆみ. 2017.12; 263 1153-1157.

  3. 渡邉 健, 吉藤 康太, 齋藤 達也, 山下 知子, 野上 彩子, 山本 正英, 坂下 千瑞子, 福田 哲也, 新井 文子, 東田 修二, 川又 紀彦, 三浦 修: 腫瘍随伴性天疱瘡と閉塞性細気管支炎を合併した濾胞性リンパ腫の1例 臨床血液. 2017.11; 58 (11): 2274. ( 医中誌 )

  4. 叶内 匡: 反復神経刺激試験でおさえておきたい基本事項 臨床神経生理学. 2017.10; 45 (5): 365. ( 医中誌 )

  5. 叶内 匡: 神経生理検査に関わる検査依頼と報告書の作成-医師と技術師の立場から　神経伝導検査の依頼と報告書の作成　医師の立場から(主に依頼について) 臨床神経生理学. 2017.10; 45 (5): 342. ( 医中誌 )

  6. 鳴海 純, 叶内 匡, 赤座 実穂, 飯田 真太朗, 青柳 栄子, 太田 那津美, 宮崎 健太郎, 角 勇樹, 横田 隆徳, 萩原 三千男, 東田 修二: 手根管症候群の異なる電気診断法における検査間変動を考慮した特異度に関する考察 臨床神経生理学. 2017.10; 45 (5): 451. ( 医中誌 )

  7. 赤座 実穂, 赤座 至, 叶内 匡, 笹野 哲郎, 角 勇樹, 横田 隆徳: 血糖変動と糖尿病神経障害との関連の検討 臨床神経生理学. 2017.10; 45 (5): 443. ( 医中誌 )

  8. 白鳥 恵理香, 大高 美香, 伊藤 真以, 東田 修二: リンパ系腫瘍細胞に対するMYD88阻害薬の細胞分子生物学的作用 臨床病理. 2017.10; 65 (補冊): 275. ( 医中誌 )

  9. 山本 雄彬, 岩崎 由美, 萩原 三千男, 東田 修二: 先進医療として実施している多項目迅速ウイルスPCR法によるウイルス感染症の早期診断 臨床病理. 2017.10; 65 (補冊): 159. ( 医中誌 )

  10. 甲田 祐樹, 大高 美香, 白鳥 恵理香, 伊藤 真以, 東田 修二: MERチロシンキナーゼ阻害による白血病細胞の増殖抑制作用 臨床病理. 2017.10; 65 (補冊): 146. ( 医中誌 )

  11. 本橋 智子, 島野 志都子, 大川 龍之介, 戸塚 実, 萩原 三千男, 東田 修二: LABOSPECT 008を用いた「ナノピアIL-2R」試薬の性能評価 臨床病理. 2017.10; 65 (補冊): 137. ( 医中誌 )

  12. 奥橋 佑基, 細萱 茂実, 東田 修二: siRNAとCRISPR/Cas9システムを用いたゲノム編集による白血病細胞の増殖への効果 臨床病理. 2017.10; 65 (補冊): 147. ( 医中誌 )

  13. 大高 美香, 白鳥 恵理香, 伊藤 真以, 東田 修二: siRNAを用いた白血病細胞におけるBMI1の機能解析 臨床病理. 2017.10; 65 (補冊): 147. ( 医中誌 )

  14. 市村 直也, 小山 祥美, 佐藤 明日香, 町田 友美, 萩原 三千男, 東田 修二: 尿沈渣検査鏡検法における分類精度定量化の試み 臨床病理. 2017.10; 65 (補冊): 221. ( 医中誌 )

  15. 永野 勝稔, 小山 祥美, 山本 雄彬, 佐藤 明日香, 町田 友美, 萩原 三千男, 東田 修二, 山本 貴信: Fabry病を疑う契機となった尿沈渣のmulberry cellの意義 臨床病理. 2017.10; 65 (補冊): 222. ( 医中誌 )

  16. 迎 純一, 新井 康祐, 齊藤 達也, 秋山 めぐみ, 東田 修二, 山本 晃: 仙骨形質細胞腫、骨髄腫に対するタンデムPBSCTの11年後に発症したPOEMS症候群 臨床血液. 2017.09; 58 (9): 1697. ( 医中誌 )

  17. 中山 智祥, 糸賀 栄, 青木 留美子, 野村 文夫, 横田 浩充, 南木 融, 渡邉 直樹, 内海 健, 斉藤 邦明, 末岡 榮三朗, 末広 寛, 長井 篤, 菱沼 昭, 宮島 栄治, 宮地 勇人, 村上 正巳, 和田 隆志, 竹越 一博, 東田 修二, 中谷 中, 渡邉 淳, 松下 一之, 中西 豊文, 日高 恵以子, 竹田 真由, 曽川 一幸, 草場 耕二, 松本 竹久, 渡邊 正治, 渡 智久, 清祐 麻紀子, 品川 雅明, 中村 明子, 大隈 雅紀, 東山 智宣, 長田 誠, 藤本 英也, 中條 聖子, 山口 敏和, 福井 崇史, 神山 誠, 森 篤雄, 三浦 俊昭, 関口 幸恵, 松山 由美子, 濱崎 梓, 副島 隆浩, 日本臨床検査自動化学会: いまどきの遺伝子・プロテオミクス技術と自動分析機器2017 日本臨床検査自動化学会会誌. 2017.08; 42 (Suppl.2): 1-267. ( 医中誌 )

  18. 山本 雄彬, 萩原 三千男, 東田 修二: Microsoft Excel Visual Basic for Applications及びVLOOKUP関数を利用した機材管理方法 日本臨床検査自動化学会会誌. 2017.08; 42 (4): 458. ( 医中誌 )

  19. 垂門 碧, 島野 志都子, 大川 龍之介, 戸塚 実, 萩原 三千男, 東田 修二: Dimension EXL200によるタクロリムス測定の基礎的検討とTurn Around Timeの評価 日本臨床検査自動化学会会誌. 2017.08; 42 (4): 485. ( 医中誌 )

  20. 東田修二: 腫瘍マーカーとコンパニオン診断の適切利用による個別化医療の推進 臨床病理. 2017.08; 65 314-316.

  21. 角 勇樹, 加藤 優子, 萩原 三千男, 東田 修二, 窪田 哲朗, 戸塚 実, 田中 雄二郎: 卒後臨床教育として修士学生(生体検査学専攻)に導入したHealth Care Assistant制度の1年目評価 医学教育. 2017.08; 48 (Suppl.): 202. ( 医中誌 )

  22. Iwasawa Eri, Ohkubo Takuya, Kanouchi Tadashi, Kanda Takashi, Mizusawa Hidehiro, Yokota Takanori: 重症多巣性運動ニューロパチー(MMN)患者に対するシクロホスファミド静注とメスナ静注/膀胱内注入併用の長期効果(Long-term Effects of Intravenous Cyclophosphamide in Combination with Mesna Provided Intravenously and via Bladder Perfusion in a Patient with Severe Multifocal Motor Neuropathy) Internal Medicine. 2017.07; 56 (14): 1893-1896. ( 医中誌 )

  23. 東田 修二: 【造血器・リンパ系腫瘍のWHO分類 2016 version】骨髄系腫瘍と急性白血病 胚細胞変異を伴う(生殖細胞素因を有する)骨髄系腫瘍 臨床検査. 2017.07; 61 (7): 814-815. ( 医中誌 )

  24. 東田修二: 胚細胞変異を伴う（生殖細胞素因を有する）骨髄系腫瘍 臨床検査. 2017.07; 61 814-815.

  25. 赤羽 あゆみ, 本多 弘子, 萩原 三千男, 東田 修二: 全自動免疫測定装置HISCL-5000によるKL-6測定試薬の性能評価 日本臨床検査自動化学会会誌. 2017.06; 42 (3): 283-287. ( 医中誌 )

  26. 西家 里奈, 大久保 有希, 永野 勝稔, 金盛 英里子, 甲田 祐樹, 糸井 彩子, 萩原 三千男, 東田 修二: 基礎疾患を認めない成人発症の血球貪食症候群の一例 日本検査血液学会雑誌. 2017.06; 18 (学術集会): S232. ( 医中誌 )

  27. 甲田 祐樹, 糸井 彩子, 大久保 有希, 金盛 英里子, 永野 勝稔, 西家 里奈, 萩原 三千男, 長濱 裕, 東田 修二: LPIAジェネシスDダイマー試薬の試験管内凝固によるDダイマー測定値への影響に関する検討 日本検査血液学会雑誌. 2017.06; 18 (学術集会): S220. ( 医中誌 )

  28. 大久保 有希, 甲田 祐樹, 糸井 彩子, 金盛 英里子, 永野 勝稔, 西家 里奈, 萩原 三千男, 長濱 裕, 東田 修二: LPIAジェネシスDダイマー試薬の基礎的検討 日本検査血液学会雑誌. 2017.06; 18 (学術集会): S221. ( 医中誌 )

  29. 東田 修二: sIL-2Rと最近の免疫検査の臨床トピックス 東京都医学検査. 2017.06; 45 (2): 105-106. ( 医中誌 )

  30. 市村 直也, 赤羽 あゆみ, 大野 一彦, 阿部 広輝, 大西 澪奈子, 本橋 智子, 須賀 洋子, 萩原 三千男, 東田 修二: 患者-検体容器照合システムの開発と導入効果の検証 日本臨床検査自動化学会会誌. 2017.06; 42 (3): 248-256. ( 医中誌 )

  31. 貫井 陽子, 齋藤 良一, 谷 千尋, 相曽 啓史, 藤江 俊秀, 東田 修二, 小池 竜司, 茅野 崇: Helicobacter cinaedi菌血症の臨床的・分子疫学的解析 感染症学雑誌. 2017.03; 91 (臨増): 298. ( 医中誌 )

  32. 東田 修二: 臨床検査のガイドラインJSLM2015活用のポイント　腫瘍マーカーとコンパニオン診断の適切利用による個別化医療の推進 臨床病理. 2017.03; 65 (3): 314-316. ( 医中誌 )

  33. 本多弘子, 赤羽あゆみ, 萩原三千男, 東田修二: 全自動化学発光酵素免疫測定システム「ルミパルスL2400」プロトタイプ機の性能評価 日本臨床検査自動化学会会誌. 2017.03; 42 76-82.

  34. 本多 弘子, 赤羽 あゆみ, 萩原 三千男, 東田 修二: 全自動化学発光酵素免疫測定システム「ルミパルスL2400」プロトタイプ機の性能評価 日本臨床検査自動化学会会誌. 2017.02; 42 (1): 76-82. ( 医中誌 )

  35. 山本 雄彬, 堂前 祐一, 佐藤 明日香, 小山 祥美, 萩原 三千男, 東田 修二: 自動血球分析装置XN-9000を用いた髄液・体液の細胞数と分画測定の性能評価 日本臨床検査自動化学会会誌. 2017.02; 42 (1): 45-51. ( 医中誌 )

  36. 市村 直也, 糸井 彩子, 甲田 祐樹, 大久保 有希, 萩原 三千男, 東田 修二: 顆粒球系幼若細胞分類における内部精度管理の構築と技師間差是正効果の検証 医学検査. 2017.01; 66 (1): 25-32. ( 医中誌 )

  37. 赤座 実穂, 原 恵子, 永森 千寿子, 沼沢 祥行, 叶内 匡, 相馬 沙紀, 笹野 哲郎, 稲次 基希, 角 勇樹, 前原 健寿, 横田 隆徳: 扁桃体腫大を伴う側頭葉てんかんが疑われる一例 てんかん研究. 2017.01; 34 (3): 657. ( 医中誌 )

  38. 山本雄彬, 堂前祐一, 佐藤明日香, 小山祥美, 萩原三千男, 東田修二: 自動血球分析装置XN-9000を用いた髄液・体液の細胞数と分画測定の性能評価 日本臨床検査自動化学会会誌. 2017.01; 42 45-51.

  1. 秋山　めぐみ,吉藤　康太,福田　哲也,東田　修二,三木　徹,三浦　修,山本　正英: 自己免疫性溶血性貧血に対するprednisolone治療中に発症した皮膚症状を伴わない劇症型内臓播種性VZV感染症 臨床血液. 2016.04; 57 (4): 467-471. ( PubMed , DOI )

  2. 横田隆徳、叶内　匡、大久保卓哉: ALS：新たな視点による進行様式の定量的解析 厚生労働科学研究費補助金 難治性疾患政策研究事業 神経変性疾患領域における基盤的調査研究　平成27年度　総括・分担研究報告書. 2016.03; 58-61.

  3. 東田修二: 医療安全の観点からの感染対策の医科歯科大学病院検査部の取り組み 臨床病理. 2016; 64 334-337.

  4. 東田修二: M蛋白の検査の現状と適切な利用法 日本臨床検査自動化学会会誌. 2016; 41 259-263.

  5. 島野志都子、額千裕、本橋智子、細川幹夫、神原久美子、萩原三千男、東田修二、東條尚子: M蛋白による尿酸測定の異常反応に対する「セロテックUA-L」改良試薬の効果 日本臨床検査自動化学会会誌. 2016; 41 13-19.

  6. 東田修二: これだけでAMLと診断できるアウエル小体 検査と技術. 2016; 44 866-868.

  1. 市村直也, 萩原三千男, 東田修二, 東條尚子: 検査依頼伝票による外部委託検査結果のオンライン報告システムの構築 日本臨床検査自動化学会会誌. 2015; 40 214-218.

  2. 東田修二: 白血球数、白血球分類 medicina 増刊号. 2015; 52 53-55.

  3. 東田修二: 造血器腫瘍のバイオマーカー：白血病幹細胞の個性診断をめざして 臨床病理. 2015; 63 1110-1113.

  4. 東田修二: 特殊染色 medicina 増刊号. 2015; 52 66-67.

  5. 東田修二: 骨髄像 medicina 増刊号. 2015; 52 64-65.

  1. 関口輝彦，叶内　匡，横田隆徳: 伝播する蛋白質： プリオノイド仮説．TDP-43 proteinopathy としてのALS: 病変は不連続に広がるか 神経内科. 2014.12; 81 (6): 644-649.

  2. 叶内　匡: 重症筋無力症―診療New Standards 診断と鑑別診断　テンシロンテスト Clinical Neuroscience. 2014.09; 32 (9): 1011-1012.

  3. 叶内　匡: 反復刺激検査 Monthly Book Medical Rehabilitation. 2014.01; 166 25-32.

  1. 東田修二: 未分化大細胞リンパ腫 臨床検査. 2013; 57 1638-1640.

  2. 東田修二: 微少残存白血病の検出法 検査と技術. 2013; 41 19-24.

  1. 東田修二: リンパ系腫瘍：造血器腫瘍の新展開 WHO分類第4版. 臨床病理. 2012.06; 60 (6): 560-564. ( PubMed )

  2. 山本 正英, 粂川 華恵, 佐々木 宏治, 村田 諭孝, 大木 学, 黒須 哲也, 福田 哲也, 新井 文子, 村上 直己, 三浦 修: 再生不良性貧血の経過中に薬疹に伴い生じた著明な反応性形質細胞増加 臨床血液. 2012.05; 53 (5): 526-530. ( 医中誌 )

  3. 東田修二: MDSの染色体・遺伝子検査 臨床検査. 2012; 56 1355-1358.

  4. 東田修二: 悪性リンパ腫の診断に必要な遺伝子解析と結果の読み方 日本検査血液学会雑誌. 2012; 13 432-434.

  5. 東田修二: 白血病の分子マーカーと分子標的治療 レジデント. 2012; 5 11-16.

  1. 澤辺悦子, 北村優佳, 古畑紀子, 高橋 里枝子, 市村 直也, 春山 友希, 武部 功, 萩原 三千男, 東田 修二, 東條 尚子: Clostridium difficile感染症の迅速診断における糞便中C. difficile抗原およびトキシンA/B同時検出キット：C. DIFF QUIK CHEK COMPLETEの有用性に関する検討 日本臨床微生物学雑誌. 2011; 21 253-259.

  2. 島野志都子, 小島和茂, 菅沼真紀子、萩原三千男, 東田修二, 東條尚子: クリオグロブリンによりCRP値に影響を及ぼしたマクログロブリン血症の１例-異常反応検出方法- 日本臨床検査自動化学会会誌. 2011; 36 26-31.

  1. 粂川 華恵, 佐々木 宏治, 村田 諭孝, 山本 正英, 大木 学, 黒須 哲也, 福田 哲也, 新井 文子, 三浦 修, 村上 直巳: 再生不良性貧血の経過中に反応性形質細胞増加を合併した1例 臨床血液. 2010.03; 51 (3): 223-224. ( 医中誌 )

  2. 東田修二: 白血病の分子標的治療のケミカルバイオロジー 臨床化学. 2010; 38 234-237.

  3. 東田修二: 臨床的検査データのとらえ方-赤芽球癆 Medical Technology. 2010; 38 187-189.

  4. 東田修二: 骨髄検査のすべて-遺伝子検査 Medical Technology. 2010; 38 797-800.

  1. 東田修二: 白血病の病態におけるNotchの機能解析. 臨床病理. 2009.04; 57 (4): 351-356. ( PubMed )

  2. 新井文子, 廣田理子, 福田哲也, 東田修二, 森吉寛, 寺田典生, 佐々木成, 三浦修: 腎障害を有する日本人多発性骨髄腫患者のサリドマイド血中濃度の解析 臨床血液. 2009.04; 50 (4): 295-299. ( PubMed )

  3. 東田修二: 白血病とNotch 検査と技術. 2009; 37 1340-1342.

  4. 東田修二: BおよびT前駆細胞の腫瘍成熟B細胞腫瘍、成熟T細胞・NK細胞腫瘍：顕微鏡検査のコツ 検査と技術. 2009; 37 1118-1126.

  5. 東田　修二、鈴木　利哉、奈良　信雄: ドイツにおける医学教育の改革 医学教育. 2009; 40 317-321.

  1. 東田修二、奈良信雄: 血液疾患にみられる症候-発熱 Medicina. 2008; 45 2137-2139.

  2. 東田修二、奈良信雄: 血液検査から何がわかるか-染色体・遺伝子検査 Medicina. 2008; 45 2161-2165.

  3. 東田修二、奈良信雄: 遺伝子検査の動向と利用法-従来検査との使い分け-造血器疾患 Medical Technology. 2008; 36 1208-1213.

  4. 東田修二、奈良信雄: 血液型判定・交差適合試験 Junior. 2008; 469 8-9.

  5. 東田修二、奈良信雄: ツベルクリン反応の手技・判定 Junior. 2008; 470 8-9.

  6. 東田修二: Reversed C.P.C. 同胞間末梢血幹細胞移植後に皮疹と下痢を来した36歳女性 Junior. 2008; 478 37-43.

  7. 小笠原 弘子、林 恭子、遠井 初子、萩原 三千男、東田 修二、宮坂 信之、東條 尚子: ブシラミンに起因する尿中ケトン体の偽陽性について 臨床病理. 2008; 56 (584): 588.

  8. 東田　修二、仁田　善雄、福島　統、奈良　信雄: オーストラリアの医学教育と学士入学制度 医学教育. 2008; 39 367-369.

  1. 東田修二: 遺伝子検査の実際：白血病 臨床検査. 2007; 51 1388-1394.

  2. 東田修二: 貧血の診断と治療 医学と薬学. 2007; 58 5-8.

  3. 東田修二: 臨床的検査データのとらえ方-慢性リンパ性白血病 Medical Technology. 2007; 35 1277-1279.

  4. 東田修二: 細菌検査の検体の採取 Junior. 2007; 468 8-9.

  1. 新井文子、押川学、黒須哲也、三木徹、東田修二、小山高敏、村上直巳、三浦修: Bortezomib投与により著明な高LDH血症を伴う腫瘍崩壊症候群の所見を呈した再発性治療抵抗性多発性骨髄腫. 臨床血液. 2006.08; 47 (8): 777-780. ( PubMed )

  2. 鈴木隆之、新井文子、小山高敏、押川学、山本正英、水地大輔、黒須哲也、東田修二、村上直巳、三木徹、三浦修: 後天性血友病Aの急性出血に対する治療後に発症した虚血性大腸炎. 臨床血液. 2006.04; 47 (4): 310-314. ( PubMed )

  3. 東田修二: 遺伝子検査の有用性　特に診断と治療効果判定 日本検査血液学会雑誌. 2006; 7 340-343.

  4. 東田修二: 白血病発症におけるNOTCH遺伝子異常- Notch阻害剤による治療の可能性 医学のあゆみ. 2006; 217 1093-1096.

  1. 東田修二: これだけは知っておきたい検査のポイント　赤沈（赤血球沈降速度） Medicina 増刊号. 2005; 36 160-161.

  1. 東田修二: 造血器腫瘍の遺伝子検査. 「一目でわかる遺伝子検査マニュアル」 日本臨床検査自動化学会会誌. 2004; 29 56-65.

  2. 東田修二: DNAマイクロアレイの血液疾患の検査への応用 日本検査血液学会雑誌. 2004; 5 289-293.

  3. 東田修二: リンパ節を正しく見るために／リンパ節生検と生検適応となる疾患の総論 日本検査血液学会雑誌. 2004; 5 378-379.

  4. 東田修二: リンパ節の臨床検査／遺伝子検査 Medical Technology. 2004; 32 49-52.

  5. 東田修二: 深部静脈血栓症／凝固検査系 Medical Technology. 2004; 32 910-912.

  6. 東田修二: 虚血性心疾患の検体検査／von Willebrand因子 Medical Technology. 2004; 32 1498-1499.

  1. 東田修二: 臨床血液学における遺伝子検査 日本検査血液学会雑誌. 2003; 4 340-345.

  1. 垣花和彦、水地大輔、山口光子、坂下千瑞子、福田哲也、山本晃、三木徹、東田修二、小山高敏、村上直巳、三浦修: 慢性骨髄性白血病急性転化にみられた副甲状腺ホルモン関連蛋白(PTHrP)産生に伴う高カルシウム血症. 臨床血液. 2002.02; 43 (2): 102-106. ( PubMed )

  2. 東田修二: 血清IgG高値からIgA高値へ移行した61歳女性 日本医事新報ジュニア. 2002; 409 31-36.

  3. 東田修二: 持続する頭重感により来院した76歳男性 日本医事新報ジュニア418. 2002; 418 29-34.

  4. 東田修二: 検査データを読みきる”原発性マクログロブリン血症” Medical Technology. 2002; 30 1145-1147.

  5. 東田修二: 慢性白血病-誰でもわかる遺伝子検査 検査と技術. 2002; 30 1070-1073.

  1. 東田修二、奈良信雄: 血液疾患の遺伝子検査. 臨床病理. 2001.03; 49 (3): 205-209. ( PubMed )

  2. 東田修二: 血液・造血器腫瘍-最近の動向-　遺伝子検査 Medical Technology. 2001; 29 297-303.

  3. 東田修二: 遺伝子検査の流れ、造血器腫瘍とFISH - 遺伝子検査マニュアル 日本臨床検査自動化学会会誌. 2001; 26 28-31.

  1. 東田修二: 芽球化反応 Medical Technology. 2000; 28 1209.

  2. 東田修二: 感染症による発熱 レジデントノート. 2000; 2 17-26.

  3. 東田修二: 遺伝子検査の実際-造血器腫瘍を中心に-：DNAとRNAの抽出 Medical Technology. 2000; 28 69-72.

  4. 東田修二: 遺伝子検査の実際-造血器腫瘍を中心に-：PCR法とRT-PCR法 Medical Technology. 2000; 28 157-162.

  5. 東田修二: 遺伝子検査の実際-造血器腫瘍を中心に-：サザンブロット法 Medical Technology. 2000; 28 395-400.

  1. 奈良信雄、東田修二: 造血器腫瘍の遺伝子検査. 臨床病理. 1999.11; 47 (11): 1014-1019. ( PubMed )

  2. 東田修二: 血栓止血のメカニズム Medicina 増刊号. 1999; 36 143-145.

  3. 東田修二: EBウイルス Medicina 増刊号. 1999; 36 534-535.

  4. 東田修二: 医学に関わる最近のトピックス：血液学 Laboratory and Clinical Practice. 1999; 17 104-106.

  5. 東田修二: 検査の進め方と読み方の疾患系統別マニュアル：感染症が疑われる場合 レジデントノート. 1999; 1 89-94.

  1. 東田修二: 遺伝子検査の実際-造血器腫瘍を中心に-：サザンブロット法 Medical Technology. 1998; 26 1076-1081.

  2. 東田修二: 止血機構と検査の進め方 Medical Technology. 1998; 26 1076-1081.

  3. 東田修二、奈良信雄: G-CSFの急性骨髄性白血病細胞に対する作用 血液・免疫・腫瘍. 1998; 3 41-45.

  1. 黒須哲也、坂下千瑞子、山本晃、東田修二、三木徹、小山高敏、三浦修、村上直巳、根本哲生、宮坂信之、神山隆一、広沢信作: 髄外性形質細胞腫の部位にアミロイド沈着と骨形成像を認めた形質細胞性白血病. 臨床血液. 1997.01; 38 (1): 58-63. ( PubMed )

  2. 東田修二、奈良信雄: 急性混合型白血病 Medical Technology. 1997; 24 60-64.

  3. 東田修二、黒川浩、奈良信雄: インターロイキン-３ 動脈硬化. 1997; 25 35-38.

  4. 東田修二、奈良信雄: DICにみられる検査データ 検査と技術. 1997; 25 541-544.

  1. 東田修二、椎貝達夫、地引政利、青井東呉、上江田芳明、川崎恒雄、黒川浩、奈良信雄: 薬剤性溶血性尿毒症症候群の3例. 癌と化学療法. 1996.02; 23 (3): 361-364. ( PubMed )

  2. 東田修二、黒川浩、奈良信雄: アポトーシス Medical Technology. 1996; 24 874-879.

  1. 東田修二、奈良信雄: 白血病幹細胞と細胞増殖因子 生体の科学. 1995; 45 352-355.

  2. 東田修二、黒川浩、奈良信雄: 造血幹細胞腫瘍と細胞増殖因子 病理と臨床. 1995; 13 1518-1522.

  1. 今井康文、山本晃、鈴木謙、東田修二、三木徹、中村裕一、加藤淳、広沢信作、奈良信雄、青木延雄、松原修、神山隆一: 瀘胞性リンパ腫寛解中に発症したLymphomatoid granulomatosisの1例. 臨床血液. 1992.04; 33 (4): 507-513. ( PubMed )

  1. 山本克也、東田修二、三木徹、鈴木利哉、長田薫、神山尚、三浦修、今井康文、村上直巳、加藤淳、奈良信雄、青木延雄: 原発性マクログロブリン血症の経過中に急性骨髄性白血病と肝細胞癌を合併した1例. 臨床血液. 1990.07; 31 (7): 984-988. ( PubMed )

  1. 東田修二、中村聡子、坂巻寿、小野沢康輔: 膵腫脹と汎血球減少を呈したCastlemanリンパ腫の1例 臨床血液. 1989.10; 30 (10): 1815-1819. ( PubMed )

  2. 東田修二、赤川志のぶ、三浦寧子、佐藤隆、室田直樹、田ノ上雅彦、大玉信一、橋本憲一、青木延雄、須田吉広: 尿崩症、下垂体前葉機能障害と中枢性肺胞低換気を合併したサルコイドーシスの1例. 日本内科学会誌. 1989.03; 78 (3): 374-378. ( PubMed )

  1. 小山高敏、東田修二、神山尚、鈴木利哉、長田薫、中村裕一、三浦修、丸山保夫、加藤淳、村上直巳、室橋郁生、広沢信作、奈良信雄、青木延雄: Ara-C療法におけるmyeloblastomaヘの効果と血液学的効果の解離. 臨床血液. 1988.12; 29 (12): 2302-2306. ( PubMed )

  2. 東田修二、山中昭良、小林泰文、天川孝則: 内視鏡的食道静脈瘤硬化療法後に乳び胸・腹水を生じた肝硬変の1例. 日本内科学会誌. 1988.08; 77 (8): 1282-1283. ( PubMed )

  3. 東田修二、小林泰文、鈴木利哉、小山高敏、神山尚、中村裕一、三浦修、丸山保夫、加藤淳、村上直巳、室橋郁生、広沢信作、奈良信雄、青木延雄: Daunorubicinにより急性心膜炎をきたしたAMLの1例. 臨床血液. 1988.06; 29 (6): 874-878. ( PubMed )

  1. Niche-level immune evasion in TP53 mutant AML residual disease revealed by spatial proteomics 2026.05; ( DOI )

  2. Duan C, Yu Z, Li X, Sakai M, Maejima Y, Shimomura K, Furuyashiki T, Kikuchi S, Kobayashi N, Sasaki K, Matsuki T, Komatsu H, Hino M, Kunii Y, Kasahara T, Ishikuro M, Murakami K, Orui M, Abe T, Nagami F, Fuse N, Ogishima S, Kinoshita K, Yamamoto M, Nakaya N, Hozawa A, Obara T, Kuriyama S, Tomita H: Sex differences in the risk of autistic-related traits in toddlers born to mothers with perinatal depression: Evidence from human cohort and mouse study. Molecular psychiatry. 2026.02; ( PubMed , DOI )

  3. Decitabine-cedazuridine in patients with MDS and TP53 mutations 2026.02; 10 (3): ( DOI )

  4. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia 2026.01; 10 (1): ( DOI )

  1. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia 2025.12; ( DOI )

  2. Mortality and relapse dynamics in AML after three years of complete remission 2025.11; ( DOI )

  3. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome 2025.11; ( DOI )

  4. FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML 2025.11; 146 (21): ( DOI )

  5. Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase 2025.10; ( DOI )

  6. Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients 2025.09; ( DOI )

  7. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy 2025.09; ( DOI )

  8. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML 2025.08; ( DOI )

  9. Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. 2025.08; 26 (1): ( PubMed , DOI )

  10. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. 2025.08; ( PubMed , DOI )

  11. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation 2025.08; ( DOI )

  12. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. 2025.07; 9 (19): ( PubMed , DOI )

  13. Management of chronic myeloid leukemia in 2025 2025.07; ( DOI )

  14. Central nervous system relapse of core-binding factor acute myeloid leukemia 2025.07; ( DOI )

  15. PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. 2025.07; 110 (12): ( PubMed , DOI )

  16. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia. 2025.06; 110 (12): ( PubMed , DOI )

  17. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. 2025.06; ( PubMed , DOI )

  18. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. 2025.05; ( PubMed , DOI )

  19. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results 2025.05; ( DOI )

  20. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. 2025.05; 9 (16): ( PubMed , DOI )

  21. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. 2025.05; 146 (7): ( PubMed , DOI )

  22. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. 2025.05; ( PubMed , DOI )

  23. Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research 2025.04; ( DOI )

  24. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results: CHRONIC MYELOID LEUKEMIA 2025.04; ( DOI )

  25. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. 2025.04; ( PubMed , DOI )

  26. Dual MYC and GSPT1 Protein Degrader for MYC-Driven Cancers 2025.04; ( DOI )

  27. Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. 2025.04; ( PubMed , DOI )

  28. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. 2025.04; 15 (1): ( PubMed , DOI )

  29. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. 2025.04; 153 ( PubMed , DOI )

  30. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. 2025.04; ( PubMed , DOI )

  31. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). 2025.03; ( PubMed , DOI )

  32. Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. 2025.03; ( PubMed , DOI )

  33. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia 2025.03; ( DOI )

  34. Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia 2025.03; ( DOI )

  35. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. 2025.03; ( PubMed , DOI )

  36. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study 2025.03; 15 (1): ( DOI )

  37. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. 2025.02; ( PubMed , DOI )

  38. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms 2025.02; 39 (2): 524-528. ( PubMed , DOI )

  39. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy 2025.02; ( DOI )

  40. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. 2025.02; 150 ( PubMed , DOI )

  41. Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid) 2025.01; 131 (1): ( PubMed , DOI )

  42. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. 2025.01; 100 (3): 402-407. ( PubMed , DOI )

  43. Novel therapeutic strategies targeting MECOM rearranged AMLs discovered by unbiased drug screen 2025; ( DOI )

  44. ASXL1 mutations in AML are associated with a distinct epigenetic state that results in vulnerabilities to epigenetic-targeted agents 2025; ( DOI )

  45. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes 2025; ( DOI )

  1. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. 2024.11; 17 (1): ( PubMed , DOI )

  2. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. 2024.11; 131 (1): ( PubMed , DOI )

  3. Artificial Intelligence Assessment of Chest Radiographs for COVID-19 2024.11; ( DOI )

  4. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. 2024.11; 25 (4): 254-257. ( PubMed , DOI )

  5. Current status and research directions in acute myeloid leukemia 2024.09; 14 (1): ( PubMed , DOI )

  6. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. 2024.08; 38 (10): 2073-2084. ( PubMed , DOI )

  7. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. 2024.08; 144 ( PubMed , DOI )

  8. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. 2024.06; 24 (11): 783-788. ( PubMed , DOI )

  9. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage 2024.06; 130 (20): 3452-3462. ( PubMed , DOI )

  10. Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis 2024.06; 24 (10): e376-e384. ( PubMed , DOI )

  11. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia 2024.06; 99 (6): 1175-1176. ( PubMed , DOI )

  12. TP53 Y220C mutations in patients with myeloid malignancies (vol 10, pg 1, 2024) 2024.06; 65 (10): 1511-1515. ( PubMed , DOI )

  13. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results 2024.05; 38 (7): 1522-1533. ( PubMed , DOI )

  14. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse 2024.05; 109 (11): 3543-3556. ( PubMed , DOI )

  15. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia 2024.04; 130 (15): 2652-2659. ( PubMed , DOI )

  16. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression 2024.04; 204 (6): 2259-2263. ( PubMed , DOI )

  17. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy 2024.04; 99 (7): 1423-1426. ( PubMed , DOI )

  18. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial 2024.04; 11 (4): e287-e298. ( PubMed , DOI )

  19. Are there new relevant therapeutic endpoints in the modern era of the BCR:: ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? 2024.03; 38 (5): 1-4. ( PubMed , DOI )

  20. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm 2024.03; 8 (11): 2695-2706. ( PubMed , DOI )

  21. Outcome of Patients with Relapsed Acute Promyelocytic Leukemia 2024.02; 24 (6): 375-381. ( PubMed , DOI )

  22. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 2024.02; 143 (20): blood-2023022832. ( PubMed , DOI )

  23. Using Proton Pump Inhibitors is not Associated with Adverse Outcomes in Patients with Chronic Myeloid Leukemia Treated with Dasatinib 2024.02; 24 (7): 484-487. ( PubMed , DOI )

  24. Comprehensive characterization of IFN$γ$ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies 2024.02; 15 (1): 1821. ( PubMed , DOI )

  25. Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens 2024; ( DOI )

  26. Improved survival and unique mutational signatures in small cell lung cancer arising in patients with limited tobacco use 2024; 84 (6\_Supplement): 5061. ( DOI )

  27. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis 2024; 20 (12): 1637-1644. ( PubMed , DOI )

  28. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia 2024; ( DOI )

  29. Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse 2024; ( DOI )

  30. Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation 2024; ( DOI )

  31. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML 2024; ( DOI )

  32. Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML 2024; ( DOI )

  33. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation 2024; 130 (19): 3333-3343. ( PubMed , DOI )

  34. Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update 2024; ( DOI )

  35. A Phase Ib/II Study of Ivosidenib with Venetoclax f Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update 2024; ( DOI )

  36. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions 2024;

  37. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome 2024; ( DOI )

  38. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome 2024; ( PubMed , DOI )

  39. Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds 2024; ( DOI )

  40. A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes: Trial in Progress 2024; ( DOI )

  41. Myelodysplastic Syndromes with Concomitant SF381 Mutation and Deletion of the Long Arm of Chromosome 5 (SF381del5q): Outcomes and Response to Treatment 2024; ( DOI )

  42. Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5 2024;

  43. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series 2024; 11 ( DOI )

  44. A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse 2024; ( DOI )

  45. Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial 2024; ( DOI )

  46. Approximation of Glomerular Filtration Rate after 1 Year Using Annual Medical Examination Data 2024; ( DOI )

  47. Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS) 2024; ( DOI )

  48. Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T3151-Mutated CML-CP: Final Analysis from a Phase 1 Trial 2024; ( DOI )

  49. ASXLI Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents 2024; ( DOI )

  50. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis 2024; ( DOI )

  51. Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission 2024; ( DOI )

  52. Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL 2024; ( DOI )

  53. Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) 2024; ( DOI )

  54. CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia 2024; ( DOI )

  55. Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms 2024; ( DOI )

  56. Identifying novel therapies from unbiased screens in AML with MECOM re-arrangement 2024; 84 (6\_Supplement): 3351. ( DOI )

  57. Identifying 'Druggable' Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1 2024; ( DOI )

  58. Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes 2024;

  59. Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib 2024;

  60. Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax 2024; ( DOI )

  61. Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 2024; ( DOI )

  62. Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker 2024; 145 (25): ( PubMed , DOI )

  63. Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse 2024; ( DOI )

  64. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms 2024; 13 (5): ( PubMed , DOI )

  65. Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL 2024; ( DOI )

  66. Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia 2024; ( DOI )

  67. Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis 2024; ( DOI )

  68. Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost? 2024;

  69. Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia 2024; ( DOI )

  70. Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naive CLL 2024; ( DOI )

  71. Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) 2024; ( DOI )

  72. Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia 2024; ( DOI )

  73. Efficacy of Combinations of Targeted Agents Against Dependencies in Mecom Rearranged AML Identified By Unbiased Chemical and CRISPR Screens 2024; ( DOI )

  74. Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph plus ALL Not Undergoing Allogeneic Transplant 2024; ( DOI )

  75. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome 2024; 24 (9): 629-633. ( PubMed , DOI )

  76. FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML 2024; ( DOI )

  77. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia 2024; 148 (1): 105-110. ( PubMed , DOI )

  78. Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory 2024; ( DOI )

  79. Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis 2024;

  80. Genomic Evolution of Patients With Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis 2024;

  81. Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia 2024;

  82. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia 2024;

  83. Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model 2024;

  84. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase 2024; 130 (19): 3344-3352. ( PubMed , DOI )

  85. Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML 2024; ( DOI )

  86. Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials 2024; ( DOI )

  87. Clinical Outcomes of Patients with AML Receiving Lower Intensity Chemotherapy with or without the Use of Granulocyte-Colony Stimulating Factor (GCSF) 2024; ( DOI )

  88. Clinical Outcomes Using Frontline "Triplet" Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials 2024; ( DOI )

  89. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies 2024; ( DOI )

  90. Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial 2024; ( DOI )

  91. Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update 2024; ( DOI )

  92. Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease 2024; ( DOI )

  1. Outcome of patients with chronic myeloid leukemia after more than 10 years of follow-up 2023.12; 1 (343): 070. ( DOI )

  2. Deeper Insight into Splicing Mutations in Myelofibrosis 2023.11; 142 (Supplement 1): 4580. ( DOI )

  3. Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features 2023.11; 142 (Supplement 1): 1881. ( DOI )

  4. Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms 2023.11; 142 (Supplement 1): 4220. ( DOI )

  5. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs) 2023.11; 142 (Supplement 1): 4264. ( DOI )

  6. Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort 2023.11; 142 (Supplement 1): 3237. ( DOI )

  7. MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation 2023.09; 23 S357-S358. ( DOI )

  8. ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) 2023.09; 23 S348-S349. ( DOI )

  9. Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations 2023.09; 23 S374-S375. ( DOI )

  10. Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation 2023.09; 23 ( DOI )

  11. First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors 2023.09; 23 ( DOI )

  12. T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML) 2023.09; 23 ( DOI )

  13. Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. 2023.08; 7 (S3): ( DOI )

  14. P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA 2023.08; 7 (S3): ( DOI )

  15. P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES 2023.08; 7 (S3): ( DOI )

  16. P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND 2023.08; 7 (S3): ( DOI )

  17. P485: Azacitidine, venetoclax and gilteritinib for patients with newly diagnosed flt3-mutated acute myeloid leukemia: A subgroup analysis from a phase ii study 2023.08; 7 (S3):

  18. P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) 2023.08; 7 (S3):

  19. P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE 2023.08; 7 (S3): ( DOI )

  20. P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS 2023.08; 7 (S3): ( DOI )

  21. P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS 2023.08; 7 (S3): ( DOI )

  22. P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE 2023.08; 7 (S3):

  23. P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS 2023.08; 7 (S3): ( DOI )

  24. P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX 2023.08; 7 (S3):

  25. S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL 2023.08; 7 (S3): ( DOI )

  26. Supplementary Figure 2 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

  27. Supplementary Table 2 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

  28. Supplementary Table 1 from Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma 2023.07; ( DOI )

  29. Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. 2023.06; 41 (16_suppl): ( DOI )

  30. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. 2023.03; 201 (3): e25-e29. ( PubMed , DOI )

  31. Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis 2023; 142 4282. ( DOI )

  32. Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience. 2023; ( DOI )

  33. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia 2023; 142 (5): 4601. ( PubMed , DOI )

  34. Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. 2023; ( DOI )

  35. Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study 2023;

  36. Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML) 2023; 142 870. ( DOI )

  37. Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features 2023; ( DOI )

  38. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph plus ) acute myeloid leukemia (AML). 2023; ( DOI )

  39. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph plus ) acute myeloid leukemia (AML) 2023;

  40. Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement 2023; 142 1419. ( DOI )

  41. Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas 2023; 4 (3\_Supplement): A31.

  42. NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage 2023; 142 957. ( DOI )

  43. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results 2023; 142 233. ( DOI )

  44. ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment 2023; 142 6389. ( DOI )

  45. Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia ChromosomePositive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph plus CMLCP/AP): Final Results from the Asciminib Phase 1 Study 2023; 142 868. ( DOI )

  46. ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI). 2023; ( DOI )

  47. ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI) 2023;

  48. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes 2023; 142 1857. ( DOI )

  49. IFN. Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies 2023; 142 2796. ( DOI )

  50. Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses 2023; 142 3267. ( DOI )

  51. Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study 2023; 142 2884. ( DOI )

  52. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). 2023; ( DOI )

  53. With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study 2023; ( DOI )

  54. Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation 2023; 23

  55. With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study 2023; 142 450.

  56. Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia 2023; 117 (2): e486-e487.

  57. Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience 2023;

  58. P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA 2023; 7 (S3):

  59. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) 2023;

  60. Porównanie asciminibu z bosutynibem w leczeniu pacjentów z przewlekłą białaczką szpikową w fazie przewlekłej leczonych wczésniej co najmniej dwoma inhibitorami kinazy tyrozynowej: dłuższa obserwacja ASCEMBL 2023; 3 (3-4): 119-133.

  61. Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer 2023; 142 4593. ( DOI )

  62. Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results 2023; 142 2903. ( DOI )

  63. Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms ( TRMN) 2023; 142 3224. ( DOI )

  64. Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Followup from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population 2023; ( DOI )

  65. Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population 2023; 142 4536.

  66. Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria 2023; 142 3228. ( DOI )

  67. Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use 2023; 83 (7\_Supplement): 1398. ( DOI )

  68. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data 2023; 142 4635. ( DOI )

  69. Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes 2023; 142 4616. ( DOI )

  70. Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure 2023; 142 4612. ( DOI )

  71. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update 2023; 142 968. ( DOI )

  1. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML 2022.11;

  2. P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES--A TERTIARY CANCER CENTER EXPERIENCE 2022.06; 6 1471-1472.

  3. P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME 2022.06; 6 664-665. ( DOI )

  4. P767: CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES 2022.06; 6 662-663. ( DOI )

  5. P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS 2022.06; 6 598-599. ( DOI )

  6. P695: Prognostic impact of ASXL1 mutations in chronic phase cml 2022.06; 6 590-591. ( DOI )

  7. P762: NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS 2022.06; 6 ( DOI )

  8. Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity 2022.04; ( DOI )

  9. S114: ponatinib and blinatumomab for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study 2022; 6 15-16.

  10. S149: Long term outcomes of iFCG regimen for firstline treatment of patients with CLL with mutated IGHV and without Del (17p)/TP53 mutation 2022; 6 50-51.

  11. S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER≥ 2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE 2022; 6 56-57.

  12. 96-Week Update from the Phase 3 ASCEMBL Study for Evaluating the Safety and Efficacy of Asciminib versus Bosutinib in Patients with chronic phase chronic myeloid Leukemia after Pretreatment with 2 TKIs 2022;

  13. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis 2022; 138 631. ( DOI )

  14. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD) 2022; 22 S243. ( PubMed , DOI )

  15. Effect of Early Caffeine Therapy on the Prevention of Severe Hyperkalemia in Preterm Infants 2022; 149 (1 Meeting Abstracts February 2022): 667.

  16. P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL 2022; 6 599-600.

  17. HEALTH CARE RESOURCE UTILIZATION WITH ASCIMINIB AND BOSUTINIB AMONG ADULTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH=2 TYROSINE KINASE INHIBITORS: WEEK 48 AND WEEK 96 RESULTS FROM ASCEMBL TRIAL 2022;

  18. P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 2022; 6 268-269.

  19. P371: hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia 2022; 6 271-272.

  20. P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB 2022; 6 272-273.

  21. P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE 2022; 6 395-396.

  22. P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS 2022; 6 440-441.

  23. CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI) 2022; 22 S299. ( PubMed , DOI )

  24. Phase II study of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia 2022; 33 ( DOI )

  25. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia 2022; 140 (Supplement 1): 6170-6172. ( DOI )

  26. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib (Leukemia, (2022), 36, 5, (1253-1260), 10.1038/s41375-021-01496-8) 2022; 36 (5): 1448. ( PubMed , DOI )

  1. Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer 2021.09; 144 (5): 585-590. ( PubMed , DOI )

  2. Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial 2021.09; 21 ( DOI )

  3. Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine 2021.09; 21 S303-S304. ( DOI )

  4. Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) 2021.09; 21 ( DOI )

  5. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors 2021; 138 1480.

  6. Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors 2021;

  7. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis 2021; 136 4-5. ( DOI )

  8. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia 2021; 136 22-25. ( DOI )

  9. Contemporary outcomes for adults with AML requiring ICU admission. 2021; ( DOI )

  10. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results 2021; 138 3720. ( DOI )

  1. Md, YO; Mdphd, KY; Huang, YJ; Kuo, MC; Sasaki, K; Hosoya, N; Hiramoto, N; Bera, R; Nannya, Y; Shiozawa, Y; Takeda, J; Watatani, Y; Makishima, H; Shiraishi, Y; Chiba, K; Tanaka, H; Sanada, M; Ishikawa, T; Takaori-Kondo, A; Miyano, S; Mitani, K; Ogawa, S; Shih, LY: Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia BLOOD. 2020.11; 136 ( DOI )

  2. Nakamura, F; Seo, S; Arai, H; Nakamura, Y; Handa, T; Takahashi, W; Furuichi, S; Nagasawa, F; Tadokoro, J; Tsurumi, S; Nakamura, Y; Sasaki, K; Ichikawa, M; Mitani, K: Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia BLOOD. 2020.11; 136 31-32. ( DOI )

  3. Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy 2020; 20 S164-S165. ( DOI )

  4. Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis 2020; 20 ( DOI )

  5. Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes 2020; 2020-09. ( DOI )

  6. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse 2020;

  7. Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes 2020; 2020-07.

  8. CML 治療と予後の最前線 2020;

  9. Clarifying the structure of serious head and spine injury in youth Rugby Union players 2020; ( DOI )

  10. Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma 2020; 136 25-26. ( DOI )

  11. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia 2020; 136 54-56. ( PubMed , DOI )

  12. Ten-day decitabine with venetoclax in acute myeloid leukemia: a single-arm phase 2 trial 2020; 7 (10):

  1. LILRB4 expression in CMML and MDS based on response to hypomethylating agents. 2019.05; 37 (15_suppl): ( DOI )

  2. Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. 2019;

  3. Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2019; 19 S180-S181. ( DOI )

  4. Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 2019; 19 ( DOI )

  5. Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia 2019; 19 S186-S187. ( DOI )

  6. The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor 2019; 19 ( DOI )

  1. Tomiyama, Y; Jang, JH; Lee, JW; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Keta, H; Matsuda, A; Ozawa, K; Mitani, K; Nakao, S: Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial BLOOD. 2018.11; 132 ( DOI )

  2. Double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS) 2018.11; 132 (Supplement 1): 1831. ( DOI )

  3. Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase 2018.11; 132 (Supplement 1): 3026. ( DOI )

  1. INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL 2017;

  2. Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia 2017; 130 1623.

  3. A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE OR FLUDARABINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA 2017;

  4. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) 2017; 130 (Supplement 1): 2597.

  5. UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 2017;

このページの先頭へ▲